Polio vaccine and congenital defects. British Medical Journal. 1967 Feb 25;1(5538):510. PMID: 6017538. Study design [PubMed: 6017538]

Pneumococcal polysaccharide vaccine. Recommendation of the Immunization Practices Advisory Committee. Annals of Internal Medicine. 1982 Feb;96(2):203–5. PMID: 6277218. Study design [PubMed: 6277218]

Pneumococcal vaccine. Health and Public Policy Committee, American College of Physicians. Annals of Internal Medicine. 1986 Jan;104(1):118–20. PMID: 3940479. Study design [PubMed: 3940479]

Immunization during pregnancy. ACOG technical bulletin number 160--October 1991. International Journal of Gynaecology & Obstetrics. 1993 Jan;40(1):69–79. PMID: 8094357. Study design [PubMed: 8094357]

Facts about pertussis and DTP vaccine. EPI Newsletter. 1994 Jun;16(3):5. PMID: 12345538. Study design [PubMed: 12345538]

Erratum: Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines - Report of the National Multicenter Trial (Pediatrics (1996) 97 (7–13)). Pediatrics. 1996 1996;98(1):A38. PMID: 1996204872. Study design [PubMed: 8545227]

From the Centers for Disease Control and Prevention. Status report on the Childhood Immunization Initiative: national, state, and urban area vaccination coverage levels among children aged 19–35 months--United States, 1996. JAMA. 1997 Aug 27;278(8):622–3. PMID: 9272882. Outcome [PubMed: 9272882]

WHO meeting on maternal and neonatal pneumococcal immunization. Weekly Epidemiological Record. 1998 Jun 19;73(25):187–8. PMID: 9648498. Study design [PubMed: 9648498]

From the Centers for Disease Control and Prevention. Withdrawal of rotavirus vaccine recommendation. JAMA. 1999 Dec 8;282(22):2113–4. PMID: 10591321. Study design [PubMed: 10591321]

Measles immunization in HIV-infected children. American Academy of Pediatrics. Committee on Infectious Diseases and Committee on Pediatric AIDS. Pediatrics. 1999 May;103(5 Pt 1):1057–60. PMID: 10224192. Study design [PubMed: 10224192]

Infections and vaccinations as risk factors for childhood type I (insulin-dependent) diabetes mellitus: a multicentre case-control investigation. EURODIAB Substudy 2 Study Group. Diabetologia. 2000 Jan;43(1):47–53. PMID: 10663215. Publication year [PubMed: 10663215]

Pneumococcal vaccination for elderly subjects: license extension. Still no proof of clinical efficacy. Prescrire International. 2000 Aug;9(48):106–9. PMID: 11067718. Study design [PubMed: 11067718]

The safety of inactivated influenza vaccine in adults and children with asthma. N Engl J Med. 2001 Nov 22;345(21):1529–36. doi: 10.1056/NEJMoa011961. PMID: 11794219. Publication year [PubMed: 11794219] [CrossRef]

Erratum: Intussusception among infants given an oral rotavirus vaccine (New England Journal of Medicine (Feb. 22, 2001) 344 (564–72)). New England Journal of Medicine. 2001 17;344(20):1564. PMID: 2001174517. Study design [PubMed: 11207352]

7-valent pneumococcal conjugate vaccine: new preparation. Prevents rare invasive infections in infants. Prescrire International. 2002 Feb;11(57):7–10. PMID: 11985376. Study design [PubMed: 11985376]

Rotavirus vaccine ready for licensing. WHO Drug Information. 2004 2004;18(2):129–30. PMID: 2004362555. Study design

CDC’s advisory committee recommends new vaccine to prevent rotavirus. Indian Journal of Medical Sciences. 2006 Feb;60(2):89–90. PMID: 16538799. Study design [PubMed: 16538799]

Global Advisory Committee on Vaccine Safety, 1–2 December 2005. Weekly Epidemiological Record. 2006 Jan 13;81(2):15–9. PMID: 16671243. Study design [PubMed: 16671243]

Global Advisory Committee on Vaccine Safety, 6–7 June 2006. Weekly Epidemiological Record. 2006 Jul 14;81(28):273–8. PMID: 16841398. Publication type [PubMed: 16841398]

New rotavirus vaccine is likely on its way. Child Health Alert. 2006 Feb;24:1. PMID: 16526105. Study design [PubMed: 16526105]

Infant immunisation with a pneumococcal conjugate vaccine: from the age of two months, for all infants. Prescrire International. 2006 Dec;15(86):227–33. PMID: 17167934. Study design [PubMed: 17167934]

RotaTeq: A new oral rotavirus vaccine. Medical Letter on Drugs and Therapeutics. 2006 31;48(1240):61–3. PMID: 2008221795 MEDLINE PMID 16874281 (http://www​.ncbi.nlm.nih​.gov/pubmed/16874281). Study design [PubMed: 16874281]

New rotavirus vaccines safe and effective in large clinical trials. Gastroenterology. 2006 Mar;130(3):627–8. PMID: WOS:000236210100001. Study design

Global Advisory Committee on Vaccine Safety, 12–13 June 2007. Weekly Epidemiological Record. 2007 Jul 20;82(28–29):252–9. PMID: 17642098. Publication type [PubMed: 17642098]

Rotavirus vaccine and intussusception. WHO Drug Information. 2007 2007;21(1):8. PMID: 2008001204. Study design

Safety updates on rotavirus vaccine. Expert Review of Vaccines. 2007 Apr;6(2):130-. PMID: WOS:000245821400005. Study design

Erratum: Safety and immunogenicity of a fully liquid vaccine containing five-component pertussis-diphtheria-tetanus-inactivated poliomyelitis- Haemophilus influenzae type b conjugate vaccines administered at two, four, six and 18 months of age (Clinical Journal of Infectious Diseases and Medical Microbiology (2007) 18, 4, (241–248)). Canadian Journal of Infectious Diseases and Medical Microbiology. 2007 September/October;18(5):318. PMID: 2007589433. Outcome [PMC free article: PMC2533632] [PubMed: 18923741]

Global Advisory Committee on Vaccine Safety, 12–13 December 2007. Weekly Epidemiological Record. 2008 Jan 25;83(4):37–44. PMID: 18219807. Publication type [PubMed: 18219807]

Adjuvanted hepatitis B vaccine: new drug. Patients with renal failure: similar response rate but fewer boosters needed. Prescrire International. 2008 Dec;17(98):234–6. PMID: 19422145. Study design [PubMed: 19422145]

Global Advisory Committee on Vaccine Safety, 17–18 December 2008. Weekly Epidemiological Record. 2009 Jan 30;84(5):37–40. PMID: 19180768. Publication type [PubMed: 19180768]

Global Advisory Committee on Vaccine Safety, report of meeting held 17–18 June 2009. Weekly Epidemiological Record. 2009 Aug 7;84(32):325–32. PMID: 19860024. Publication type [PubMed: 19860024]

Updated recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding routine poliovirus vaccination. MMWR Morb Mortal Wkly Rep. 2009 Aug 7;58(30):829–30. PMID: 19661857. Outcome [PubMed: 19661857]

Risk levels for febrile seizures with combined measles-mumps-rubella-varicella vaccine. Expert Review of Vaccines. 2010 Aug;9(8):810-. PMID: WOS:000281104800004. Study design

Herpes zoster vaccine (Zostavax) revisited. Medical Letter on Drugs and Therapeutics. 2010 31;52(1339):41. PMID: 2010390996 MEDLINE PMID 20508580 (http://www​.ncbi.nlm.nih​.gov/pubmed/20508580). Study design [PubMed: 20508580]

Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting 2010. Allergy, Asthma and Clinical Immunology. 2010;6(2):2010–11. Publication type

Pneumococcal immunization in older adults. Clinical Geriatrics. 2010 June;18(6):13–4. PMID: 2010389740. Publication type

Adverse effects of papillomavirus vaccination: 2009 data. Prescrire International. 2010 Jun;19(107):124. PMID: 20738043. Study design [PubMed: 20738043]

FDA panel recommends continued use of rotarix and rotateq vaccines viral DNA contamination. Formulary. 2010 May;45(5):167. PMID: 2010397508. Outcome

Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep. 2010 Sep 3;59(34):1102–6. PMID: 20814406. Outcome [PubMed: 20814406]

Benefits and risks of vaccination against papillomavirus human ORIGINAL (NON-ENGLISH) TITLE Beneficios y riesgos de la vacunacion contra el virus del papiloma humano. Ginecologia y Obstetricia de Mexico. 2011 December;79(12):803–7. PMID: 2012155624 MEDLINE PMID 22384535 (http://www​.ncbi.nlm.nih​.gov/pubmed/22384535). Not in English [PubMed: 22384535]

Safety of rotavirus vaccines: postmarketing surveillance in the WHO Region of the Americas. Weekly Epidemiological Record. 2011 Feb 18;86(8):66–72. PMID: 21337810. Study design [PubMed: 21337810]

Rotavirus vaccination and risk of intussusception: Investigation of a possible safety signal. Australian Prescriber. 2011 April;34(2):47. PMID: 2011237396. Outcome

Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2012 Oct 12;61(40):816–9. PMID: 23051612. Outcome [PubMed: 23051612]

Safety and Immunogenicity of Tetanus, Diphtheria, and Acellular Pertussis Immunization During Pregnancy in Mothers and Infants: A Randomized Clinical Trial EDITORIAL COMMENT. Obstetrical & Gynecological Survey. 2014 Sep;69(9):517–9. PMID: WOS:000342571300001. Duplicate

GEN-004 pneumococcal vaccine development stopped after clinical trial failure. Human Vaccines & Immunotherapeutics. 2015 Dec;11(12):2748-. PMID: WOS:000367066700011. Study design

Erratum: eff ectiveness of the ten-valent pneumococcal Haemophilus infl uenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial(Lancet (2013) 381 (214–22)). Lancet. 2015;385(9983):2152. doi: 10.1016/S0140-6736%2815%2961023-6. PMID: CN-01102786. Intervention [PubMed: 23158882] [CrossRef]

Adjuvanted A/H1N1 (2009) influenza vaccination during pregnancy: description of a prospective cohort and spontaneously reported pregnancy-related adverse reactions in the Netherlands. Essentially MIDIRS. 2015;6(1):44-. PMID: 101113317. Language: English. Entry Date: 20150224. Revision Date: 20190711. Publication Type: Article. Intervention

IPVS Policy statement on safety of HPV vaccines. Papillomavirus Research. 2016;2:9–10. doi: 10.1016/j.pvr.2015.11.001. Study design [PMC free article: PMC5886868] [PubMed: 29074192] [CrossRef]

Influenza vaccination during pregnancy. Prescrire international. 2016;25(168):51. Duplicate [PubMed: 27042735]

A universal influenza vaccine candidate enters clinical trials. Human Vaccines & Immunotherapeutics. 2016;12(9):2218-. PMID: WOS:000384217200012. Study design

Therapeutic HPV vaccine GTL001 initiated US-based clinical trials. Human Vaccines & Immunotherapeutics. 2016 Jan;12(1):4-. PMID: WOS:000375931700010. Study design

Immune responses in U.S. military personnel who received meningococcal conjugate vaccine (MenACWY) concomitantly with other vaccines were higher than in personnel who received MenACWY alone. Clinical and vaccine immunology. 23 (8) (pp 672–680), 2016. Date of publication: august 2016. 2016. doi: 10.1128/CVI.00267-16. PMID: CN-01194015. Comparator [PMC free article: PMC4979175] [PubMed: 27280619] [CrossRef]

Universal influenza vaccine enters Phase 2 clinical trial. Human Vaccines & Immunotherapeutics. 2017;13(12):2753-. doi: 10.1080/21645515.2017.1327109. PMID: WOS:000418052100009. Intervention [CrossRef]

Clinical effect of different pneumococcal vaccination schedules in patients with chronic obstructive pulmonary disease (COPD): long-term follow-up results. European respiratory journal. 2017;50. doi: 10.1183/1393003.congress-2017.PA4954. PMID: CN-01932385. Publication type [CrossRef]

Is inadvertent HPV vaccination in pregnancy safe? Contemporary OB/GYN. 2017;62(2):14–6. PMID: 121310940. Language: English. Entry Date: 20170221. Revision Date: 20170223. Publication Type: Article. Journal Subset: Biomedical. Duplicate

Safety and immunogenicity of an upper-range release titer measles-mumps-rubella vaccine in children vaccinated at 12 to 15 months of age: a phase III, randomized study. Human Vaccines and Immunotherapeutics. 2018;14(12):2921–31. doi: 10.1080/21645515.2018.1502527. Intervention [PMC free article: PMC6343620] [PubMed: 30118386] [CrossRef]

Immunogenicity and safety of measles-mumps-rubella vaccine at two different potency levels administered to healthy children aged 12–15months: A phase III, randomized, non-inferiority trial. Vaccine. 2018;36(38):5781–8. doi: 10.1016/j.vaccine.2018.07.076. Duplicate [PubMed: 30104117] [CrossRef]

HBSAG-1018, a two-dose hepatitis b vaccine, is well tolerated and effective in diabetic patients aged 60 years or older. Diabetes. 2018;Conference: 78th Scientific Sessions of the American Diabetes Association, ADA 2018. United States. 67(Supplement 1):LB60. PMID: CN-01921465. Participants

Comparison of reported adverse events of premature and term born infants following childhood vaccinations in the Netherlands. Drug safety. 2018;Conference: 18th Annual Meeting of the International Society of Pharmacovigilance, ISoP 2018. Switzerland. 41(11):1198. doi: 10.1007/s40264-018-0719-2. PMID: CN-01923149. Comparator [CrossRef]

Effect of HBIG combined with hepatitis B vaccineon blocking HBV transmission between motherand infant and its effect on immune cells. Experimental and therapeutic medicine. 2018;15(1):919–23. doi: 10.3892/etm.2017.5474. PMID: CN-01643730. Comparator [PMC free article: PMC5772875] [PubMed: 29399100] [CrossRef]

Recently approved HEPLISAV-B shows a lower proportion of subjects with non-and low response compared with ENGERIX-B [hepatitis B vaccine (recombinant)] in pooled analysis of trials. Hepatology (baltimore, md.). 2018;Conference: 69th Annual Meeting of the American Association for the Study of Liver Diseases, AASLD 2018. United States. 68(Supplement 1):231A–2A. doi: 10.1002/hep.30257. PMID: CN-01923131. Publication type [CrossRef]

Immunogenicity and safety of measles-mumps-rubella vaccine at two different potency levels administered to healthy children aged 12–15 months: a phase III, randomized, non-inferiority trial. Vaccine. 2018;36(38):5781–8. doi: 10.1016/j.vaccine.2018.07.076. PMID: CN-01655596. Duplicate [PubMed: 30104117] [CrossRef]

A second dose of a measles-mumps-rubella vaccine administered to healthy four-to-six-year-old children: a phase III, observer-blind, randomized, safety and immunogenicity study comparing GSK MMR and MMR II with and without DTaP-IPV and varicella vaccines co-administration. Human Vaccines and Immunotherapeutics. 2019;15(4):786–99. doi: 10.1080/21645515.2018.1554971. Intervention [PMC free article: PMC6605865] [PubMed: 30785357] [CrossRef]

The Efficacy and Safety of Tipapkinogen Sovacivec Therapeutic HPV Vaccine in Cervical Intraepithelial Neoplasia Grades 2 and 3: Randomized Controlled Phase II Trial with 2.5 Years of Follow-up. Obstetrical & Gynecological Survey. 2019 Sep;74(9):529–30. PMID: WOS:000493546800012. Intervention [PubMed: 30955915]

Erratum: comparison of the Impact of Pneumococcal Conjugate Vaccine 10 or Pneumococcal Conjugate Vaccine 13 on Invasive Pneumococcal Disease in Equivalent Populations(Clinical Infectious Diseases (2017) 65 (1780–1789) DOI: 10.1093/cid/ciy857). Clinical infectious diseases. 2019;68(1):175-. doi: 10.1093/cid/ciy316. PMID: CN-01966677. Study design [PMC free article: PMC5848315] [PubMed: 29020171] [CrossRef]

Corrigendum: use of UV treated milk powder to increase vaccine efficacy in the elderly (Frontiers in Immunology (2018) 9 (2254) DOI: 10.3389/fimmu.2018.02254). Frontiers in immunology. 2019;10(MAR). doi: 10.3389/fimmu.2019.00427. PMID: CN-02003452. Intervention [PMC free article: PMC6200024] [PubMed: 30386327] [CrossRef]

Correction: effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial (JAMA - Journal of the American Medical Association (2019) 322L: 2 (123–133) DOI: 10.1001/jama.2019.9053). JAMA - journal of the american medical association. 2019;322(8):785-. doi: 10.1001/jama.2019.11467. PMID: CN-02011114. Participants [PMC free article: PMC6618796] [PubMed: 31287523] [CrossRef]

Correction to Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial (The Lancet Infectious Diseases (2019) 19(9) (1001–1012), (S147330991930310X), (10.1016/S1473-3099(19)30310-X)). Lancet infectious diseases. 2019;19(10):e337. doi: 10.1016/S1473-3099(19)30469-4. PMID: CN-02003928. Publication type [PubMed: 31399378] [CrossRef]

Postlicensure Safety Surveillance of Recombinant Zoster Vaccine (Shingrix) - United States, October 2017–June 2018. MMWR. Morbidity and mortality weekly report. 2019;68(4):91–4. doi: 10.15585/mmwr.mm6804a4. PMID: CN-01966755. Duplicate [PMC free article: PMC6400583] [PubMed: 30703077] [CrossRef]

Large Cohort Study Shows No Link Between MMR and ASD. ASHA Leader. 2019;24(5):12-. doi: 10.1044/leader.NIB1.24052019.12. PMID: 136191240. Language: English. Entry Date: 20190504. Revision Date: 20190520. Publication Type: Article. Study design [CrossRef]

Erratum to: 13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6–17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study: PCV13 in Pre-PPSV23-Vaccinated SCD Children (Pediatric Blood & Cancer, (2015), 62, 8, (1427–1436), 10.1002/pbc.25502). Pediatric Blood and Cancer. 2019;66(2). doi: 10.1002/pbc.27554. Publication type [PubMed: 25810327] [CrossRef]

Measles-mumps-rubella vaccine (MMR): No link with autism. Prescrire International. 2020;29(215):125–6. Publication type

Efficacy, duration of protection, birth outcomes, and infant growth associated with influenza vaccination in pregnancy: a pooled analysis of three randomised controlled trials. The lancet respiratory medicine. 2020;8(6):597–608. doi: 10.1016/S2213-2600(19)30479-5. PMID: CN-02182518. Intervention [PMC free article: PMC7284303] [PubMed: 32526188] [CrossRef]

Aaby P, Benn C, Nielsen J, et al. Testing the hypothesis that diphtheria-tetanus-pertussis vaccine has negative non-specific and sex-differential effects on child survival in high-mortality countries. BMJ Open. 2012;2(3). PMID: 2012335376. Study design [PMC free article: PMC3364456] [PubMed: 22619263]

Aaby P, Benn CS. Non-specific and sex-differential effects of routine vaccines: what evidence is needed to take these effects into consideration in low-income countries? Human Vaccines. 2011 Jan 1;7(1):120–4. PMID: 21278492. Outcome [PubMed: 21278492]

Aaby P, Jensen H, Samb B, et al. Differences in female-male mortality after high-titre measles vaccine and association with subsequent vaccination with diphtheria-tetanus-pertussis and inactivated poliovirus: reanalysis of West African studies. Lancet. 2003 Jun 28;361(9376):2183–8. PMID: 12842371. Study design [PubMed: 12842371]

Aaby P, Knudsen K, Whittle H, et al. Long-term survival after Edmonston-Zagreb measles vaccination in Guinea-Bissau: increased female mortality rate. Journal of Pediatrics. 1993 Jun;122(6):904–8. PMID: 8501567. Study design [PubMed: 8501567]

Aaby P, Martins C, Bale C, et al. Sex Differences in the Effect of Vaccines on the Risk of Hospitalization Due to Measles in Guinea-Bissau. Pediatric Infectious Disease Journal. 2010 Apr;29(4):324–8. PMID: WOS:000276565600008. Study design [PubMed: 19934785]

Aaby P, Martins CL, Garly ML, et al. Non-specific effects of standard measles vaccine at 4.5 and 9 months of age on childhood mortality: randomised controlled trial. British Medical Journal. 2010 Nov;341. PMID: WOS:000285090100006. Outcome [PMC free article: PMC2994348] [PubMed: 21118875]

Aaby P, Mogensen SW, Rodrigues A, et al. Evidence of Increase in Mortality After the Introduction of Diphtheria-Tetanus-Pertussis Vaccine to Children Aged 6–35 Months in Guinea-Bissau: A Time for Reflection? Frontiers in Public Health. 2018 Mar;6:10. doi: 10.3389/fpubh.2018.00079. PMID: WOS:000429556900001. Comparator [PMC free article: PMC5868131] [PubMed: 29616207] [CrossRef]

Aaby P, Nielsen J, Benn CS, et al. Sex-differential and non-specific effects of routine vaccinations in a rural area with low vaccination coverage: an observational study from Senegal. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2015 Jan;109(1):77–84. doi: 10.1093/trstmh/tru186. PMID: WOS:000350102400012. Outcome [PubMed: 25573112] [CrossRef]

Aaby P, Ravn H, Roth A, et al. Early diphtheria-tetanus-pertussis vaccination associated with higher female mortality and no difference in male mortality in a cohort of low birthweight children: an observational study within a randomised trial. Archives of Disease in Childhood. 2012 Aug;97(8):685–91. PMID: 22331681. Intervention [PMC free article: PMC3409557] [PubMed: 22331681]

Aaby P, Roth A, Ravn H, et al. Randomized Trial of BCG Vaccination at Birth to Low-Birth-Weight Children: Beneficial Nonspecific Effects in the Neonatal Period? Journal of Infectious Diseases. 2011 Jul;204(2):245–52. PMID: WOS:000292562200013. Intervention [PubMed: 21673035]

Aagaard L, Hansen EW, Hansen EH. Adverse events following immunization in children: Retrospective analysis of spontaneous reports over a decade. European Journal of Clinical Pharmacology. 2011 March;67(3):283–8. PMID: 2011203245 MEDLINE PMID 21079934 (http://www​.ncbi.nlm.nih​.gov/pubmed/21079934). Study design [PubMed: 21079934]

Aagaard L, Weber CB, Hansen EH. Adverse drug reactions in the paediatric population in denmark: A retrospective analysis of reports made to the danish medicines agency from 1998 to 2007. Drug Safety. 2010 2010;33(4):327–39. PMID: 2010179689 MEDLINE PMID 20297864 (http://www​.ncbi.nlm.nih​.gov/pubmed/20297864). Study design [PubMed: 20297864]

Aalst Mv, Garrido HMG, van der Leun J, et al. Immunogenicity of the Currently Recommended Pneumococcal Vaccination Schedule in Patients With Inflammatory Bowel Disease. Clinical Infectious Diseases. 2020;70(4):595–604. doi: 10.1093/cid/ciz226. PMID: 141534929. Language: English. Entry Date: 20200206. Revision Date: 20200207. Publication Type: Article. Comparator [PubMed: 30899961] [CrossRef]

Aavitsland P, Bjune G, Aasen S, et al. Adverse events following vaccine or placebo injection in an efficacy trial of an outer membrane vesicle vaccine against group B meningococcal disease in Norwegian secondary schools 1988–1991. NIPH Annals. 1991 Dec;14(2):133–4; discussion 6–7. PMID: 1812426. Intervention [PubMed: 1812426]

Abarca K, Ibanez I, de la Fuente P, et al. Immunogenicity and tolerability of a paediatric presentation of a virosomal hepatitis A vaccine in Chilean children aged 1–16 years. Vaccine. 2011 08;29(48):8855–62. PMID: 2011659714 MEDLINE PMID 21983354 (http://www​.ncbi.nlm.nih​.gov/pubmed/21983354). Study design [PubMed: 21983354]

Abbas KM, van Zandvoort K, Brisson M, et al. Effects of updated demography, disability weights, and cervical cancer burden on estimates of human papillomavirus vaccination impact at the global, regional, and national levels: a PRIME modelling study. The Lancet Global Health. 2020;8(4):e536–e44. doi: 10.1016/S2214-109X(20)30022-X. Intervention [PMC free article: PMC7083230] [PubMed: 32105613] [CrossRef]

Abbott KC, Yuan CM, Lee JL. Nothing to sneeze at: Efficacy and cost-effectiveness of the influenza vaccine in patients receiving long-term dialysis. American Journal of Kidney Diseases. 2011 May;57(5):651–3. PMID: 2011205912 MEDLINE PMID 21496725 (http://www​.ncbi.nlm.nih​.gov/pubmed/21496725). Outcome [PubMed: 21496725]

Abd AK, Kadhim DJ, Younus MM. Assessment of causality, severity and seriousness of adverse event following immunization in Iraq: A retrospective study based on Iraqi pharmacovigilance database. Iraqi Journal of Pharmaceutical Sciences. 2019;28(2):142–50. doi: 10.31351/vol28iss2pp142-150. Comparator [CrossRef]

Abdelnour A, Silas PE, Lamas MRV, et al. Safety of a quadrivalent meningococcal serogroups A, C, W and Y conjugate vaccine (MenACWY-CRM) administered with routine infant vaccinations: Results of an open-label, randomized, phase 3b controlled study in healthy infants. Vaccine. 2014;32(8):965–72. doi: 10.1016/j.vaccine.2013.12.034. Duplicate [PubMed: 24397906] [CrossRef]

Abedi GR, Mutuc JD, Lawler J, et al. Adverse events following a third dose of measles, mumps, and rubella vaccine in a mumps outbreak. Vaccine. 2012 Nov 19;30(49):7052–8. doi: 10.1016/j.vaccine.2012.09.053. PMID: 23041123. Study design [PubMed: 23041123] [CrossRef]

Aberdein J, Heyderman R, Gordon S, et al. MODIFICATION OF ADULT PNEUMOCOCCAL CARRIAGE BY VACCINATION: EFFECT OF 7-CONJUGATE VACCINE ON CARRIAGE IN MALAWIAN ADULTS, RESULTS FROM A RANDOMISED CONTROLLED TRIAL. Journal of Infection. 2015 Dec;71(6):687-. doi: 10.1016/j.jinf.2015.09.028. PMID: WOS:000368480600019. Intervention [CrossRef]

Ablin JN, Aloush V, Brill A, et al. Influenza vaccination is safe and effective in patients suffering from fibromyalgia syndrome. Reumatismo. 2015;67(2):57–61. doi: 10.4081/reumatismo.2015.823. Intervention [PubMed: 26492963] [CrossRef]

Abraham E. Intranasal Immunization with Bacterial Polysaccharide Containing Liposomes Enhances Antigen-Specific Pulmonary Secretory Antibody-Response. Vaccine. 1992;10(7):461–8. PMID: WOS:A1992HV88400007. Participants [PubMed: 1609549]

Abrams JY, Weintraub ES, Baggs JM, et al. Childhood vaccines and Kawasaki disease, Vaccine Safety Datalink, 1996–2006. Vaccine. 2015 Jan 3;33(2):382–7. doi: 10.1016/j.vaccine.2014.10.044. PMID: 25444786. Outcomes [PubMed: 25444786] [CrossRef]

Abramson JS, Almquist JR, Jenkins RR, et al. Prioritisation of routine vaccines: a mistake for the USA. The Lancet. 2008 20080315/21;371(9616):881–2. PMID: 2008126512 MEDLINE PMID 18342670 (http://www​.ncbi.nlm.nih​.gov/pubmed/18342670). Outcome [PubMed: 18342670]

Abramson JS, Baker CJ, Fisher MC, et al. Possible association of intussusception with rotavirus vaccination. Pediatrics. 1999 1999;104(3 I):575. PMID: 1999316531 MEDLINE PMID 10469790 (http://www​.ncbi.nlm.nih​.gov/pubmed/10469790). Study design [PubMed: 10469790]

Abreo A, Wu P, Donovan BM, et al. Infant Respiratory Syncytial Virus Bronchiolitis and Subsequent Risk of Pneumonia, Otitis Media, and Antibiotic Utilization. Clin Infect Dis. 2019 Oct 21. doi: 10.1093/cid/ciz1033. PMID: 31630167. Intervention [PMC free article: PMC7312311] [PubMed: 31630167] [CrossRef]

Abu-Elyazeed R, Jennings W, Severance R, et al. Immunogenicity and safety of a second dose of a measles-mumps-rubella vaccine administered to healthy participants 7 years of age or older: A phase III, randomized study. Human vaccines & immunotherapeutics. 2018;14(11):2624–31. doi: 10.1080/21645515.2018.1489186. Intervention [PMC free article: PMC6314414] [PubMed: 29902133] [CrossRef]

Abu-Elyazeed R, Klein NP, Moerman L, et al. Concomitant administration of a liquid formulation of human rotavirus vaccine (porcine circovirus-free) with routine childhood vaccines in infants in the United States: Results from a phase 3, randomized trial. Vaccine. 2020. doi: 10.1016/j.vaccine.2020.08.070. Intervention [PubMed: 33077301] [CrossRef]

Abu-Shakra M, Zalmanson S, Neumann L, et al. Influenza virus vaccination of patients with systemic lupus erythematosus: effects on disease activity. J Rheumatol. 2000 Jul;27(7):1681–5. PMID: 10914851. Publication year [PubMed: 10914851]

Abuelenen T, Khalil S, Simoneit E, et al. Prevent and Protect: A Vaccination Initiative for Uninsured Patients at a Student-Run Free Clinic. Journal of Community Health.6. doi: 10.1007/s10900-020-00808-w. PMID: WOS:000520786800003. Intervention [PubMed: 32189211] [CrossRef]

Abzug MJ, Nachman SA, Muresan P, et al. Safety and immunogenicity of 2009 pH1N1 vaccination in HIV-infected pregnant women. Clinical Infectious Diseases. 2013;56(10):1488–97. doi: 10.1093/cid/cit057. Duplicate [PMC free article: PMC3634309] [PubMed: 23378284] [CrossRef]

Abzug MJ, Nachman SA, Muresan P, et al. Safety and immunogenicity of 2009 pH1N1 vaccination in HIV-infected pregnant women. Clinical Infectious Diseases. 2013 May;56(10):1488–97. doi: 10.1093/cid/cit057. PMID: 23378284. Study design [PMC free article: PMC3634309] [PubMed: 23378284] [CrossRef]

Abzug MJ, Pelton SI, Song L-Y, et al. Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. Pediatric Infectious Disease Journal. 2006 Oct;25(10):920–9. PMID: 17006288. Study design [PubMed: 17006288]

Abzug MJ, Qin M, Levin MJ, et al. Immunogenicity, immunologic memory, and safety following measles revaccination in HIV-infected children receiving highly active antiretroviral therapy. Journal of Infectious Diseases. 2012 Aug 15;206(4):512–22. doi: 10.1093/infdis/jis386. PMID: 22693229. Study design [PMC free article: PMC3491735] [PubMed: 22693229] [CrossRef]

Acharya D, Desai A, Nanavaty N, et al. Evaluation of immunogenicity and tolerance of single dose haemophilus influenzae type B (PRP-T) vaccine. Indian Pediatrics. 1995 Oct;32(10):1077–82. PMID: 8984044. Study design [PubMed: 8984044]

Ackerman K, Cohen DC, Erickson RA. Hepatitis B Vaccination Induced Idiopathic Thrombocytopenic Purpura. Gastroenterology. 2011 May;140(5):S976–S. PMID: WOS:000290167304500. Publication type

Actrn. ProVac: probiotic adjuvant to enhance the efficacy of pnemococcal vaccination: a pilot study. http://www​.who.int/trialsearch/Trial2​.aspx?TrialID​=ACTRN12613000368730. 2013. PMID: CN-01842629. Intervention

Actrn. Duration of Pertussis Immunity in Adults: a study of Healthcare Workers. http://www​.who.int/trialsearch/Trial2​.aspx?TrialID​=ACTRN12615001262594. 2015. PMID: CN-01806345. Comparator

Actrn. Comparison of boosting of mucosal immunity after full and fractional dose of inactivated poliovirus vaccine, clinical trial in children in Sri Lanka, 2016. http://www​.who.int/trialsearch/Trial2​.aspx?TrialID​=ACTRN12616000124437. 2016. PMID: CN-01800705. Intervention

Actrn. OPTimising IMmunisation Using Mixed schedules (OPTIMUM): comparing allergic outcomes in infants following pertussis vaccination. http://www​.who.int/trialsearch/Trial2​.aspx?TrialID​=ACTRN12617000065392. 2017. PMID: CN-01805270. Intervention

Actrn. PneuMatters: maternal immunisation to prevent pneumonia in children. http://www​.who.int/trialsearch/Trial2​.aspx?TrialID​=ACTRN12618000150246. 2018. PMID: CN-01897948. Intervention

Actrn. A randomised trial to assess antibody response to hepatitis B vaccine in patients with chronic kidney disease. http://www​.who.int/trialsearch/Trial2​.aspx?TrialID​=ACTRN12618000631202. 2018. PMID: CN-01903282. Outcome

Actrn. Pertaprime: a study to assess the immune response and safety of a new pertussis vaccine (Pertagen^®) in healthy young adults. http://www​.who.int/trialsearch/Trial2​.aspx?TrialID​=ACTRN12619000944134. 2019. PMID: CN-01975508. Intervention

Actrn. MenGO: does the licensed meningococcal vaccine Bexsero^® provide cross-protection against gonorrhoea? http://www​.who.int/trialsearch/Trial2​.aspx?TrialID​=ACTRN12619001478101. 2019. PMID: CN-02064900. Outcome

Adam D, Fehnle K. Safety and effectiveness against respiratory tract infections for pneumococcal conjugate vaccine co-administered with routine vaccine combinations. Vaccine. 2008 Nov 5;26(47):5944–51. PMID: 18801402. Study design [PubMed: 18801402]

Adamkiewicz TV, Silk BJ, Howgate J, et al. Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life. Pediatrics. 2008 Mar;121(3):562–9. PMID: WOS:000253780100015. Outcome [PubMed: 18310206]

Adedinsewo DA, Noory L, Bednarczyk RA, et al. Impact of maternal characteristics on the effect of maternal influenza vaccination on fetal outcomes. Vaccine. 2013;31(49):5827–33. doi: 10.1016/j.vaccine.2013.09.071. Outcome [PubMed: 24120677] [CrossRef]

Adegbola RA, Leach A, Mulholland K, et al. Antigenuria in Gambian infants following immunization with a Haemophilus influenzae type b polyribosylribitol phosphate-tetanus toxoid protein conjugate (PRP-T) vaccine. Diagnostic Microbiology & Infectious Disease. 1998 Sep;32(1):15–9. PMID: 9791752. Outcome [PubMed: 9791752]

Adegnika AA, de Vries SG, Zinsou FJ, et al. Safety and immunogenicity of co-administered hookworm vaccine candidates Na-GST-1 and Na-APR-1 in Gabonese adults: a randomised, controlled, double-blind, phase 1 dose-escalation trial. The Lancet. Infectious diseases. 2020. doi: 10.1016/S1473-3099(20)30288-7. Intervention [PubMed: 32926834] [CrossRef]

Adunsky A, Bernheim J. Pneumococcal vaccine in systemic lupus erythematosus. Arthritis & Rheumatism. 1980 Nov;23(11):1330. PMID: 7447971. Study design [PubMed: 7447971]

Afonso ET, Minamisava R, Bierrenbach AL, et al. Effect of 10-Valent Pneumococcal Vaccine on Pneumonia among Children, Brazil. Emerging Infectious Diseases. 2013 Apr;19(4):589–97. doi: 10.3201/eid1904.121198. PMID: WOS:000328173100009. Intervention [PMC free article: PMC3647414] [PubMed: 23628462] [CrossRef]

Agarkhedkar S, Chhatwal J, Kompithra RZ, et al. Immunogenicity and safety of an intramuscular split-virion quadrivalent inactivated influenza vaccine in individuals aged ≥ 6 months in India. Human Vaccines and Immunotherapeutics. 2019;15(4):973–7. doi: 10.1080/21645515.2019.1565259. Comparator [PMC free article: PMC6605869] [PubMed: 30762467] [CrossRef]

Agarkhedkar S, Juergens C, Balasundaram K, et al. Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Children 6–17 Years of Age in India: An Open-label Trial. Pediatric Infectious Disease Journal. 2017;36(11):e283–e5. doi: 10.1097/INF.0000000000001695. Duplicate [PubMed: 28719496] [CrossRef]

Agarkhedkar S, Juergens C, Balasundaram K, et al. Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Children 6–17 Years of Age in India: An Open-label Trial. The Pediatric infectious disease journal. 2017;36(11):e283–e5. doi: 10.1097/INF.0000000000001695. Comparator [PubMed: 28719496] [CrossRef]

Agarkhedkar S, Kulkarni PS, Winston S, et al. Safety and immunogenicity of dry powder measles vaccine administered by inhalation: A randomized controlled Phase I clinical trial. Vaccine. 2014;32(50):6791–7. doi: 10.1016/j.vaccine.2014.09.071. Intervention [PubMed: 25446830] [CrossRef]

Agergaard J, Nante E, Poulstrup G, et al. Diphtheria-tetanus-pertussis vaccine administered simultaneously with measles vaccine is associated with increased morbidity and poor growth in girls. A randomised trial from Guinea-Bissau. Vaccine. 2011 Jan 10;29(3):487–500. PMID: 21093496. Study design [PubMed: 21093496]

Aggarwal C, Cohen RB, Morrow MP, et al. Immune therapy targeting E6/E7 oncogenes of human paillomavirus type 6 (Hpv-6) reduces or eliminates the need for surgical intervention in the treatment of HPV-6 associated recurrent respiratory papillomatosis. Vaccines. 2020;8(1). doi: 10.3390/vaccines8010056. Intervention [PMC free article: PMC7158680] [PubMed: 32013270] [CrossRef]

Aghasadeghi MR, Velayati AA, Mamishi S, et al. Low prevalence of hepatitis B vaccine escape mutants among individuals born after the initiation of a nationwide vaccination program in Iran. Archives of Virology. 2016;161(12):3405–11. doi: 10.1007/s00705-016-3050-1. Outcome [PubMed: 27613286] [CrossRef]

Aghdam MK, Sadeghzadeh M, Fakhimi S, et al. Evaluation of Aseptic Meningitis Following Measles-Mumps-Rubella Vaccine in Children Admitted due to Febrile Convulsion. International Journal of Pediatrics-Mashhad. 2018 Aug;6(8):8147–52. doi: 10.22038/ijp.2018.31953.2828. PMID: WOS:000433255800015. Comparator [CrossRef]

Agier MS, Marchand S, Paret N, et al. [Post-licensure safety surveillance for Prevenar 13 in France]. Bilan francais des effets indesirables du vaccin Prevenar 13. 2017;24(5):439–44. doi: 10.1016/j.arcped.2017.01.018. Not in English [PMC free article: PMC7133411] [PubMed: 28242152] [CrossRef]

Agnandji ST, Lell B, Fernandes JF, et al. Efficacy and Safety of the RTS,S/AS01 Malaria Vaccine during 18 Months after Vaccination: A Phase 3 Randomized, Controlled Trial in Children and Young Infants at 11 African Sites. PLoS Medicine. 2014;11(7). doi: 10.1371/journal.pmed.1001685. Intervention [PMC free article: PMC4114488] [PubMed: 25072396] [CrossRef]

Agudelo CI, Castaneda-Orjuela C, Brandileone MCdC, et al. The direct effect of pneumococcal conjugate vaccines on invasive pneumococcal disease in children in the Latin American and Caribbean region (SIREVA 2006–17): a multicentre, retrospective observational study. The Lancet. Infectious diseases. 2020. doi: 10.1016/S1473-3099(20)30489-8. Outcome [PMC free article: PMC9759960] [PubMed: 32986996] [CrossRef]

Aguilar-Betancourt A, Gonzalez-Delgado CA, Cinza-Estevez Z, et al. Safety and immunogenicity of a combined hepatitis B virus-Haemophilus influenzae type B vaccine comprising a synthetic antigen in healthy adults. Human Vaccines. 2008 Jan-Feb;4(1):54–9. PMID: 18441530. Study design [PubMed: 18441530]

Aguilar-Betancourt A, Gonzalez-Delgado CA, Cinza-Estevez Z, et al. Safety and immunogenicity of a combined hepatitis B virus Haemophilus influenzae type B vaccine comprising a synthetic antigen in healthy adults. Human Vaccines. 2008 Jan-Feb;4(1):54–9. PMID: WOS:000257001000008. Study design [PubMed: 18441530]

Ahlgren C, Oden A, Haghighi S, et al. The effect of live attenuated measles vaccine and measles infection on measles antibody levels in serum and CSF of multiple sclerosis patients. Multiple Sclerosis. 2010 October;16(10 SUPPL. 1):S28. Outcome [PubMed: 21550125]

Ahlgren C, Toren K, Oden A, et al. A population-based case-control study on viral infections and vaccinations and subsequent multiple sclerosis risk. Eur J Epidemiol. 2009;24(9):541–52. doi: 10.1007/s10654-009-9367-2. PMID: 19633994. Publication year [PubMed: 19633994] [CrossRef]

Ahmad SM, Alam J, Afsar NA, et al. Comparisons of the effect of naturally acquired maternal pertussis antibodies and antenatal vaccination induced maternal tetanus antibodies on infant’s antibody secreting lymphocyte responses and circulating plasma antibody levels. Human Vaccines and Immunotherapeutics. 2016;12(4):886–93. doi: 10.1080/21645515.2015.1136759. Outcome [PMC free article: PMC4962938] [PubMed: 27176823] [CrossRef]

Ahman H, Kayhty H, Tamminen P, et al. Pentavalent pneumococcal oligosaccharide conjugate vaccine PncCRM is well- tolerated and able to induce an antibody response in infants. Pediatric Infectious Disease Journal. 1996 1996;15(2):134–9. PMID: 1996059433 MEDLINE PMID 8822286 (http://www​.ncbi.nlm.nih​.gov/pubmed/8822286). Study design [PubMed: 8822286]

Ahmed F, Steinhoff MC, Rodriguez-Barradas MC, et al. Effect of human immunodeficiency virus type 1 infection on the antibody response to a glycoprotein conjugate pneumococcal vaccine: Results from a randomized trial. Journal of Infectious Diseases. 1996 1996;173(1):83–90. PMID: 1996005021 MEDLINE PMID 8537687 (http://www​.ncbi.nlm.nih​.gov/pubmed/8537687). Study design [PubMed: 8537687]

Ahmed MA, Naus M, Singer J, et al. Investigating the association of receipt of seasonal influenza vaccine with occurrence of anesthesia/paresthesia and severe headaches, Canada 2012/13–2016/17, the Canadian Vaccine Safety Network. Vaccine. 2020;38(19):3582–90. doi: 10.1016/j.vaccine.2020.03.018. Duplicate [PubMed: 32229052] [CrossRef]

Ahmed MA, Naus M, Singer J, et al. Investigating the association of receipt of seasonal influenza vaccine with occurrence of anesthesia/paresthesia and severe headaches, Canada 2012/13-2016/17, the Canadian Vaccine Safety Network. Vaccine. 2020;38(19):3582–90. doi: 10.1016/j.vaccine.2020.03.018. Duplicate [PubMed: 32229052] [CrossRef]

Ahmed MA, Naus M, Singer J, et al. Investigating the association of receipt of seasonal influenza vaccine with occurrence of anesthesia/paresthesia and severe headaches, Canada 2012/13–2016/17, the Canadian Vaccine Safety Network. Vaccine. 2020. doi: 10.1016/j.vaccine.2020.03.018. Intervention [PubMed: 32229052] [CrossRef]

Ahmed S, Perveen I. Safety, Immunogenicity and reactogenicity of recombinant hepatitis B vaccine Engerix(trademark)-B. Immunology. 2011 December;135 SUPPL. 1:81. Publication type

Ahmeti A, Preza I, Simaku A, et al. Cost-effectiveness of rotavirus vaccination in Albania. Vaccine. 2015;33(S1):A201–A8. doi: 10.1016/j.vaccine.2014.12.075. Outcome [PubMed: 25919162] [CrossRef]

Aho C, Michael A, Yoannes M, et al. Limited impact of neonatal or early infant schedules of 7-valent pneumococcal conjugate vaccination on nasopharyngeal carriage of Streptococcus pneumoniae in Papua New Guinean children: A randomized controlled trial. Vaccine reports. 2016;6:36–43. doi: 10.1016/j.vacrep.2016.08.002. Intervention [PMC free article: PMC5446595] [PubMed: 28580433] [CrossRef]

Ahonen A, Berry A, Chatterjee A, et al. Immunogenicity and safety of measles-mumps-rubella vaccine at two different potency levels administered to healthy children aged 12–15 months: A phase III, randomized, non-inferiority trial The MMR-161 Study Group. Vaccine. 2018 Sep;36(38):5781–8. doi: 10.1016/j.vaccine.2018.07.076. PMID: WOS:000445984000016. Duplicate [PubMed: 30104117] [CrossRef]

Ahonkhai VI, Lukacs LJ, Jonas LC, et al. Clinical experience with PedvaxHIB, a conjugate vaccine of Haemophilus influenzae type b polysaccharide--Neisseria meningitidis outer membrane protein. Vaccine. 1991 Jun;9 Suppl:S38–41; discussion S2–3. PMID: 1891956. Study design [PubMed: 1891956]

Ahonkhai VI, Lukacs LJ, Jonas LC, et al. Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) (PedvaxHIB(registered trademark)): Clinical evaluation. Pediatrics. 1990 1990;85(4 SUPPL.):676–81. PMID: 1990099879 MEDLINE PMID 2107518 (http://www​.ncbi.nlm.nih​.gov/pubmed/2107518). Study design [PubMed: 2107518]

Ahrens KA, Louik C, Kerr S, et al. Seasonal influenza vaccination during pregnancy and the risks of preterm delivery and small for gestational age birth. Paediatr Perinat Epidemiol. 2014 Nov;28(6):498–509. doi: 10.1111/ppe.12152. PMID: 25331380. Intervention [PMC free article: PMC4813306] [PubMed: 25331380] [CrossRef]

Aichinger G, Grohmann-Izay B, van der Velden MVW, et al. Phase I/II randomized double-blind study of the safety and immunogenicity of a nonadjuvanted vero cell culture-derived whole-virus H9N2 influenza vaccine in healthy adults. Clinical and vaccine immunology : CVI. 2015;22(1):46–55. doi: 10.1128/CVI.00275-14. Intervention [PMC free article: PMC4278922] [PubMed: 25355797] [CrossRef]

Aikawa NE, Campos LM, Goldenstein-Schainberg C, et al. Effective seroconversion and safety following the pandemic influenza vaccination (anti-H1N1) in patients with juvenile idiopathic arthritis. Scandinavian Journal of Rheumatology. 2013;42(1):34–40. doi: 10.3109/03009742.2012.709272. PMID: 22992045. Study design [PubMed: 22992045] [CrossRef]

Aikawa NE, Campos LMA, Silva CA, et al. Glucocorticoid: major factor for reduced immunogenicity of 2009 influenza A (H1N1) vaccine in patients with juvenile autoimmune rheumatic disease. Journal of Rheumatology. 2012 Jan;39(1):167–73. PMID: 22089462. Study design [PubMed: 22089462]

Aikawa NE, Campos LMA, Silva CA, et al. Glucocorticoid: Major factor for reduced immunogenicity of 2009 influenza A (H1N1) vaccine in juvenile autoimmune rheumatic diseases patients. Arthritis and Rheumatism. 2011;63(10):2011–11. Study design

Aikawa NE, França ILA, Ribeiro AC, et al. Short and long-term immunogenicity and safety following the 23-valent polysaccharide pneumococcal vaccine in juvenile idiopathic arthritis patients under conventional DMARDs with or without anti-TNF therapy. Vaccine. 2015;33(5):604–9. doi: 10.1016/j.vaccine.2014.12.030. Comparator [PubMed: 25554240] [CrossRef]

Airey J, Albano FR, Sawlwin DC, et al. Immunogenicity and safety of a quadrivalent inactivated influenza virus vaccine compared with a comparator quadrivalent inactivated influenza vaccine in a pediatric population: A phase 3, randomized noninferiority study. Vaccine. 2017;35(20):2745–52. doi: 10.1016/j.vaccine.2017.03.028. Comparator [PubMed: 28390934] [CrossRef]

Akatsu H, Kanematsu T, Arakawa K, et al. Interventional trial to enhance effect of influenza vaccination in elderly with jelly. Clinical nutrition. 2013;32:S33–S4. PMID: CN-01078521. Intervention

Akazawa M. Economic analysis of vaccine programs. Japanese Journal of Clinical Pharmacology and Therapeutics. 2010 September;41(5):245–52. PMID: 2010626428. Not in English

Akbar SMF, Al-mahtab M, Aguilar J, et al. Dichotomy of antiviral effect at end of treatment and during off treatment period in patients with chornic hepatitis B treated by therapeutic vaccine versus pegylated interferon. Hepatology international. 2015;9(1 SUPPL. 1):S23. doi: 10.1007/s12072-015-9609-1. PMID: CN-01077571. Publication type [CrossRef]

Akbar SMF, Horike N, Al-Mahtab M, et al. Mechanisms underlying limited therapeutic efficacy of combination therapy containing antiviral drug and hepatitis B virus vaccine in chronic hepatitis B. Hepatology international. 2013;7:S187-. doi: 10.1007/s12072-013-9429-0. PMID: CN-01011837. Publication type [CrossRef]

Akbar SMF, Mahtab MA, Rahman S, et al. A phase III clinical trial with a therapeutic vaccine containing both HBsAg and HBcAg administered via both mucosal and parenteral routes in patients with chronic hepatitis B. Hepatology. 2013 Oct;58:647A–A. PMID: WOS:000330252203091. Intervention

Akinbosoye OE, Taitel MS, Grana J, et al. Factors associated with Zostavax abandonment. American Journal of Pharmacy Benefits. 2016;8(4):84–9. Outcome

Al Qudah Z, Abukwaik W, Souayah N. Stroke after vaccination in United States. A report from the CDC/FDA vaccine adverse event reporting system. [1990–2010. Neurology. 2012;78(1):2012–04. Publication type

Al-Dabbagh M, Lapphra K, Scheifele DW, et al. Elevated inflammatory mediators in adults with oculorespiratory syndrome following influenza immunization: A public health agency of Canada/Canadian institutes of health research influenza research network study. Clinical and Vaccine Immunology. 2013;20(8):1108–14. doi: 10.1128/CVI.00659-12. Comparator [PMC free article: PMC3754507] [PubMed: 23697573] [CrossRef]

al-Eissa YA. Reactogenicity and safety of meningococcal A and C vaccine in Saudi children. Annals of Tropical Paediatrics. 1994;14(4):275–9. PMID: 7880088. Study design [PubMed: 7880088]

Al-Mazrou Y, Khalil M, Findlow H, et al. Immunogenicity and Safety of a Meningococcal Quadrivalent Conjugate Vaccine in Saudi Arabian Adolescents Previously Vaccinated with One Dose of Bivalent and Quadrivalent Meningococcal Polysaccharide Vaccines: a Phase III, Controlled, Randomized, and Modified Blind-Observer Study. Clinical & Vaccine Immunology: CVI. 2012 Jul;19(7):999–1004. PMID: 22552602. Study design [PMC free article: PMC3393373] [PubMed: 22552602]

Al-Mendalawi MD. Post varicella zoster virus myelitis in immunocompetent patients. Neurosciences. 2011 October;16(4):388. PMID: 2011575327 MEDLINE PMID 21983391 (http://www​.ncbi.nlm.nih​.gov/pubmed/21983391). Study design [PubMed: 21983391]

Al-Sukaiti N, Reid B, Lavi S, et al. Safety and efficacy of measles, mumps, and rubella vaccine in patients with DiGeorge syndrome. Journal of Allergy & Clinical Immunology. 2010 Oct;126(4):868–9. PMID: 20810153. Study design [PubMed: 20810153]

Alam MJ, Rashid MM, Kabir Y, et al. On birth single dose live attenuated OPV and BCG vaccination induces gut cathelicidin LL37 responses at 6 week of age: A natural experiment. Vaccine. 2015;33(1):18–21. doi: 10.1016/j.vaccine.2014.10.075. Intervention [PubMed: 25444792] [CrossRef]

Alami Chentoufi A, Kritzer E, Yu DM, et al. Towards a rational design of an asymptomatic clinical herpes vaccine: The old, the new, and the unknown. Clinical and Developmental Immunology. 2012;187585. PMID: 2012212220. Intervention [PMC free article: PMC3324142] [PubMed: 22548113]

Alashkar F, Herich-Terhurne D, Duhrsen U, et al. Serologic response in patients with paroxysmal nocturnal hemoglobinuria (PNH) after vaccination against meningococci for the chronic treatment with the terminal complement inhibitor eculizumab: A retrospective analysis. Oncology Research and Treatment. 2014 Oct;37:245–6. PMID: WOS:000343816900598. Intervention

Alavian SM, Tabatabaei SV. Effects of Oral Levamisole as an Adjuvant to Hepatitis B Vaccine in Adults With End-Stage Renal Disease: A Meta-Analysis of Controlled Clinical Trials. Clinical Therapeutics. 2010 Jan;32(1):1–10. PMID: WOS:000275078600001. Study design [PubMed: 20171406]

Alberer M, Burchard G, Jelinek T, et al. Co-administration of a meningococcal glycoconjugate ACWY vaccine with travel vaccines: a randomized, open-label, multi-center study. Travel medicine and infectious disease. 2014;12(5):485–93. doi: 10.1016/j.tmaid.2014.04.011. Comparator [PubMed: 24873986] [CrossRef]

Alcalde-Cabero E, Almazan-Isla J, Garcia Lopez FJ, et al. Guillain-Barre syndrome following the 2009 pandemic monovalent and seasonal trivalent influenza vaccination campaigns in Spain from 2009 to 2011: outcomes from active surveillance by a neurologist network, and records from a country-wide hospital discharge database. BMC neurology. 2016;16:75. doi: 10.1186/s12883-016-0598-z. Intervention [PMC free article: PMC4875759] [PubMed: 27206524] [CrossRef]

Alfageme I, Vazquez R, Reyes N, et al. Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax. 2006 Mar;61(3):189–95. doi: 10.1136/thx.2005.043323. PMID: 16227328. Outcome [PMC free article: PMC2080738] [PubMed: 16227328] [CrossRef]

Alguacil-Ramos AM, Muelas-Tirado J, Garrigues-Pelufo TM, et al. Surveillance for adverse events following immunization (AEFI) for 7 years using a computerised vaccination system. Public health. 2016;135:66–74. doi: 10.1016/j.puhe.2015.11.010. Comparator [PubMed: 26976484] [CrossRef]

Ali A, Kazi AM, Cortese MM, et al. Impact of Withholding Breastfeeding at the Time of Vaccination on the Immunogenicity of Oral Rotavirus Vaccine-A Randomized Trial (vol 10, e0127622, 2015). Plos One. 2015 Dec;10(12):1. doi: 10.1371/journal.pone.0145568. PMID: WOS:000366722700126. Comparator [PMC free article: PMC4682735] [PubMed: 26673426] [CrossRef]

Ali A, Kazi AM, Cortese MM, et al. Impact of Withholding Breastfeeding at the Time of Vaccination on the Immunogenicity of Oral Rotavirus Vaccine-A Randomized Trial. Plos One. 2015 Jun;10(6):12. doi: 10.1371/journal.pone.0127622. PMID: WOS:000355699100016. Comparator [PMC free article: PMC4452702] [PubMed: 26035743] [CrossRef]

Ali AK. Vaccine-associated guillain-barre syndrome: A pharmacovigilance analysis of data in the United States’ vaccine adverse event reporting system (1990–2009). Value in Health. 2011 May;14(3):A113–A4. Publication type

Ali M, Sur D, You YA, et al. Herd Protection by a Bivalent Killed Whole-Cell Oral Cholera Vaccine in the Slums of Kolkata, India. Clinical Infectious Diseases. 2013 Apr;56(8):1123–31. doi: 10.1093/cid/cit009. PMID: WOS:000316700100014. Outcome [PubMed: 23362293] [CrossRef]

Ali M, You YA, Sur D, et al. Validity of the estimates of oral cholera vaccine effectiveness derived from the test-negative design. Vaccine. 2016 Jan;34(4):479–85. doi: 10.1016/j.vaccine.2015.12.004. PMID: WOS:000368868100014. Intervention [PubMed: 26707378] [CrossRef]

Ali NK, Bhutta ZA. A review of rotavirus diarrhea in Pakistan: How much do we know? Journal of the College of Physicians and Surgeons Pakistan. 2003 1;13(5):297–301. PMID: 2003256170 MEDLINE PMID 12757686 (http://www​.ncbi.nlm.nih​.gov/pubmed/12757686). Outcome [PubMed: 12757686]

Ali SS, Chandrashekar SR, Singh M, et al. A multicenter, prospective, open-label, non-comparative study to evaluate the immunogenicity and tolerance of a new, fully liquid pentavalent vaccine (DTwP-HepB-Hib vaccine). Human Vaccines. 2007 Jul-Aug;3(4):116–20. PMID: 17617743. Intervention [PubMed: 17617743]

Aljadhey H, Alyabsi M, Alrwisan A, et al. The Safety of H1N1 Vaccine in Children in Saudi Arabia: A Cohort Study Using Modern Technology in a Developing Country. Drug Safety. 2012 Jul 1;35(7):555–61. doi: 10.2165/11597450-000000000-00000. PMID: 22671865. Intervention [PubMed: 22671865] [CrossRef]

Aljunid S, Maimaiti N, Nur AM, et al. Cost-effectiveness of HPV vaccination regime: comparing twice versus thrice vaccinations dose regime among adolescent girls in Malaysia. Bmc Public Health. 2016 Jan;16:5. doi: 10.1186/s12889-016-2754-1. PMID: WOS:000368489600002. Outcome [PMC free article: PMC4724398] [PubMed: 26803814] [CrossRef]

Aljunid S, Maimaiti N, Nur AM, et al. Cost- effectiveness of HPV vaccination regime: Comparing twice versus thrice vaccinations dose regime among adolescent girls in Malaysia Health policies, systems and management in high-income countries. BMC Public Health. 2016;16(1). doi: 10.1186/s12889-016-2754-1. Comparator [PMC free article: PMC4724398] [PubMed: 26803814] [CrossRef]

Allen JD, Ray S, Ross TM. Split inactivated COBRA vaccine elicits protective antibodies against H1N1 and H3N2 influenza viruses. Plos One. 2018 Sep;13(9):15. doi: 10.1371/journal.pone.0204284. PMID: WOS:000446005500025. Intervention [PMC free article: PMC6161894] [PubMed: 30265682] [CrossRef]

Allsup S, Gosney M, Haycox A, et al. Cost-benefit evaluation of routine influenza immunisation in people 65–74 years of age. Health Technology Assessment (Winchester, England). 2003;7(24):iii–x, 1–65. PMID: 14499051. Publication year [PubMed: 14499051]

Allsup S, Haycox A, Regan M, et al. Is influenza vaccination cost effective for healthy people between ages 65 and 74 years? A randomised controlled trial. Vaccine. 2004 Dec 16;23(5):639–45. PMID: 15542184. Publication year [PubMed: 15542184]

Allsup SJ, Gosney M, Regan M, et al. Side effects of influenza vaccination in healthy older people: A randomised single-blind placebo-controlled trial. Gerontology. 2001 2001;47(6):311–4. PMID: 2001434764 MEDLINE PMID 11721144 (http://www​.ncbi.nlm.nih​.gov/pubmed/11721144). Publication year [PubMed: 11721144]

Allwin R, Gauer S, Roessel, et al. Eficacy and side effects of H1N1 vaccination in renal transplant and dialysis patients. Transplant International. 2011 September;24 SUPPL. 2:289. Publication type

Allwinn R, Gauer S, Hofeld H, et al. Efficacy and side effects of H1N1 vaccination in renal transplant and dialysis patients. Transplant International. 2011 October;24 SUPPL. 3:34. Study design

Allyn B, Talya U, India W, et al. Safety of live attenuated influenza vaccine (LAIV) in children and adults with asthma. 2020. PMID: CRD42020171839. Study design

Almada G, Haro C, Vintini E, et al. Safety of a nasal vaccine against Streptococcus pneumoniae using heat-killed Lactobacillus casei as adjuvant. Immunobiology. 2015 Jan;220(1):109–16. doi: 10.1016/j.imbio.2014.08.013. PMID: WOS:000346393500015. Intervention [PubMed: 25240632] [CrossRef]

Almeida VDC, Mussi-Pinhata MM, De Souza CBS, et al. Immunogenicity of 23-valent pneumococcal polysaccharide vaccine in HIV-infected pregnant women and kinetics of passively acquired antibodies in young infants. Vaccine. 2009 Jun 12;27(29):3856–61. PMID: 19443091. Study design [PubMed: 19443091]

Almudena L-G, Beate K, Alexander J, et al. Safety of immunization with live vaccines during gestation: a systematic review of pregnancy outcomes. 2019. PMID: CRD42019138360. Study design

Almuneef M, Memish Z, Khan Y, et al. Childhood bacterial meningitis in Saudi Arabia. Journal of Infection. 1998 Mar;36(2):157–60. PMID: 9570646. Intervention [PubMed: 9570646]

AlonsoDeVelasco E, Verheul AF, Verhoef J, et al. Streptococcus pneumoniae: virulence factors, pathogenesis, and vaccines. Microbiological Reviews. 1995 Dec;59(4):591–603. PMID: 8531887. Outcome [PMC free article: PMC239389] [PubMed: 8531887]

Alter M, Speer J. Clinical evaluation of possible etiologic factors in multiple sclerosis. Neurology. 1968 Feb;18(2):109–16. doi: 10.1212/wnl.18.2.109. PMID: 5688752. Publication year [PubMed: 5688752] [CrossRef]

Altobelli E, Petrocelli R, Verrotti A, et al. Infections and risk of type I diabetes in childhood: a population-based case-control study. Eur J Epidemiol. 2003;18(5):425–30. PMID: 12889689. Publication year [PubMed: 12889689]

Alvarez MM, Fernandez CG, Exposito AG. Antibody response to the standard hepatitis B vaccination in patients with rheumatoid arthritis and ankylosign spondylitis treated with infliximab. Arthritis and Rheumatism. 2011;63(10):1316. Publication type

Alvarez-Soria MJ, Hernandez-Gonzalez A, Carrasco-Garcia de Leon S, et al. Demyelinating disease and papillomavirus vaccine: Report of three cases. Journal of Neurology. 2010 June;257 SUPPL. 1:S119. Publication type

Amador JJ, Vasquez J, Orozco M, et al. Rotavirus disease burden, Nicaragua 2001–2005: defining the potential impact of a rotavirus vaccination program. International Journal of Infectious Diseases. 2010 July;14(7):e592–e5. PMID: 2010324049 MEDLINE PMID 20022778 (http://www​.ncbi.nlm.nih​.gov/pubmed/20022778). Outcome [PubMed: 20022778]

Amanna IJ. Balancing the efficacy and safety of vaccines in the elderly. Open Longevity Science. 2012 2012;6:64–72. PMID: 2012422054. Study design [PMC free article: PMC3616444] [PubMed: 23565132]

Ambrosch F, Wiedermann G, Crooy P, et al. Immunogenicity and side-effects of a new tetravalent meningococcal polysaccharide vaccine. Bulletin of the World Health Organization. 1983;61(2):317–23. PMID: 6407768. Study design [PMC free article: PMC2536123] [PubMed: 6407768]

Ambrose CS, Dubovsky F, Yi T, et al. The safety and efficacy of live attenuated influenza vaccine in young children with asthma or prior wheezing. European Journal of Clinical Microbiology and Infectious Diseases. 2012. Duplicate [PMC free article: PMC3456911] [PubMed: 22410646]

Ambrose CS, Wu XH. The safety and effectiveness of self-administration of intranasal live attenuated influenza vaccine in adults. Vaccine. 2013 Jan;31(6):857–60. doi: 10.1016/j.vaccine.2012.12.028. PMID: WOS:000314435400001. Intervention [PubMed: 23261050] [CrossRef]

Amdekar YK, Lalwani SK, Bavdekar A, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine vaccines in India. Pediatric infectious disease journal. 2013;32(5):509–16. doi: 10.1097/INF.0b013e31827b478d. PMID: CN-01705684. Duplicate [PubMed: 23190777] [CrossRef]

Amelia L, Chiara G, Annalisa De S, et al. What is the efficacy, immunogenicity, and safety of available vaccines in children with chronic conditions treated with biologic drugs? A systematic review and meta-analysis. 2020. PMID: CRD42020176227. Study design

Amendola A, Tanzi E, Zappa A, et al. Safety and immunogenicity of 23-valent pneumococcal polysaccharide vaccine in HIV-1 infected former drug users. Vaccine. 2002 Nov 1;20(31–32):3720–4. PMID: 12399200. Study design [PubMed: 12399200]

Ameratunga SN, Lennon DR, Entwistle B, et al. The immunogenicity of Haemophilus influenzae: Meningococcal protein conjugate vaccine in Polynesian and non-Polynesian New Zealand infants. Journal of Paediatrics and Child Health. 1997 1997;33(2):138–41. PMID: 1997158608 MEDLINE PMID 9145357 (http://www​.ncbi.nlm.nih​.gov/pubmed/9145357). Outcome [PubMed: 9145357]

Amir J, Melamed R, Bader J, et al. Immunogenicity and safety of a liquid combination of DTP-PRP-T [corrected] vs lyophilized PRP-T reconstituted with DTP.[Erratum appears in Vaccine 1997 Nov;15(16):1813]. Vaccine. 1997 Feb;15(2):149–54. PMID: 9066031. Study design [PubMed: 9066031]

Amjad W, Doycheva IB, Zhang T, et al. COMPARISON OF IMMUNOGENICITY OF TWO DOSE HEPATITIS B VACCINE (HEPLISAV-B) WITH THREE DOSE CONVENTIONAL VACCINE (ENERGIX-B) IN LIVER DISEASE COHORT. Hepatology. 2019 Oct;70:619A–20A. PMID: WOS:000488653502168. Study design

Anand A, Zaman K, Estivariz CF, et al. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: A randomized controlled trial. Vaccine. 2015;33(48):6816–22. doi: 10.1016/j.vaccine.2015.09.039. Comparator [PMC free article: PMC10423714] [PubMed: 26476367] [CrossRef]

Anar C, Bicmen C, Yapicioglu S, et al. Evaluation of clinical data and antibody response following influenza vaccination in patients with chronic obstructive pulmonary disease. New Microbiologica. 2010 Apr;33(2):117–27. PMID: WOS:000277651700003. Outcome [PubMed: 20518273]

Andersen A, Bjerregaard-Andersen M, Rodrigues A, et al. Sex-differential effects of diphtheria-tetanus-pertussis vaccine for the outcome of paediatric admissions? A hospital based observational study from Guinea-Bissau. Vaccine. 2017 Dec;35(50):7018–25. doi: 10.1016/j.vaccine.2017.10.047. PMID: WOS:000418971100014. Comparator [PubMed: 29107347] [CrossRef]

Andersen A, Fisker AB, Rodrigues A, et al. National Immunization Campaigns with Oral Pao Vaccine Reduce All-Cause Mortality: A Natural Experiment within Seven Randomized Trials. Frontiers in Public Health. 2018 Feb;6:10. doi: 10.3389/fpubh.2018.00013. PMID: WOS:000424150800001. Intervention [PMC free article: PMC5801299] [PubMed: 29456992] [CrossRef]

Andersen DV, Jorgensen IM. MMR vaccination of children with egg allergy is safe. Danish Medical Journal. 2013 Feb;60(2):A4573. PMID: 23461988. Study design [PubMed: 23461988]

Andersen E, Isager H, Hyllested K. Risk factors in multiple sclerosis: tuberculin reactivity, age at measles infection, tonsillectomy and appendectomy. Acta Neurol Scand. 1981 Feb;63(2):131–5. doi: 10.1111/j.1600-0404.1981.tb00756.x. PMID: 7211178. Publication year [PubMed: 7211178] [CrossRef]

Anderson EJ. Rotavirus vaccines: viral shedding and risk of transmission. The Lancet Infectious Diseases. 2008 October;8(10):642–9. PMID: 2008443646 MEDLINE PMID 18922486 (http://www​.ncbi.nlm.nih​.gov/pubmed/18922486). Study design [PubMed: 18922486]

Anderson EJ, Shippee DB, Weinrobe MH, et al. Indirect Protection of Adults From Rotavirus by Pediatric Rotavirus Vaccination. Clinical Infectious Diseases. 2013 Mar;56(6):755–60. doi: 10.1093/cid/cis1010. PMID: WOS:000315630800006. Comparator [PubMed: 23349228] [CrossRef]

Anderson EL, Belshe RB, Bartram J. Evaluation of rhesus rotavirus vaccine (MMU 18006) in infants and young children. Journal of Infectious Diseases. 1986 1986;153(5):823–31. PMID: 1986148918 MEDLINE PMID 3009633 (http://www​.ncbi.nlm.nih​.gov/pubmed/3009633). Study design [PubMed: 3009633]

Anderson EL, Bowers T, Mink CM, et al. Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults. Infection & Immunity. 1994 Aug;62(8):3391–5. PMID: 8039909. Intervention [PMC free article: PMC302970] [PubMed: 8039909]

Anderson EL, Decker MD, Englund JA, et al. Interchangeability of conjugated Haemophilus influenzae type b vaccines in infants. JAMA. 1995 Mar 15;273(11):849–53. PMID: 7869554. Study design [PubMed: 7869554]

Anderson EL, Kennedy DJ, Geldmacher KM, et al. Immunogenicity of heptavalent pneumococcal conjugate vaccine in infants. Journal of Pediatrics. 1996 May;128(5 Pt 1):649–53. PMID: 8627437. Outcome [PubMed: 8627437]

Anderson ML, Dobkin C, Gorry D. The Effect of Influenza Vaccination for the Elderly on Hospitalization and Mortality An Observational Study With a Regression Discontinuity Design. Annals of Internal Medicine. 2020 Apr;172(7):445-+. doi: 10.7326/m19-3075. PMID: WOS:000524036500003. Outcome [PubMed: 32120383] [CrossRef]

Anderson P, Insel RA, Smith DH, et al. A polysaccharide-protein complex from Haemophilus influenzae type b. III. Vaccine trial in human adults. Journal of Infectious Diseases. 1981 Dec;144(6):530–8. PMID: 7035578. Intervention [PubMed: 7035578]

Anderson P, Pichichero M, Edwards K, et al. Priming and induction of Haemophilus influenzae type b capsular antibodies in early infancy by Dpo20, an oligosaccharide-protein conjugate vaccine. Journal of Pediatrics. 1987 Nov;111(5):644–50. PMID: 3499499. Study design [PubMed: 3499499]

Anderson P, Pichichero ME. Haemophilus influenzae type b vaccine. Pediatrics. 1989 Jan;83(1):145–6. PMID: 2909967. Study design [PubMed: 2909967]

Andersson L. Contradictory data on type 1 diabetes in a recently published article ‘Risks of neurological and immune-related diseases, including narcolepsy, after vaccination with Pandemrix: a population- and registry-based cohort study with over 2 years of follow-up’ (J Intern Med 2013). Journal of internal medicine. 2014;276(4):414–7. doi: 10.1111/joim.12246. Intervention [PubMed: 24698654] [CrossRef]

Andersson L. RETRACTED: Hidden authority study data have come to light: besides narcolepsy, the swine influenza vaccine Pandemrix caused type 1 diabetes (Retracted article. See vol. 284, pg. 328, 2018). Journal of Internal Medicine. 2017 Jan;281(1):99–101. doi: 10.1111/joim.12583. PMID: WOS:000393950000010. Intervention [PubMed: 27995691] [CrossRef]

Ando S. Effectiveness of quadrivalent influenza vaccine based on the test-negative control study in children during the 2016–2017 season. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy. 2018;24(10):782–8. doi: 10.1016/j.jiac.2018.05.012. Outcome [PubMed: 29945763] [CrossRef]

Ando S. Effectiveness of quadrivalent influenza vaccine based on the test-negative control study in children during the 2016–2017 season. Journal of Infection and Chemotherapy. 2018;24(10):782–8. doi: 10.1016/j.jiac.2018.05.012. Duplicate [PubMed: 29945763] [CrossRef]

Andrade AL, da Silva Vieira MA, Minamisava R, et al. Single-dose varicella vaccine effectiveness in Brazil: A case-control study. Vaccine. 2018;36(4):479–83. doi: 10.1016/j.vaccine.2017.12.011. Intervention [PubMed: 29249544] [CrossRef]

Andrade D, Seguro L, Ribeiro A, et al. Is H1N1 influenza vaccine safe and effective in patients with SSc? Rheumatology. 2012 February;51 SUPPL. 2:ii23. Study design

Andrade DC, Borges IC, Adrian PV, et al. Effect of Pneumococcal Conjugate Vaccine on the Natural Antibodies and Antibody Responses Against Protein Antigens From Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in Children With Community-acquired Pneumonia. Pediatric Infectious Disease Journal. 2016 Jun;35(6):683–9. doi: 10.1097/inf.0000000000001126. PMID: WOS:000379343700019. Intervention [PubMed: 26954601] [CrossRef]

Andre FE, D’Hondt E, Delem A, et al. Clinical assessment of the safety and efficacy of an inactivated hepatitis A vaccine: Rationale and summary of findings. Vaccine. 1992 1992;10(SUPPL. 1):S160–S8. PMID: 1992360501 MEDLINE PMID 1335652 (http://www​.ncbi.nlm.nih​.gov/pubmed/1335652). Study design [PubMed: 1335652]

Andrea T, Wasifa Z, Roberta C, et al. Efficacy, effectiveness, and safety of herpes zoster vaccines in individuals 50 years of age and older: a systematic review. 2017. PMID: CRD42017056389. Study design

Andreas J, Jenke A, Weckelmann A, et al. Incidence, management and protective factors of intussusception in children: Results from a nationwide german surveillance. Journal of Pediatric Gastroenterology and Nutrition. 2009 May;48 SUPPL. 3:E52–E3. Publication type

Andrew MK, Shinde V, Hatchette T, et al. Influenza vaccine effectiveness against influenza-related hospitalization during a season with mixed outbreaks of four influenza viruses: a test-negative case-control study in adults in Canada. BMC infectious diseases. 2017;17(1):805. doi: 10.1186/s12879-017-2905-8. Outcome [PMC free article: PMC5747268] [PubMed: 29284435] [CrossRef]

Andrew MK, Shinde V, Ye L, et al. The Importance of Frailty in the Assessment of Influenza Vaccine Effectiveness Against Influenza-Related Hospitalization in Elderly People. The Journal of infectious diseases. 2017;216(4):405–14. doi: 10.1093/infdis/jix282. Outcome [PMC free article: PMC5853583] [PubMed: 28931244] [CrossRef]

Andrew MK, Shinde V, Ye LY, et al. The Importance of Frailty in the Assessment of Influenza Vaccine Effectiveness Against Influenza-Related Hospitalization in Elderly People. Journal of Infectious Diseases. 2017 Aug;216(4):405–14. doi: 10.1093/infdis/jix282. PMID: WOS:000410526900004. Duplicate [PMC free article: PMC5853583] [PubMed: 28931244] [CrossRef]

Andrews N, Kent A, Amin-Chowdhury Z, et al. Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: The indirect cohort design, 2006–2018. Vaccine. 2019;37(32):4491–8. doi: 10.1016/j.vaccine.2019.06.071. Outcome [PubMed: 31272872] [CrossRef]

Andrews N, Miller E, Grant A, et al. Thimerosal exposure in infants and developmental disorders: A retrospective cohort study in the United Kingdom does not support a causal association. Pediatrics. 2004 September;114(3):584–91. PMID: 2005485136 MEDLINE PMID 15342825 (http://www​.ncbi.nlm.nih​.gov/pubmed/15342825). Study design [PubMed: 15342825]

Andrews N, Stowe J, Al-Shahi Salman R, et al. Guillain-Barre syndrome and H1N1 (2009) pandemic influenza vaccination using an AS03 adjuvanted vaccine in the United Kingdom: self-controlled case series. Vaccine. 2011 Oct 19;29(45):7878–82. PMID: 21875631. Intervention [PubMed: 21875631]

Andrews N, Stowe J, Miller E. No increased risk of Guillain-Barre syndrome after human papilloma virus vaccine: A self-controlled case-series study in England. Vaccine. 2017 Mar 23;35(13):1729–32. doi: 10.1016/j.vaccine.2017.01.076. PMID: 28245941. Intervention [PubMed: 28245941] [CrossRef]

Andrews N, Stowe J, Miller E, et al. Post-licensure safety of the meningococcal group C conjugate vaccine. Hum Vaccin. 2007 Mar-Apr;3(2):59–63. doi: 10.4161/hv.3.2.3878 [pii]. PMID: 17312400. Publication year [PubMed: 17312400] [CrossRef]

Andrews N, Stowe J, Thomas SL, et al. The risk of non-specific hospitalised infections following MMR vaccination given with and without inactivated vaccines in the second year of life. Comparative self-controlled case-series study in England. Vaccine. 2019;37(36):5211–7. doi: 10.1016/j.vaccine.2019.07.059. Outcome [PubMed: 31375437] [CrossRef]

Andrews N, Waight P, Yung CF, et al. Age-specific effectiveness of an oil-in-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in England. Journal of Infectious Diseases. 2011 1;203(1):32–9. PMID: 2011084070 MEDLINE PMID 21148494 (http://www​.ncbi.nlm.nih​.gov/pubmed/21148494). Outcome [PMC free article: PMC3086445] [PubMed: 21148494]

Andrews N, Waight PA, Borrow R, et al. Using the indirect cohort design to estimate the effectiveness of the seven valent pneumococcal conjugate vaccine in England and Wales. PLoS ONE. 2011;6(12). PMID: 2011662171. Outcome [PMC free article: PMC3229580] [PubMed: 22164292]

Andrews NJ, Walker WT, Finn A, et al. Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines. Vaccine. 2011 Oct 19;29(45):7913–9. PMID: 21875635. Study design [PubMed: 21875635]

Andrisani G, Frasca D, Armuzzi A, et al. Response to the 2009 vaccine for influenza A/H1N1 in patients with inflammatory bowel disease on anti TNF(alpha) therapy. Journal of Crohn’s and Colitis. 2011 February;5(1):S78–S9. Study design

Andrisani G, Frasca D, Romero M, et al. Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-(alpha) agents: Effects of combined therapy with immunosuppressants. Journal of Crohn’s and Colitis. 2012. Study design [PMC free article: PMC3862353] [PubMed: 22673636]

Andrisani G, Frasca D, Romero M, et al. Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-alpha agents: effects of combined therapy with immunosuppressants. Journal of Crohn’s & colitis. 2013;7(4):301–7. doi: 10.1016/j.crohns.2012.05.011. Duplicate [PMC free article: PMC3862353] [PubMed: 22673636] [CrossRef]

Aneesa M, Susanne H, Courtney G, et al. Safety of Vaccines Used for Routine Immunization in the United States: An update. 2020. PMID: CRD42020180089. Duplicate

Angel JB, Routy JP, Graziani GM, et al. The Effect of Therapeutic HIV Vaccination With ALVAC-HIV With or Without Remune on the Size of the Viral Reservoir (A CTN 173 Substudy). Journal of acquired immune deficiency syndromes (1999). 2015;70(2):122–8. doi: 10.1097/QAI.0000000000000734. PMID: CN-01096673. Intervention [PMC free article: PMC4577611] [PubMed: 26375464] [CrossRef]

Anh DD, Carlos CC, Thiem DV, et al. Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 (Rotarix (TM)) oral suspension (liquid formulation) when co-administered with expanded program on immunization (EPI) vaccines in Vietnam and the Philippines in 2006–2007. Vaccine. 2011 Mar;29(11):2029–36. PMID: WOS:000288731000008. Study design [PubMed: 21256876]

Anh DD, Jayadeva G, Kuriyakose S, et al. The safety and reactogenicity of a reduced-antigen-content diphtheria-tetanus-acellular pertussis (dTpa) booster vaccine in healthy Vietnamese children. Vaccine. 2016;34(37):4360–3. doi: 10.1016/j.vaccine.2016.07.005. Comparator [PubMed: 27435387] [CrossRef]

Anh DD, Thiem VD, Anh NTH, et al. Randomized safety and immunogenicity trial of a seasonal trivalent inactivated split virion influenza vaccine (IVACFLU-S) in healthy young Vietnamese adults. Vaccine. 2016;34(45):5457–62. doi: 10.1016/j.vaccine.2016.08.052. Intervention [PubMed: 27567493] [CrossRef]

Anh DD, Thiem VD, Anh NTH, et al. Randomized safety and immunogenicity trial of a seasonal trivalent inactivated split virion influenza vaccine (IVACFLU-S) in healthy young Vietnamese adults. Vaccine. 2016 Oct;34(45):5457–62. doi: 10.1016/j.vaccine.2016.08.052. PMID: WOS:000386642000013. Duplicate [PubMed: 27567493] [CrossRef]

Anh DD, Thiem VD, Hutagalung Y, et al. Immunogenicity, Reactogenicity and Safety of the Oral Live Attenuated Human Rotavirus Vaccine RIX4414(Rotarix (TM)) Oral Suspension (Liquid Formulation) in Vietnamese Infants. International Journal of Infectious Diseases. 2008 Dec;12:E147–E. PMID: WOS:000263287800365. Publication type

Anh DD, Van Der Meeren O, Karkada N, et al. Safety and reactogenicity of the combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b (DTPa-IPV/Hib) vaccine in healthy Vietnamese toddlers: An open-label, phase III study. Human vaccines & immunotherapeutics. 2016;12(3):655–7. doi: 10.1080/21645515.2015.1084451. Comparator [PMC free article: PMC4964705] [PubMed: 26337197] [CrossRef]

Anh DD, Van Der Meeren O, Karkada N, et al. Safety and reactogenicity of the combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b (DTPa-IPV/Hib) vaccine in healthy Vietnamese toddlers: An open-label, phase III study. Human Vaccines and Immunotherapeutics. 2016;12(3):655–7. doi: 10.1080/21645515.2015.1084451. Duplicate [PMC free article: PMC4964705] [PubMed: 26337197] [CrossRef]

Ankrah DN, Mantel-Teeuwisse AK, De Bruin ML, et al. Incidence of adverse events among healthcare workers following H1N1 Mass immunization in Ghana: a prospective study. Drug Safety. 2013 Apr;36(4):259–66. doi: 10.1007/s40264-013-0037-7. PMID: 23508545. Study design [PubMed: 23508545] [CrossRef]

Ankrah DNA, Mantel-Teeuwisse AK, De Bruin ML, et al. Incidence of adverse events among healthcare workers following H1N1 Mass immunization in Ghana: a prospective study. Drug safety. 2013;36(4):259–66. doi: 10.1007/s40264-013-0037-7. Duplicate [PubMed: 23508545] [CrossRef]

Annunziata P, Carnicelli N, Galluzzi P, et al. Erratum: Miller-Fisher syndrome following vaccination against influenza virus A/H1N1 in an AIDS patient. Infection. 2012 April;40(2):233. PMID: 2012378205. Study design [PubMed: 21877180]

Anonymous. Intranasal live attenuated seasonal influenza vaccine: does not challenge current practice. Prescrire international. 2013;22(141):201–4. Intervention [PubMed: 24171209]

Anonymous. Fluzone high-dose vaccine is significantly more effective than the standard dose of fluzone vaccine in preventing influenza in adults >=65 years of age. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2013;57(10):i–i. doi: 10.1093/cid/cit561. Outcome [PubMed: 24014736] [CrossRef]

Anonymous. [Vaccination against Herpes Zoster after 50 years-of-age is effective]. Impfung gegen Herper zoster ab 50 Jahren nutzen. 2015;157(14):74–5. doi: 10.1007/s15006-015-3380-z. Not in English [PubMed: 26289853] [CrossRef]

Anonymous. Efficacy HPV vaccine in late 2014. Prescrire international. 2015;24(160):126–7. Comparator [PubMed: 26034805]

Anonymous. Tetanus shot may improve glioblastoma treatment. Cancer discovery. 2015;5(6):571. doi: 10.1158/2159-8290.CD-NB2015-053. PMID: CN-01265897. Intervention [PubMed: 25877510] [CrossRef]

Anonymous. Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial. BMJ (Clinical research ed.). 2016;353:i2605. doi: 10.1136/bmj.i2605. Duplicate [PubMed: 27153852] [CrossRef]

Anonymous. Pneumococcal conjugate vaccine: do not routinely vaccinate adults aged 65 years and older. Prescrire international. 2016;25(172):157–8. Outcome [PubMed: 27486649]

Anonymous. Influenza vaccination during pregnancy. Prescrire international. 2016;25(168):51. Outcome [PubMed: 27042735]

Anonymous. Human Vaccines & Immunotherapeutics: News. Human vaccines & immunotherapeutics. 2017;13(3):491–2. doi: 10.1080/21645515.2017.1294958. Outcome [PMC free article: PMC5360146] [PubMed: 28300500] [CrossRef]

Anonymous. Correction: Evaluation of the safety of live attenuated influenza vaccine (LAIV) in children and adolescents with asthma and high-risk conditions: a population-based prospective cohort study conducted in England with the Clinical Practice Research Datalink. BMJ open. 2019;9(2):e023118corr1. doi: 10.1136/bmjopen-2018-023118corr1. Intervention [PMC free article: PMC6398688] [PubMed: 30819718] [CrossRef]

Anonymous. The MMR Vaccine Is Not Associated With Risk for Autism. Annals of internal medicine. 2019;170(8). doi: 10.7326/P19-0002. Publication type [PubMed: 30831599] [CrossRef]

Ansaldi F, Orsi A, de Florentiis D, et al. Head-to-head comparison of an intradermal and a virosome influenza vaccine in patients over the age of 60: evaluation of immunogenicity, cross-protection, safety and tolerability. Human vaccines & immunotherapeutics. 2013;9(3):591–8. Comparator [PMC free article: PMC3891716] [PubMed: 23295262]

Ansaldi F, Sticchi L, Durando P, et al. Decline in pneumonia and acute otitis media after the introduction of childhood pneumococcal vaccination in Liguria, Italy. Journal of International Medical Research. 2008 2008;36(6):1255–60. PMID: 2009188000 MEDLINE PMID 19094434 (http://www​.ncbi.nlm.nih​.gov/pubmed/19094434). Outcome [PubMed: 19094434]

Ansari F, Baker RD, Patel R, et al. Varicella immunity in inflammatory bowel disease. Journal of Pediatric Gastroenterology & Nutrition. 2011 Oct;53(4):386–8. PMID: 21505365. Study design [PubMed: 21505365]

Antachopoulos C, Tsolia MN, Tzanakaki G, et al. Parapneumonic pleural effusions caused by Streptococcus pneumoniae serotype 3 in children immunized with 13-valent conjugated pneumococcal vaccine. The Pediatric infectious disease journal. 2014;33(1):81–3. doi: 10.1097/INF.0000000000000041. Outcome [PubMed: 24172850] [CrossRef]

Anthony MOKKP. Performance and safety of WHO-prequalified rotavirus vaccines: a systematic review and metaanalysis. 2020. PMID: CRD42020179133. Study design

Anttila M, Eskola J, Ahman H, et al. Differences in the avidity of antibodies evoked by four different pneumococcal conjugate vaccines in early childhood. Vaccine. 1999 9;17(15 16):1970–7. PMID: 1999131917 MEDLINE PMID 10217596 (http://www​.ncbi.nlm.nih​.gov/pubmed/10217596). Outcome [PubMed: 10217596]

Anuwutnavin S, Sompagdee N, Phongsamart W, et al. 1146: seroprevalence of Bordetella pertussis antibodies and anti- pertussis antibody response after Tdap vaccine in pregnant women. American journal of obstetrics and gynecology. 2020;222(1):S705–S6. doi: 10.1016/j.ajog.2019.11.1158. PMID: CN-02076384. Comparator [CrossRef]

Aoki T, Kamimura T, Yoshida S, et al. Safety and Seropositivity after Live Attenuated Vaccine in Adult Patients Receiving Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation. 2019;25(8):1576–85. doi: 10.1016/j.bbmt.2019.04.006. Comparator [PubMed: 30959161] [CrossRef]

Aoki T, Koh K, Kawano Y, et al. Safety of Live Attenuated High-Titer Varicella-Zoster Virus Vaccine in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2016;22(4):771–5. doi: 10.1016/j.bbmt.2015.12.025. Participants [PubMed: 26748161] [CrossRef]

Aoshima M, Nakashima K, Ohfuji S. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine for the patients with lung comorbidities; a single center, retrospective, self-controlled case series study. European Respiratory Journal. 2017 Sep;50:2. doi: 10.1183/1393003.congress-2017.PA4515. PMID: WOS:000431748903558. Comparator [CrossRef]

Aplasca-De Los Reyes MR, Dimaano E, Macalalad N, et al. The investigational meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (ACWY-TT) and the seasonal influenza virus vaccine are immunogenic and well-tolerated when co-administered in adults. Human Vaccines and Immunotherapeutics. 2012 July;8(7):881–7. PMID: 2012427210. Study design [PMC free article: PMC3495724] [PubMed: 22485048]

Apter D, Wheeler CM, Paavonen J, et al. Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial. Clinical and vaccine immunology : CVI. 2015;22(4):361–73. doi: 10.1128/CVI.00591-14. Outcome [PMC free article: PMC4375348] [PubMed: 25651922] [CrossRef]

Aqua KA, Basu P, Petit RG. ADXS11-001 immunotherapy targeting HPV-E7: Preliminary safety data from two phase 2 studies in women with CIN 2/3 and with recurrent/refractory cervical cancer. Journal of Immunotherapy. 2011 November-December;34(9):700. Publication type

Arakane R, Annaka R, Takahama A, et al. Superior immunogenicity profile of the new intradermal influenza vaccine compared to the standard subcutaneous vaccine in subjects 65 years and older: A randomized controlled phase III study. Vaccine. 2015;33(48):6650–8. doi: 10.1016/j.vaccine.2015.10.088. Intervention [PubMed: 26519549] [CrossRef]

Arakane R, Nakatani H, Fujisaki E, et al. Immunogenicity and safety of the new intradermal influenza vaccine in adults and elderly: A randomized phase 1/2 clinical trial. Vaccine. 2015;33(46):6340–50. doi: 10.1016/j.vaccine.2015.09.010. Intervention [PubMed: 26431983] [CrossRef]

Araujo EC, Clemens SAC, Oliveira CS, et al. Safety, immunogenicity, and protective efficacy of two doses of RIX4414 live attenuated human rotavirus vaccine in healthy infants. Jornal de Pediatria. 2007 May-Jun;83(3):217–24. PMID: 17380232. Intervention [PubMed: 17380232]

Araujo KLRd, Aquino ECd, Silva LLSd, et al. Factors associated with Severe Acute Respiratory Syndrome in a Brazilian central region. Fatores associados a Sindrome Respiratoria Aguda Grave em uma Regiao Central do Brasil. 2020;25(suppl 2):4121–30. doi: 10.1590/1413-812320202510.2.26802020. Intervention [PubMed: 33027348] [CrossRef]

Ardern-Holmes SL, Lennon D, Pinnock R, et al. Trends in hospitalization and mortality from rotavirus disease in New Zealand infants. Pediatric Infectious Disease Journal. 1999 July;18(7):614–9. PMID: 1999261413 MEDLINE PMID 10440437 (http://www​.ncbi.nlm.nih​.gov/pubmed/10440437). Outcome [PubMed: 10440437]

Arguedas A, Soley C, Abdelnour A, et al. Assessment of the safety, tolerability and kinetics of the immune response to A/H1N1v vaccine formulations with and without adjuvant in healthy pediatric subjects from 3 through 17 years of age. Human Vaccines. 2011 Jan 1;7(1):58–66. PMID: 21285531. Study design [PubMed: 21285531]

Arguedas A, Soley C, Lindert K. Responses to 2009 H1N1 vaccine in children 3 to 17 years of age. N Engl J Med. 2010 Jan 28;362(4):370–2. doi: 10.1056/NEJMc0909988. PMID: 20042746. Study design [PubMed: 20042746] [CrossRef]

Aristegui J, Dal-Re R, Diez-Delgado J, et al. Comparison of the reactogenicity and immunogenicity of a combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa-HBV-IPV) vaccine, mixed with the Haemophilus influenzae type b (Hib) conjugate vaccine and administered as a single injection, with the DTPa-IPV/Hib and hepatitis B vaccines administered in two simultaneous injections to infants at 2, 4 and 6 months of age. Vaccine. 2003 Sep 8;21(25–26):3593–600. PMID: 12922087. Study design [PubMed: 12922087]

Aristegui J, Dal-Re R, Garrote E, et al. Assessment of the immunogenicity and reactogenicity of a quadrivalent diphtheria, tetanus, acellular pertussis and hepatitis B (DTPa-HBV) vaccine administered in a single injection with Haemophilus influenzae type b conjugate vaccine, to infants at 2, 4 and 6 months of age. Vaccine. 1998 Dec;16(20):1976–81. PMID: 9796053. Study design [PubMed: 9796053]

Arkwright PD, Patel L, Moran A, et al. Atopic eczema is associated with delayed maturation of the antibody response to pneumococcal vaccine. Clinical and Experimental Immunology. 2000 2000;122(1):16–9. PMID: 2000364135 MEDLINE PMID 11012612 (http://www​.ncbi.nlm.nih​.gov/pubmed/11012612). Outcome [PMC free article: PMC1905748] [PubMed: 11012612]

Armah. A randomized, controlled trial of the impact of alternative dosing schedules on the immune response to human rotavirus vaccine in rural Ghanaian infants (vol 213, pg 1678, 2016). Journal of Infectious Diseases. 2016 Oct;214(7):1. doi: 10.1093/infdis/jiw265. PMID: WOS:000386137800024. Publication type [PMC free article: PMC4857471] [PubMed: 26823335] [CrossRef]

Armah G, Lewis KDC, Cortese MM, et al. A Randomized, Controlled Trial of the Impact of Alternative Dosing Schedules on the Immune Response to Human Rotavirus Vaccine in Rural Ghanaian Infants. The Journal of infectious diseases. 2016;213(11):1678–85. doi: 10.1093/infdis/jiw023. Intervention [PMC free article: PMC4857471] [PubMed: 26823335] [CrossRef]

Armah GE, Kapikian AZ, Vesikari T, et al. Efficacy, immunogenicity, and safety of two doses of a tetravalent rotavirus vaccine RRV-TV in Ghana with the first dose administered during the neonatal period. The Journal of infectious diseases. 2013;208(3):423–31. doi: 10.1093/infdis/jit174. Intervention [PMC free article: PMC3699001] [PubMed: 23599316] [CrossRef]

Armed Forces Health Surveillance Center. Syncope, active and reserve components, U.S. Armed Forces, 1998–2012. MSMR. 2013 Nov;20(11):5–9. PMID: 24299262. Intervention [PubMed: 24299262]

Armstrong G, Gallagher N, Cabrey P, et al. A population based study comparing changes in rotavirus burden on the Island of Ireland between a highly vaccinated population and an unvaccinated population. Vaccine. 2016;34(39):4718–23. doi: 10.1016/j.vaccine.2016.08.004. Outcome [PubMed: 27527819] [CrossRef]

Armstrong PK, Dowse GK, Effler PV, et al. Epidemiological study of severe febrile reactions in young children in Western Australia caused by a 2010 trivalent inactivated influenza vaccine. BMJ Open. 2011 Jan 1;1(1):e000016. PMID: 22021725. Intervention [PMC free article: PMC3191393] [PubMed: 22021725]

Arnheim-Dahlstrom L, Pasternak B, Svanstrom H, et al. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ (Clinical research ed.). 2013;347:f5906. doi: 10.1136/bmj.f5906. Intervention [PMC free article: PMC3805482] [PubMed: 24108159] [CrossRef]

Arnold WC, Steele RW, Rastogi SP, et al. Response to pneumococcal vaccine in renal allograft recipients. American Journal of Nephrology. 1985;5(1):30–4. PMID: 3881958. Study design [PubMed: 3881958]

Arnou R, Eavis P, Pardo J-RDJ, et al. Immunogenicity, large scale safety and lot consistency of an intradermal influenza vaccine in adults aged 18–60 years: Randomized, controlled, phase III trial. Human Vaccines. 2010 Apr;6(4):346–54. PMID: 20372053. Study design [PubMed: 20372053]

Arnou R, Fiquet A, Thomas S, et al. Immunogenicity and safety of ZOSTAVAX([REGISTERED]) approaching expiry potency in individuals aged >=50 years. Human Vaccines. 2011 Oct;7(10):1060–5. PMID: 21941091. Study design [PMC free article: PMC3256327] [PubMed: 21941091]

Arnou R, Icardi G, De Decker M, et al. Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study. Vaccine. 2009 Dec 9;27(52):7304–12. doi: 10.1016/j.vaccine.2009.10.033. PMID: 19849996. Publication year [PubMed: 19849996] [CrossRef]

Arora NK, Das MK, Poluru R, et al. A prospective cohort study on the safety of infant pentavalent (DTwP-HBV-Hib) and oral polio vaccines in two South Indian districts. Pediatric Infectious Disease Journal. 2020:389–96. doi: 10.1097/INF.0000000000002594. Duplicate [PMC free article: PMC7170438] [PubMed: 32301918] [CrossRef]

Arora NK, Das MK, Poluru R, et al. A Prospective Cohort Study on the Safety of Infant Pentavalent (DTwP-HBV-Hib) and Oral Polio Vaccines in Two South Indian Districts. The Pediatric infectious disease journal. 2020;39(5):389–96. doi: 10.1097/INF.0000000000002594. Intervention [PMC free article: PMC7170438] [PubMed: 32301918] [CrossRef]

Arribas JMM, Martinez AC, Horn M, et al. Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib and PHiD-CV When Coadministered With MenACWY-TT in Infants: Results of an Open, Randomized Trial. Pediatric Infectious Disease Journal. 2018 Jul;37(7):704–14. doi: 10.1097/inf.0000000000002061. PMID: WOS:000435909200022. Intervention [PubMed: 29620722] [CrossRef]

Arribas JMM, Martinez AC, Horn M, et al. Safety and Immunogenicity of the Quadrivalent Meningococcal Serogroups A, C, W and Y Tetanus Toxoid Conjugate Vaccine Coadministered With Routine Childhood Vaccines in European Infants An Open, Randomized Trial. Pediatric Infectious Disease Journal. 2017 Apr;36(4):E98–E107. doi: 10.1097/inf.0000000000001484. PMID: WOS:000396222900004. Intervention [PubMed: 28002359] [CrossRef]

Arriola CS, Vasconez N, Thompson MG, et al. Association of influenza vaccination during pregnancy with birth outcomes in Nicaragua. Vaccine. 2017;35(23):3056–63. doi: 10.1016/j.vaccine.2017.04.045. Outcome [PMC free article: PMC5439533] [PubMed: 28465095] [CrossRef]

Arrizabalaga M, Borjas Y, Penaranda M, et al. Osteoarticular infections caused by Streptococcus pneumoniae since authorization of conjugate vaccines. Afectacion osteoarticular por Streptococcus pneumoniae tras la autorizacion de las vacunas conjugadas. 2019;15(5):e62–e5. doi: 10.1016/j.reuma.2017.05.003. Outcome [PubMed: 28599870] [CrossRef]

Artama M, Rinta-Kokko H, Nohynek H, et al. Register-Based Ecologic Evaluation of Safety Signals Related to Pneumococcal Conjugate Vaccine in Children. Current drug safety. 2018;13(2):107–12. doi: 10.2174/1574886313666180406164151. Intervention [PMC free article: PMC6094555] [PubMed: 29623819] [CrossRef]

Arumugham V. Evidence that Food Proteins in Vaccines Cause the Development of Food Allergies and Its Implications for Vaccine Policy. J Develop Drugs. 2015;4(4):137. Intervention

Arumugham V, Trushin M. Cancer immunology, bioinformatics and chemokine evidence link vaccines contaminated with animal proteins to autoimmune disease: a detailed look at Crohn’s disease and Vitiligo. J. Pharm. Sci. & Res. 2018;10(8):2106–10. Intervention

Arya BK, Bhattacharya SD, Sutcliffe CG, et al. Nasopharyngeal Pneumococcal Colonization and Impact of a Single Dose of 13-Valent Pneumococcal Conjugate Vaccine in Indian Children With HIV and Their Unvaccinated Parents. The Pediatric infectious disease journal. 2018;37(5):451–8. doi: 10.1097/INF.0000000000001800. Participants [PubMed: 28961675] [CrossRef]

Arya BK, Bhattacharya SD, Sutcliffe CG, et al. Immunogenicity and safety of two doses of catch-up immunization with Haemophilus influenzae type b conjugate vaccine in Indian children living with HIV. Vaccine. 2016;34(19):2267–74. doi: 10.1016/j.vaccine.2016.03.012. Comparator [PubMed: 26988256] [CrossRef]

Arya LS, Ghai OP, Saraya AK. Thrombocytopenic purpura following DPT vaccination. Pediatr Hematol Oncol. 1993 Oct-Dec;10(4):381–3. PMID: 8292527. Study design [PubMed: 8292527]

Asahina N, Matsunami Y, Sueda K, et al. Vaccine-associated paralytic poliomyelitis in a non-immunocompromised infant. Pediatrics International. 2010 Oct;52(5):838–41. doi: 10.1111/j.1442-200X.2010.03132.x. PMID: 20880307. Study design [PubMed: 20880307] [CrossRef]

Asante KP, Abdulla S, Agnandji S, et al. Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial.[Erratum appears in Lancet Infect Dis. 2011 Oct;11(10):727]. The Lancet Infectious Diseases. 2011 Oct;11(10):741–9. PMID: 21782519. Study design [PubMed: 21782519]

Asatryan A, Meyer N, Scherbakov M, et al. Immunogenicity, safety, and reactogenicity of combined reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine administered as a booster vaccine dose in healthy Russian participants: a phase III, open-label study. Human Vaccines and Immunotherapeutics. 2020. doi: 10.1080/21645515.2020.1796423. Comparator [PMC free article: PMC7993191] [PubMed: 32845735] [CrossRef]

Asavapiriyanont S, Kittikraisak W, Suntarattiwong P, et al. Tolerability of trivalent inactivated influenza vaccine among pregnant women, 2015. BMC pregnancy and childbirth. 2018;18(1):110. doi: 10.1186/s12884-018-1712-6. Intervention [PMC free article: PMC5913790] [PubMed: 29685106] [CrossRef]

Ascherio A, Zhang SM, Hernan MA, et al. Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med. 2001 Feb 1;344(5):327–32. doi: MJBA-440502 [pii] 10.1056/NEJM200102013440502. PMID: 11172163. Publication year [PubMed: 11172163] [CrossRef]

Asghar Z, Coupland C, Siriwardena N. Influenza vaccination and risk of stroke: Self-controlled case-series study. Vaccine. 2015;33(41):5458–63. doi: 10.1016/j.vaccine.2015.08.013. Intervention [PubMed: 26296496] [CrossRef]

Ashkenazi S, Vertruyen A, Aristegui J, et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J. 2006 Oct;25(10):870–9. doi: 10.1097/01.inf.0000237829.66310.85 00006454-200610000-00004 [pii]. PMID: 17006279. Publication year [PubMed: 17006279] [CrossRef]

Ashok G, Rajendran P, Jayam S, et al. Assessment of immune response and safety of two recombinant hepatitis B vaccines in healthy infants in India. African Journal of Biotechnology. 2011 Oct;10(59). PMID: WOS:000299737800027. Study design

Ashok G, Rajendran P, Jayam S, et al. Assessment of immune response and safety of two recombinant hepatitis B vaccines in healthy infants in India. African Journal of Biotechnology. 2011 3;10(59):12707–10. PMID: 2011562015. Study design

Asindi AA, Bell EJ, Browning MJ, et al. Vaccine-induced polioencephalomyelitis in Scotland. Scottish Medical Journal. 1988 1988;33(4):306–7. PMID: 1988227422 MEDLINE PMID 2847313 (http://www​.ncbi.nlm.nih​.gov/pubmed/2847313). Study design [PubMed: 2847313]

Askling HH, Rombo L, van Vollenhoven R, et al. Hepatitis A vaccine for immunosuppressed patients with rheumatoid arthritis: a prospective, open-label, multi-centre study. Travel medicine and infectious disease. 2014;12(2):134–42. doi: 10.1016/j.tmaid.2014.01.005. Outcome [PubMed: 24529746] [CrossRef]

Aspinall S, Traynor D, Bedford P, et al. Lot-to-lot consistency study of the fully liquid pentavalent DTwP-HepB-Hib vaccine Quinvaxem(registered trademark) demonstrating clinical equivalence, suitability of the vaccine as a booster and concomitant administration with measles vaccine. Human Vaccines and Immunotherapeutics. 2012 August;8(8):1109–18. PMID: 2012533269. Study design [PMC free article: PMC3551883] [PubMed: 22854660]

AstraZeneca. A Phase3 Study to Evaluate the Efficacy and Safety of MEDI3250 in Healthy Japanese Children Age 7 Years Through 18 Years. 2014. Duplicate

Asturias EJ, Bandyopadhyay AS, Self S, et al. Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial. The Lancet. 2016;388(10040):158–69. doi: 10.1016/S0140-6736(16)00703-0. Duplicate [PubMed: 27212429] [CrossRef]

Asturias EJ, Bandyopadhyay AS, Self S, et al. Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial. Lancet (London, England). 2016;388(10040):158–69. doi: 10.1016/S0140-6736(16)00703-0. Intervention [PubMed: 27212429] [CrossRef]

Asturias EJ, Bandyopadhyay AS, Self S, et al. Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial. The Lancet. 2016;388(10040):158–69. doi: 10.1016/S0140-6736(16)00703-0. Duplicate [PubMed: 27212429] [CrossRef]

Asturias EJ, Bandyopadhyay AS, Self S, et al. Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial. Lancet (london, england). 2016;388(10040):158–69. doi: 10.1016/S0140-6736(16)00703-0. PMID: CN-01167932. Duplicate [PubMed: 27212429] [CrossRef]

Asturias EJ, Contreras-Roldan IL, Ram M, et al. Post-authorization safety surveillance of a liquid pentavalent vaccine in Guatemalan children. Vaccine. 2013;31(49):5909–14. doi: 10.1016/j.vaccine.2013.09.015. Intervention [PubMed: 24055354] [CrossRef]

Asturias EJ, Dueger EL, Omer SB, et al. Randomized trial of inactivated and live polio vaccine schedules in Guatemalan infants. Journal of Infectious Diseases. 2007 Sep 1;196(5):692–8. PMID: 17674310. Publication year [PubMed: 17674310]

Atanasovski M, Dele-Michael A, Dasgeb B, et al. A case report of Gianotti-Crosti post vaccination with MMR and dTaP. International Journal of Dermatology. 2011 May;50(5):609–10. PMID: 2011221443 MEDLINE PMID 21506982 (http://www​.ncbi.nlm.nih​.gov/pubmed/21506982). Study design [PubMed: 21506982]

Atchison CJ, Stowe J, Andrews N, et al. Rapid declines in age group-specific rotavirus infection and acute gastroenteritis among vaccinated and unvaccinated individuals within 1 year of rotavirus vaccine introduction in England and Wales. Journal of Infectious Diseases. 2016;213(2):243–9. doi: 10.1093/infdis/jiv398. Outcome [PubMed: 26232438] [CrossRef]

Ateudjieu J, Stoll B, Nguefack-Tsague G, et al. Incidence and types of adverse events during mass vaccination campaign with the meningococcal a conjugate vaccine (MENAFRIVAC) in Cameroon. Pharmacoepidemiology and Drug Safety. 2016 Oct;25(10):1170–8. doi: 10.1002/pds.4027. PMID: WOS:000385483800007. Intervention [PubMed: 27174237] [CrossRef]

Atmar RL, Keitel WA, Quarles JM, et al. Evaluation of age-related differences in the immunogenicity of a G9 H9N2 influenza vaccine. Vaccine. 2011 19;29(45):8066–72. PMID: 2011559946 MEDLINE PMID 21864622 (http://www​.ncbi.nlm.nih​.gov/pubmed/21864622). Intervention [PMC free article: PMC3196602] [PubMed: 21864622]

Atsmon J, Caraco Y, Ziv-Sefer S, et al. Priming by a novel universal influenza vaccine (Multimeric-001)-a gateway for improving immune response in the elderly population. Vaccine. 2014;32(44):5816–23. doi: 10.1016/j.vaccine.2014.08.031. Comparator [PubMed: 25173483] [CrossRef]

Atsmon J, Kate-Ilovitz E, Shaikevich D, et al. Safety and immunogenicity of multimeric-001--a novel universal influenza vaccine. Journal of Clinical Immunology. 2012 Jun;32(3):595–603. PMID: 22318394. Intervention [PubMed: 22318394]

Auffret M, Bene J, Gautier S, et al. Pharmacovigilance monitoring of a cohort of pregnant women vaccinated against influenza A(H1N1) variant virus in the Nord-Pas de Calais region of northern France. European journal of obstetrics, gynecology, and reproductive biology. 2013;170(1):114–8. doi: 10.1016/j.ejogrb.2013.05.025. Intervention [PubMed: 23810001] [CrossRef]

August A, Glenn GM, Kpamegan E, et al. A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age. Vaccine. 2017 Jun;35(30):3749–59. doi: 10.1016/j.vaccine.2017.05.045. PMID: WOS:000404504900008. Intervention [PubMed: 28579233] [CrossRef]

Auriel E, Gadoth A, Regev K, et al. Seasonal and H1N1v influenza vaccines in MS: safety and compliance. Journal of the Neurological Sciences. 2012 Mar 15;314(1–2):102–3. PMID: 22056469. Outcome [PubMed: 22056469]

Auriel E, Regev K, Dori A, et al. Safety of influenza and H1N1 vaccinations in patients with myasthenia gravis, and patient compliance. Muscle & Nerve. 2011 Jun;43(6):893–4. doi: 10.1002/mus.22077. PMID: 21607970. Study design [PubMed: 21607970] [CrossRef]

Austrian R. Prevention of pneumococcal infection by immunization with capsular polysaccharides of Streptococcus pneumoniae: current status of polyvalent vaccines. Journal of Infectious Diseases. 1977 Aug;136 Suppl:S38–42. PMID: 19543. Study design [PubMed: 19543]

Autret E, Jonville-Bera AP, Galy-Eyraud C, et al. [Thrombocytopenic purpura after isolated or combined vaccination against measles, mumps and rubella]. Therapie. 1996 Nov-Dec;51(6):677–80. PMID: 9164004. Not in English [PubMed: 9164004]

Autret-Leca E, Daubin C, Poggi P, et al. Pneumococcal conjugate vaccine: national monitoring of serious adverse effects. Fundamental & Clinical Pharmacology. 2009 Jun;23:88-. PMID: WOS:000268185600444. Publication type

Autret-Leca E, Grimaldi-Bensouda L, Daubin C, et al. Heptavalent pneumococcal conjugate vaccine (PCV7): French survey of serious adverse reactions. Therapie. 2011 January-February;66(1):81–6. PMID: 2011203530. Study design [PubMed: 21466782]

Auvinen A, Hakulinen T, Groves F. Haemophilus influenzae type B vaccination and risk of childhood leukaemia in a vaccine trial in Finland. British Journal of Cancer. 2000 2000;83(7):956–8. PMID: 2000333622 MEDLINE PMID 10970701 (http://www​.ncbi.nlm.nih​.gov/pubmed/10970701). Outcome [PMC free article: PMC2374693] [PubMed: 10970701]

Avalos LA, Ferber J, Zerbo O, et al. Trivalent inactivated influenza vaccine (IIV3) during pregnancy and six-month infant development. Vaccine. 2020;38(10):2326–32. doi: 10.1016/j.vaccine.2020.01.059. Intervention [PMC free article: PMC7309563] [PubMed: 32033850] [CrossRef]

Avdicova M, Prikazsky V, Hudeckova H, et al. Immunogenicity and reactogenicity of a novel hexavalent DTPa-HBV-IPV/Hib vaccine compared to separate concomitant injections of DTPa-IPV/Hib and HBV vaccines, when administered according to a 3, 5 and 11 month vaccination schedule. European Journal of Pediatrics. 2002 Nov;161(11):581–7. PMID: 12424582. Study design [PubMed: 12424582]

Avendano A, Ferreccio C, Lagos R, et al. Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine does not depress serologic responses to diphtheria, tetanus or pertussis antigens when coadministered in the same syringe with diphtheria-tetanus-pertussis vaccine at two, four and six months of age. Pediatric Infectious Disease Journal. 1993 Aug;12(8):638–43. PMID: 8414775. Publication year [PubMed: 8414775]

Avery RK. Influenza vaccines in the setting of solid-organ transplantation: Are they safe? Current Opinion in Infectious Diseases. 2012;15. Study design [PubMed: 22710319]

Avila-Aguero ML, Ulloa-Gutierrez R, Falleiros-Arlant LH, et al. Pneumococcal conjugate vaccines in Latin America: are PCV10 and PCV13 similar in terms of protection against serotype 19A? Expert review of vaccines. 2017;16(7):1–4. doi: 10.1080/14760584.2017.1334555. Outcome [PubMed: 28535704] [CrossRef]

Awadalla M, Golden DLA, Mahmood SS, et al. Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors. Journal for ImmunoTherapy of Cancer. 2019;7(1). doi: 10.1186/s40425-019-0535-y. Intervention [PMC free article: PMC6387531] [PubMed: 30795818] [CrossRef]

Awaidy SA, Bawikar S, Prakash KP, et al. Surveillance of adverse events following immunization: 10 years’ experience in Oman ORIGINAL (NON-ENGLISH) TITLE Surveillance des manifestations postvaccinales indesirables: Dix ans d’experience a Oman. Eastern Mediterranean Health Journal. 2010 May;16(5):474–80. PMID: 2010348624 MEDLINE PMID 20799545 (http://www​.ncbi.nlm.nih​.gov/pubmed/20799545). Study design [PubMed: 20799545]

Ayoola A, Sukumaran S, Kumar R, et al. Efficacy of influenza vaccine (FluVax) in patients on chemotherapy (POCT): final data analysis from South Australia. Annals of oncology. Conference: 41st european society for medical oncology congress, ESMO 2016. Denmark. Conference start: 20161007. Conference end: 20161011. 2016;27(no pagination). doi: 10.1093/annonc/mdw390.54. PMID: CN-01295651. Intervention [CrossRef]

Azcona LR, Roman-Rodriguez M, Bove ML, et al. Prevalence of seasonal influenza vaccination in chronic obstructive pulmonary disease (COPD) patients in the Balearic Islands (Spain) and its effect on COPD exacerbations: A population-based retrospective cohort study. International Journal of Environmental Research and Public Health. 2020;17(11):1–12. doi: 10.3390/ijerph17114027. Intervention [PMC free article: PMC7312905] [PubMed: 32517007] [CrossRef]

Aziz AB, Ali M, Basunia AU, et al. Impact of vaccination on the risk factors for acute rotavirus diarrhea: An analysis of the data of a cluster randomized trial conducted in a rural area of Bangladesh. Vaccine. 2020 Feb;38(9):2190–7. doi: 10.1016/j.vaccine.2020.01.041. PMID: WOS:000518725900014. Duplicate [PubMed: 31983585] [CrossRef]

Aziz AB, Ali M, Basunia AUH, et al. Impact of vaccination on the risk factors for acute rotavirus diarrhea: An analysis of the data of a cluster randomized trial conducted in a rural area of Bangladesh. Vaccine. 2020;38(9):2190–7. doi: 10.1016/j.vaccine.2020.01.041. Outcome [PubMed: 31983585] [CrossRef]

Babu GR, Bhatnagar T. Influenza vaccination to elderly: Quantifying the potential role of unmeasured confounders through an example. Internet Journal of Epidemiology. 2010;9(1). PMID: 2011071658. Outcome

Bachtiar NS, Rusmil K, Sudigoadi S, et al. The immunogenicity and safety of the new Indonesian DTwP-HB-Hib vaccine compared to the DTwP/HB vaccine given with the Hib vaccine. Paediatrica Indonesiana. 2017 May;57(3):129–37. doi: 10.14238/pi57.3.2017.129-37. PMID: WOS:000417410000003. Intervention [CrossRef]

Baden LR, Walsh SR, Seaman MS, et al. First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector. Journal of infectious diseases. 2018;218(4):633–44. doi: 10.1093/infdis/jiy212. PMID: CN-01629558. Intervention [PMC free article: PMC6047429] [PubMed: 29669026] [CrossRef]

Bader MS. Immunization for the elderly. American Journal of the Medical Sciences. 2007 Dec;334(6):481–6. PMID: 18091370. Study design [PubMed: 18091370]

Badsha H, Daher M, Edwards CJ. Live polio vaccine exposure while receiving anti-TNF therapy for reactive arthritis. International Journal of Rheumatic Diseases. 2010 May;13(2):184–6. PMID: 2010348985 MEDLINE PMID 20536606 (http://www​.ncbi.nlm.nih​.gov/pubmed/20536606). Study design [PubMed: 20536606]

Bae WK. A phase II study to assess the immunogenicity and optimal timing of 13-valent pneumococcal conjugated vaccination during adjuvant chemotherapy. Annals of oncology. 2018;29. doi: 10.1093/annonc/mdy444.014. PMID: CN-01934340. Comparator [CrossRef]

Bagarazzi M, Morrow M, Trimble C, et al. HPV-specific immunotherapy (VGX-3100) induces potent T-cell responses and regression of cervical intraepithelial neoplasia in a phase IIB study. International journal of gynecological cancer. 2015;25(9 SUPPL. 1):61–2. doi: 10.1097/01.IGC.0000473498.85773.6e. PMID: CN-01136107. Intervention [CrossRef]

Bagatin D, Augustin G, Bagatin T. Post-vaccination dermatolipomyonecrosis. Wiener Klinische Wochenschrift. 2009 September;121(17 18):551. PMID: 2009604746 MEDLINE PMID 19890743 (http://www​.ncbi.nlm.nih​.gov/pubmed/19890743). Study design [PubMed: 19890743]

Bahl K, Senn JJ, Yuzhakov O, et al. Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses. Molecular Therapy. 2017;25(6):1316–27. doi: 10.1016/j.ymthe.2017.03.035. Intervention [PMC free article: PMC5475249] [PubMed: 28457665] [CrossRef]

Bahl R, Saxena M, Bhandari N, et al. Population-based incidence of intussusception and a case-control study to examine the association of intussusception with natural rotavirus infection among Indian children. Journal of Infectious Diseases. 2009 November;200(SUPPL. 1):S277–S81. PMID: 2010002047 MEDLINE PMID 19817609 (http://www​.ncbi.nlm.nih​.gov/pubmed/19817609). Intervention [PubMed: 19817609]

Baillie VL, Moore DP, Mathunjwa A, et al. A prospective case-control study on the association of Rhinovirus nasopharyngeal viral load and viremia in South African children hospitalized with severe pneumonia. Journal of Clinical Virology. 2020;125. doi: 10.1016/j.jcv.2020.104288. Intervention [PMC free article: PMC7086148] [PubMed: 32092643] [CrossRef]

Bakare N, Menschik D, Tiernan R, et al. Severe combined immunodeficiency (SCID) and rotavirus vaccination: reports to the Vaccine Adverse Events Reporting System (VAERS). Vaccine. 2010 Sep 14;28(40):6609–12. PMID: 20674876. Study design [PubMed: 20674876]

Baker CJ, Kasper DL. Group B streptococcal vaccines. Reviews of Infectious Diseases. 1985 Jul-Aug;7(4):458–67. PMID: 3898306. Study design [PubMed: 3898306]

Baker CJ, Paoletti LC, Rench MA, et al. Immune response of healthy women to 2 different group B streptococcal type V capsular polysaccharide-protein conjugate vaccines. Journal of Infectious Diseases. 2004 Mar;189(6):1103–12. PMID: WOS:000220001100019. Intervention [PubMed: 14999615]

Baker CJ, Paoletti LC, Wessels MR, et al. Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib. Journal of Infectious Diseases. 1999 Jan;179(1):142–50. PMID: 9841833. Intervention [PubMed: 9841833]

Baker CJ, Rench MA, Edwards MS, et al. Immunization of pregnant women with a polysaccharide vaccine of group B streptococcus. New England Journal of Medicine. 1988 Nov 3;319(18):1180–5. PMID: 3050524. Study design [PubMed: 3050524]

Baker JM, Tate JE, Leon J, et al. ASSESSING SERUM ANTI-ROTAVIRUS IMMUNOGLOBULIN A AS A CORRELATE OF VACCINE-INDUCED PROTECTION AGAINST ROTAVIRUS GASTROENTERITIS IN HIGH AND LOW CHILD MORTALITY SETTINGS: ANALYSIS OF POOLED IN DIVIDUAL-LEVEL DATA FROM NINE CLINICAL TRIALS. American Journal of Tropical Medicine and Hygiene. 2019;101:70-. PMID: WOS:000507364502232. Study design

Bakir M, Yagci A, Ulger N, et al. Pharyngeal colonization with Haemophilus influenzae type b among healthy Turkish infants and children. Pediatrics International. 2002 Aug;44(4):381–6. PMID: 12139561. Outcome [PubMed: 12139561]

Baldo V, Baldovin T, Pellegrini M, et al. Immunogenicity of Three Different Influenza Vaccines against Homologous and Heterologous Strains in Nursing Home Elderly Residents. Clinical & Developmental Immunology. 2010. PMID: WOS:000277714800001. Outcome [PMC free article: PMC2847378] [PubMed: 20369059]

Baldo V, Bonanni P, Castro M, et al. Combined hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B- inactivated poliovirus-Haemophilus influenzae type b vaccine-Infanrix (TM) hexa. Human Vaccines & Immunotherapeutics. 2014 Jan;10(1):129–37. doi: 10.4161/hv.26269. PMID: WOS:000336258800019. Intervention [PMC free article: PMC4181021] [PubMed: 24004825] [CrossRef]

Baldo V, Cocchio S, Gallo T, et al. Impact of pneumococcal conjugate vaccination: A retrospective study of hospitalization for pneumonia in North-East Italy. Journal of Preventive Medicine and Hygiene. 2016;57(2):E61–E8. Outcome [PMC free article: PMC4996041] [PubMed: 27582630]

Ball R, Ball LK, Wise RP, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis after vaccination: Reports to the Vaccine Adverse Event Reporting System. Pediatric Infectious Disease Journal. 2001 2001;20(2):219–23. PMID: 2001066762 MEDLINE PMID 11224848 (http://www​.ncbi.nlm.nih​.gov/pubmed/11224848). Study design [PubMed: 11224848]

Balmer P, Orrow RB, Arkwright PD. The 23-valent pneumococcal polysaccharide vaccine does not provide additional serotype antibody protection in children who have been primed with two doses of heptavalent pneumococcal conjugate vaccine. Vaccine. 2007 Aug;25(34):6321–5. PMID: WOS:000248955000006. Outcome [PubMed: 17629373]

Baluch A, Humar A, Egli A, et al. A randomized controlled trial of high-dose intradermal vs. standard intramuscular influenza vaccine in solid organ transplant recipients. American Journal of Transplantation. 2012 May;12 SUPPL. 3:53–4. Publication type

Baluch A, Humar A, Eurich D, et al. Randomized controlled trial of high-dose intradermal versus standard-dose intramuscular influenza vaccine in organ transplant recipients. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2013;13(4):1026–33. doi: 10.1111/ajt.12149. Intervention [PubMed: 23406320] [CrossRef]

Banaszkiewicz A, Gawronska A, Klincewicz B, et al. Immunogenicity of Pertussis Booster Vaccination in Children and Adolescents with Inflammatory Bowel Disease: A Controlled Study. Inflammatory Bowel Diseases. 2017;23(5):847–52. doi: 10.1097/MIB.0000000000001076. Comparator [PubMed: 28394806] [CrossRef]

Banaszkiewicz A, Targonska B, Kowalska-Duplaga K, et al. Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Pediatric Patients with Inflammatory Bowel Disease. Inflammatory bowel diseases. 2015;21(7):1607–14. doi: 10.1097/MIB.0000000000000406. Comparator [PubMed: 25919976] [CrossRef]

Banda R, Yambayamba V, Lalusha BD, et al. Safety of live, attenuated oral vaccines in HIV-infected Zambian adults: Oral vaccines in HIV. Vaccine. 2012 Aug 17;30(38):5656–60. PMID: 22789509. Study design [PMC free article: PMC3778926] [PubMed: 22789509]

Bansil S, Singhal BS, Ahuja GK, et al. Multiple sclerosis in India: a case-control study of environmental exposures. Acta Neurol Scand. 1997 Feb;95(2):90–5. doi: 10.1111/j.1600-0404.1997.tb00075.x. PMID: 9059727. Publication year [PubMed: 9059727] [CrossRef]

Banzhoff A, Haertel S, Praus M. Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations. Human Vaccines. 2011 May;7(5):539–48. PMID: 21422814. Study design [PubMed: 21422814]

Banzhoff A, Stoddard JJ. Effective influenza vaccines for children: A critical unmet medical need and a public health priority. Human Vaccines and Immunotherapeutics. 2012 March;8(3):389–93. PMID: 2012244556. Study design [PMC free article: PMC3426083] [PubMed: 22327501]

Bar-Zeev N, Tate JE, Pecenka C, et al. Cost-Effectiveness of Monovalent Rotavirus Vaccination of Infants in Malawi: A Postintroduction Analysis Using Individual Patient-Level Costing Data. Clinical Infectious Diseases. 2016;62:S220–S8. doi: 10.1093/cid/civ1025. Outcome [PMC free article: PMC4825884] [PubMed: 27059360] [CrossRef]

Barbaud A, Deschildre A, Waton J, et al. Hypersensitivity and vaccines: an update. European Journal of Dermatology. 2013 Apr 1;23(2):135–41. doi: 10.1684/ejd.2012.1842. PMID: 23238161. Study design [PubMed: 23238161] [CrossRef]

Bardage C, Persson I, Ortqvist A, et al. Neurological and autoimmune disorders after vaccination against pandemic influenza A (H1N1) with a monovalent adjuvanted vaccine: population based cohort study in Stockholm, Sweden. BMJ. 2011;343:d5956. doi: 10.1136/bmj.d5956. PMID: 21994316. Intervention [PMC free article: PMC3192001] [PubMed: 21994316] [CrossRef]

Bardenheier BH, Duffy J, Duderstadt SK, et al. Anthrax Vaccine and the Risk of Rheumatoid Arthritis and Systemic Lupus Erythematosus in the U.S. Military: A Case-Control Study. Mil Med. 2016 Oct;181(10):1348–56. doi: 10.7205/milmed-d-15-00485. PMID: 27753574. Intervention [PMC free article: PMC6545587] [PubMed: 27753574] [CrossRef]

Barghash MH, Taimur S, Rana M, et al. Recombinant Herpes Zoster Vaccine (RZV) after Heart Transplantation: A Single Center Experience. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 2020;39(4):S204. doi: 10.1016/j.healun.2020.01.816. Comparator [PubMed: 33067105] [CrossRef]

Baril L, Rosillon D, Willame C, et al. Risk of Spontaneous Abortion in Young Women Exposed to Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Vaccine in the United Kingdom: An Observational Cohort Study. Pharmacoepidemiology and Drug Safety. 2014 Oct;23:491-. PMID: WOS:000342763600904. Study design

Baril L, Rosillon D, Willame C, et al. Risk of spontaneous abortion and other pregnancy outcomes in 15–25 year old women exposed to human papillomavirus-16/18 AS04-adjuvanted vaccine in the United Kingdom. Vaccine. 2015;33(48):6884–91. doi: 10.1016/j.vaccine.2015.07.024. Intervention [PubMed: 26206268] [CrossRef]

Barlow WE, Davis RL, Glasser JW, et al. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. N Engl J Med. 2001 Aug 30;345(9):656–61. doi: 10.1056/NEJMoa003077. PMID: 11547719. Publication year [PubMed: 11547719] [CrossRef]

Barnabas RV, Baeten JM, Lingappa JR, et al. Acyclovir prophylaxis reduces the incidence of herpes zoster among HIV-infected individuals: Results of a randomized clinical trial. Journal of Infectious Diseases. 2016;213(4):551–5. doi: 10.1093/infdis/jiv318. Intervention [PMC free article: PMC4721901] [PubMed: 26142452] [CrossRef]

Barnes G. Intussusception and rotavirus vaccine. Journal of Pediatric Gastroenterology and Nutrition. 1999 1999;29(4):375. PMID: 2000199297 MEDLINE PMID 10512393 (http://www​.ncbi.nlm.nih​.gov/pubmed/10512393). Study design [PubMed: 10512393]

Barnes G, Srivastava A, Carlin J, et al. Delta-F508 cystic fibrosis mutation is not linked to intussusception: implications for rotavirus vaccine. Journal of Paediatrics & Child Health. 2003 Sep-Oct;39(7):516–7. PMID: 12969205. Study design [PubMed: 12969205]

Barnes GL, Lund JS, Adams L, et al. Phase 1 trial of a candidate rotavirus vaccine (RV3) derived from a human neonate. Journal of Paediatrics & Child Health. 1997 Aug;33(4):300–4. PMID: 9323616. Intervention [PubMed: 9323616]

Barnett ED, Pelton SI, Cabral HJ, et al. Immune response to pneumococcal conjugate and polysaccharide vaccines in otitis-prone and otitis-free children. Clinical Infectious Diseases. 1999 1999;29(1):191–2. PMID: 1999252965 MEDLINE PMID 10433584 (http://www​.ncbi.nlm.nih​.gov/pubmed/10433584). Study design [PubMed: 10433584]

Barry DW, Mayner RE, Hochstein HD, et al. Comparative trial of influenza vaccines. II. Adverse reactions in children and adults. Am J Epidemiol. 1976 Jul;104(1):47–59. PMID: 132867. Outcome [PubMed: 132867]

Bart S, Cannon K, Herrington D, et al. Immunogenicity and safety of a cell culture-based quadrivalent influenza vaccine in adults: A Phase III, double-blind, multicenter, randomized, non-inferiority study. Human Vaccines & Immunotherapeutics. 2016;12(9):2278–88. doi: 10.1080/21645515.2016.1182270. PMID: WOS:000384217200022. Duplicate [PMC free article: PMC5027712] [PubMed: 27322354] [CrossRef]

Bart SA, Hohenboken M, Della Cioppa G, et al. A cell culture-derived MF59-adjuvanted pandemic A/H7N9 vaccine is immunogenic in adults. Science translational medicine. 2014;6(234):234ra55. doi: 10.1126/scitranslmed.3008761. Intervention [PubMed: 24786323] [CrossRef]

Bartlett BL, Tyring SK. Safety and efficacy of vaccines. Dermatologic Therapy. 2009 March-April;22(2):97–103. PMID: 2009149338 MEDLINE PMID 19335721 (http://www​.ncbi.nlm.nih​.gov/pubmed/19335721). Study design [PubMed: 19335721]

Barton M, Wasfy S, Dipchand AI, et al. Seven-valent pneumococcal conjugate vaccine in pediatric solid organ transplant recipients: a prospective study of safety and immunogenicity. Pediatric Infectious Disease Journal. 2009 Aug;28(8):688–92. PMID: 19633514. Study design [PubMed: 19633514]

Barug D, Berbers GAM, van Houten MA, et al. Infant antibody levels following 10-valent pneumococcal-protein D conjugate and DTaP-Hib vaccinations in the first year of life after maternal Tdap vaccination: An open-label, parallel, randomised controlled trial. Vaccine. 2020;38(29):4632–9. doi: 10.1016/j.vaccine.2020.04.001. Outcome [PubMed: 32448624] [CrossRef]

Basavaraj VH, Sampath G, Hegde NR, et al. Evaluation of safety and immunogenicity of HNVAC, an MDCK-based H1N1 pandemic influenza vaccine, in Phase I single centre and Phase II/III multi-centre, double-blind, randomized, placebo-controlled, parallel assignment studies. Vaccine. 2014;32(35):4592–7. doi: 10.1016/j.vaccine.2014.05.039. Intervention [PubMed: 24856782] [CrossRef]

Baselga-Moreno V, Trushakova S, McNeil S, et al. Influenza epidemiology and influenza vaccine effectiveness during the 2016–2017 season in the Global Influenza Hospital Surveillance Network (GIHSN). BMC Public Health. 2019;19(1). doi: 10.1186/s12889-019-6713-5. Outcome [PMC free article: PMC6498567] [PubMed: 31046725] [CrossRef]

Bash MC, Lynn F, Mocca B, et al. Development and Use of a Serum Bactericidal Assay Using Pooled Human Complement To Assess Responses to a Meningococcal Group A Conjugate Vaccine in African Toddlers. Clinical and Vaccine Immunology. 2014 May;21(5):755–61. doi: 10.1128/cvi.00812-13. PMID: WOS:000337352300020. Intervention [PMC free article: PMC4018891] [PubMed: 24671551] [CrossRef]

Basilico FC, Bernat JL. Vaccine-associated poliomyelitis in a contact. Journal of the American Medical Association. 1978 1978;239(21):2275. PMID: 1978344721 MEDLINE PMID 650811 (http://www​.ncbi.nlm.nih​.gov/pubmed/650811). Study design [PubMed: 650811]

Basiri-Moghadam M, Kianmehr M, Pasban-Noghabi S, et al. Comparison of EMLA cream with rattles on reducing immunization pain in four months infants. Journal of the Pakistan Medical Association. 2014;64(8):874–8. Intervention [PubMed: 25252510]

Bassily S, Kotkat A, Gray G, et al. Comparative study of the immunogenicity and safety of two dosing schedules of hepatitis B vaccine in neonates. American Journal of Tropical Medicine & Hygiene. 1995 Oct;53(4):419–22. PMID: 7485697. Study design [PubMed: 7485697]

Bassis AV, Fairley JA, Ameln RT, et al. Cutaneous Rosai-Dorfman disease following pneumococcal vaccination. Journal of the American Academy of Dermatology. 2011 October;65(4):890–2. PMID: 2011516782 MEDLINE PMID 21920257 (http://www​.ncbi.nlm.nih​.gov/pubmed/21920257). Study design [PubMed: 21920257]

Bastidas A, de la Serna J, El Idrissi M, et al. Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation: A Randomized Clinical Trial. JAMA. 2019;322(2):123–33. doi: 10.1001/jama.2019.9053. Participants [PMC free article: PMC6618796] [PubMed: 31287523] [CrossRef]

Bastidas A, De La Serna J, El Idrissi M, et al. Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster after Autologous Stem Cell Transplantation: A Randomized Clinical Trial. JAMA - Journal of the American Medical Association. 2019;322(2):123–33. doi: 10.1001/jama.2019.9053. Duplicate [PMC free article: PMC6618796] [PubMed: 31287523] [CrossRef]

Basu I, Supe PD, Agarwal M. Comparison of Immunogenicity and Safety between Two Quadrivalent Influenza Vaccines in Healthy Indian Adults (18–60 Years) and Elderly (? 61 Years) - A Phase III, Active-Controlled, Randomized Clinical Study. Journal of the Association of Physicians of India. 2020;68(1):105-. PMID: CN-02075848. Intervention [PubMed: 31979972]

Batista-Duharte A, Lindblad EB, Oviedo-Orta E. Progress in understanding adjuvant immunotoxicity mechanisms. Toxicology Letters. 2011 10;203(2):97–105. PMID: 2011235888 MEDLINE PMID 21392560 (http://www​.ncbi.nlm.nih​.gov/pubmed/21392560). Study design [PubMed: 21392560]

Batra S, Page B. Shoulder Injury Related to Vaccine Administration: Case Series of an Emerging Occupational Health Concern. Workplace Health and Safety. 2020. doi: 10.1177/2165079920952765. Intervention [PubMed: 32967588] [CrossRef]

Baum U, Auranen K, Kulathinal S, et al. Cohort study design for estimating the effectiveness of seasonal influenza vaccines in real time based on register data: The Finnish example. Scandinavian journal of public health. 2018:1403494818808635. doi: 10.1177/1403494818808635. Outcome [PubMed: 30387371] [CrossRef]

Baum U, Kulathinal S, Auranen K, et al. Effectiveness of two influenza vaccines in nationwide cohorts of Finnish two-year-old children in the seasons 2015/16-2017/18. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2020. doi: 10.1093/cid/ciaa050. Outcome [PubMed: 31955204] [CrossRef]

Baum U, Leino T, Gissler M, et al. Perinatal survival and health after maternal influenza A(H1N1)pdm09 vaccination: A cohort study of pregnancies stratified by trimester of vaccination. Vaccine. 2015;33(38):4850–7. doi: 10.1016/j.vaccine.2015.07.061. Intervention [PubMed: 26238723] [CrossRef]

Bauman ME, Hawkes M, Bruce A, et al. Immunizations in Children Requiring Warfarin Therapy. Journal of Pediatric Hematology/Oncology. 2016;38(8):e329–e32. doi: 10.1097/MPH.0000000000000662. Intervention [PubMed: 27548340] [CrossRef]

Bavdekar A, Oswal J, Ramanan PV, et al. Immunogenicity and safety of measles-mumps-rubella vaccine delivered by disposable-syringe jet injector in India: a randomized, parallel group, non-inferiority trial. Vaccine. 2018;36(9):1220–6. doi: 10.1016/j.vaccine.2018.01.006. PMID: CN-01643053. Duplicate [PMC free article: PMC5818644] [PubMed: 29395526] [CrossRef]

Bavdekar A, Oswal J, Ramanan PV, et al. Immunogenicity and safety of measles-mumps-rubella vaccine delivered by disposable-syringe jet injector in India: A randomized, parallel group, non-inferiority trial. Vaccine. 2018 Feb;36(9):1220–6. doi: 10.1016/j.vaccine.2018.01.006. PMID: WOS:000426407800013. Duplicate [PMC free article: PMC5818644] [PubMed: 29395526] [CrossRef]

Bavdekar A, Oswal J, Ramanan PV, et al. Immunogenicity and safety of measles-mumps-rubella vaccine delivered by disposable-syringe jet injector in India: A randomized, parallel group, non-inferiority trial. Vaccine. 2018;36(9):1220–6. doi: 10.1016/j.vaccine.2018.01.006. Intervention [PMC free article: PMC5818644] [PubMed: 29395526] [CrossRef]

Bavdekar SB, Maiya PP, Subba Rao SD, et al. Immunogenicity and safety of combined diphtheria tetanus whole cell pertussis hepatitis B/ Haemophilus influenzae type b vaccine in Indian infants. Indian Pediatrics. 2007 Jul;44(7):505–10. PMID: 17684303. Study design [PubMed: 17684303]

Baxendale HE, Keating SM, Johnson M, et al. The early kinetics of circulating pneumococcal-specific memory B cells following pneumococcal conjugate and plain polysaccharide vaccines in the elderly. Vaccine. 2010 Jul 5;28(30):4763–70. PMID: 20471437. Outcome [PubMed: 20471437]

Baxter D. Impaired functioning of immune defences to infection in premature and term infants and their implications for vaccination. Human Vaccines. 2010 June;6(6):494–505. PMID: 2010504455 MEDLINE PMID 20519937 (http://www​.ncbi.nlm.nih​.gov/pubmed/20519937). Study design [PubMed: 20519937]

Baxter R, Baine Y, Ensor K, et al. Immunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10 to 25 years of age. Pediatric Infectious Disease Journal. 2011 Mar;30(3):e41–8. PMID: 21200360. Study design [PubMed: 21200360]

Baxter R, Bakshi N, Fireman B, et al. Lack of association of Guillain-Barré syndrome with vaccinations. Clinical Infectious Diseases. 2013;57(2):197–204. doi: 10.1093/cid/cit222. Duplicate [PubMed: 23580737] [CrossRef]

Baxter R, Hansen J, Timbol J, et al. Post-licensure safety surveillance study of routine use of tetanus toxoid, reduced diphtheria toxoid and 5-component acellular pertussis vaccine. Human vaccines & immunotherapeutics. 2016;12(11):2742–8. Participants [PMC free article: PMC5137522] [PubMed: 27388557]

Baxter R, Jeanfreau R, Block SL, et al. A Phase III evaluation of immunogenicity and safety of two trivalent inactivated seasonal influenza vaccines in US children. Pediatric Infectious Disease Journal. 2010 Oct;29(10):924–30. PMID: 20431425. Study design [PubMed: 20431425]

Baxter R, Patriarca PA, Ensor K, et al. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok[REGISTERED] trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50–64 years of age. Vaccine. 2011 Mar 9;29(12):2272–8. PMID: 21277410. Study design [PubMed: 21277410]

Baxter R, Reisinger K, Block SL, et al. Antibody persistence after primary and booster doses of a quadrivalent meningococcal conjugate vaccine in adolescents. Pediatric Infectious Disease Journal. 2014;33(11):1169–76. doi: 10.1097/INF.0000000000000438. Comparator [PubMed: 24911896] [CrossRef]

Baxter RP, Lewis N, Fireman B, et al. Live Attenuated Influenza Vaccination Before 3 Years of Age and Subsequent Development of Asthma: A 14-year Follow-up Study. The Pediatric infectious disease journal. 2018;37(5):383–6. doi: 10.1097/INF.0000000000001783. Intervention [PMC free article: PMC5847407] [PubMed: 28914750] [CrossRef]

Bayard V, DeAntonio R, Contreras R, et al. Impact of rotavirus vaccination on childhood gastroenteritis-related mortality and hospital discharges in Panama. International Journal of Infectious Diseases. 2012 February;16(2):e94–e8. PMID: 2012044273 MEDLINE PMID 22154592 (http://www​.ncbi.nlm.nih​.gov/pubmed/22154592). Outcome [PubMed: 22154592]

Beachler DC, Kreimer AR, Schiffman M, et al. Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection. Journal of the National Cancer Institute. 2016;108(1). doi: 10.1093/jnci/djv302. Duplicate [PMC free article: PMC4862406] [PubMed: 26467666] [CrossRef]

Beachler DC, Kreimer AR, Schiffman M, et al. Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection. Journal of the National Cancer Institute. 2016;108(1). doi: 10.1093/jnci/djv302. Intervention [PMC free article: PMC4862406] [PubMed: 26467666] [CrossRef]

Beals CR, Railkar RA, Schaeffer AK, et al. Immune response and reactogenicity of intradermal administration versus subcutaneous administration of varicella-zoster virus vaccine: an exploratory, randomised, partly blinded trial. The Lancet. Infectious diseases. 2016;16(8):915–22. doi: 10.1016/S1473-3099(16)00133-X. Intervention [PubMed: 27061887] [CrossRef]

Beam TR, Jr., Crigler ED, Goldman JK, et al. Antibody response to polyvalent pneumococcal polysaccharide vaccine in diabetics. JAMA. 1980 Dec 12;244(23):2621–4. PMID: 7431608. Intervention [PubMed: 7431608]

Beau AB, Hurault-Delarue C, Vidal S, et al. Pandemic A/H1N1 influenza vaccination during pregnancy: a comparative study using the EFEMERIS database. Vaccine. 2014;32(11):1254–8. doi: 10.1016/j.vaccine.2014.01.021. Intervention [PubMed: 24486369] [CrossRef]

Beck CR, McKenzie BC, Hashim AB, et al. Influenza vaccination for immunocompromised patients: systematic review and meta-analysis by etiology. Journal of Infectious Diseases. 2012 Oct;206(8):1250–9. PMID: 22904335. Study design [PubMed: 22904335]

Bedford HE, Elliman DAC. The adverse effects of vaccines - Fact and fiction. Current Paediatrics. 2002 2002;12(1):62–6. PMID: 2002014928. Outcome

Bednarczyk RA, Figueroa-Downing D, Ault K. Why is it appropriate to recommend human papillomavirus vaccination as cervical cancer prevention? American Journal of Obstetrics and Gynecology. 2016;214(4):490–3. doi: 10.1016/j.ajog.2015.10.920. Intervention [PMC free article: PMC5689084] [PubMed: 26529369] [CrossRef]

Beeslaar J, Absalon J, Balmer BP, et al. Clinical data supporting a 2-dose schedule of MenB-FHbp, a bivalent meningococcal serogroup B vaccine, in adolescents and young adults. Vaccine. 2018 Jun;36(28):4004–13. doi: 10.1016/j.vaccine.2018.05.060. PMID: WOS:000437815700004. Intervention [PubMed: 29861182] [CrossRef]

Begg NT, Miller E, Fairley CK, et al. Antibody responses and symptoms after DTP and either tetanus or diphtheria Haemophilus influenzae type B conjugate vaccines given for primary immunisation by separate or mixed injection. Vaccine. 1995 Nov;13(16):1547–50. PMID: 8578840. Study design [PubMed: 8578840]

Begg NT, Miller E, Fairley CK, et al. Antibody-Responses and Symptoms after Dtp and Either Tetanus or Diphtheria Haemophilus-Influenzae Type-B Conjugate Vaccines Given for Primary Immunization by Separate or Mixed Injection. Vaccine. 1995 Nov;13(16):1547–50. PMID: WOS:A1995TF20500011. Study design [PubMed: 8578840]

Begue P, Stagnara J, Vie-Le-Sage F, et al. Immunogenicity and reactogenicity of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccines given concurrently with Haemophilus type b conjugate vaccine or as pentavalent vaccine. Pediatric Infectious Disease Journal. 1997 Aug;16(8):787–94. PMID: 9271042. Study design [PubMed: 9271042]

Behjati M, Ayatollahi J. Post BCG lymphadenitis in vaccinated infants in Yazd, Iran. Iranian Journal of Pediatrics. 2008 2008;18(4):351–6. PMID: 2009150463. Intervention

Behre U, Van Der Meeren O, Crasta P, et al. Lasting immune memory against hepatitis B in 12–13-year-old adolescents previously vaccinated with 4 doses of hexavalent DTPa-HBV-IPV/Hib vaccine in infancy. Human Vaccines and Immunotherapeutics. 2016;12(11):2916–20. doi: 10.1080/21645515.2016.1202388. Comparator [PMC free article: PMC5137516] [PubMed: 27653771] [CrossRef]

Belec L, Authier F-J, Gherardi RK. Safety and immunogenicity of hepatitis B vaccine regimens in adults with HIV-1. JAMA. 2011 Jul 13;306(2):156; author reply -7. PMID: 21750288. Study design [PubMed: 21750288]

Bell F, Heath P, MacLennan J, et al. Adverse effects and sero-responses to an acellular pertussis/diphtheria/tetanus vaccine when combined with Haemophilus influenzae type b vaccine in an accelerated schedule. European Journal of Pediatrics. 1999 Apr;158(4):329–36. PMID: 10206134. Study design [PubMed: 10206134]

Bell F, Heath P, Shackley F, et al. Effect of combination with an acellular pertussis, diphtheria, tetanus vaccine on antibody response to Hib vaccine (PRP-T). Vaccine. 1998 Apr;16(6):637–42. PMID: 9569476. Study design [PubMed: 9569476]

Bell F, Martin A, Blondeau C, et al. Combined diphtheria, tetanus, pertussis, and Haemophilus influenzae type b vaccines for primary immunisation. Archives of Disease in Childhood. 1996 Oct;75(4):298–303. PMID: 8984914. Study design [PMC free article: PMC1511738] [PubMed: 8984914]

Belle A, Baumann C, Bigard MA, et al. Impact of immunosuppressive therapy on hepatitis B vaccination in inflammatory bowel diseases. European Journal of Gastroenterology and Hepatology. 2015;27(8):877–81. doi: 10.1097/MEG.0000000000000370. Comparator [PubMed: 26121376] [CrossRef]

Bellinzoni RC, Blackhall J, Baro N, et al. Efficacy of an inactivated oil-adjuvanted rotavirus vaccine in the control of calf diarrhoea in beef herds in Argentina. Vaccine. 1989 1989;7(3):263–8. PMID: 1989174507 MEDLINE PMID 2551102 (http://www​.ncbi.nlm.nih​.gov/pubmed/2551102). Participants [PMC free article: PMC7130949] [PubMed: 2551102]

Belliveau MJ, Kratky V, Evans GA, et al. Acute orbital inflammatory syndrome following H1N1 immunization. Canadian Journal of Ophthalmology. 2011 December;46(6):552–3. PMID: 2011710782 MEDLINE PMID 22153648 (http://www​.ncbi.nlm.nih​.gov/pubmed/22153648). Study design [PubMed: 22153648]

Belongia EA, Irving SA, Shui IM, et al. Real-time surveillance to assess risk of intussusception and other adverse events after pentavalent, bovine-derived rotavirus vaccine. Pediatric Infectious Disease Journal. 2010 Jan;29(1):1–5. PMID: 19907356. Study design [PubMed: 19907356]

Belongia EA, Levine MZ, Olaiya O, et al. Clinical trial to assess immunogenicity of high-dose, adjuvanted, and recombinant influenza vaccines against cell-grown A(H3N2) viruses in adults 65 to 74 years, 2017–2018. Vaccine. 2020;38(15):3121–8. doi: 10.1016/j.vaccine.2020.02.055. Outcome [PubMed: 32145994] [CrossRef]

Belshe RB, Ambrose CS, Yi T. Safety and efficacy of live attenuated influenza vaccine in children 2–7 years of age. Vaccine. 2008 Sep 12;26 Suppl 4:D10–6. doi: 10.1016/j.vaccine.2008.06.083. PMID: 18611422. Publication year [PubMed: 18611422] [CrossRef]

Belshe RB, Edwards KM, Vesikari T, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med. 2007 Feb 15;356(7):685–96. doi: 356/7/685 [pii] 10.1056/NEJMoa065368. PMID: 17301299. Publication year [PubMed: 17301299] [CrossRef]

Belshe RB, Frey SE, Graham I, et al. Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant. Journal of Infectious Diseases. 2011 Mar 1;203(5):666–73. PMID: 21282194. Study design [PMC free article: PMC3071280] [PubMed: 21282194]

Belshe RB, Frey SE, Graham IL, et al. Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial. JAMA. 2014;312(14):1420–8. doi: 10.1001/jama.2014.12609. Intervention [PubMed: 25291578] [CrossRef]

Belshe RB, Gruber WC, Mendelman PM, et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr. 2000 Feb;136(2):168–75. PMID: 10657821. Publication year [PubMed: 10657821]

Belshe RB, Leone PA, Bernstein DI, et al. Efficacy results of a trial of a herpes simplex vaccine. New England Journal of Medicine. 2012 Jan 5;366(1):34–43. PMID: 22216840. Intervention [PMC free article: PMC3287348] [PubMed: 22216840]

Belshe RB, Mendelman PM, Treanor J, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med. 1998 May 14;338(20):1405–12. doi: 10.1056/NEJM199805143382002. PMID: 9580647. Publication year [PubMed: 9580647] [CrossRef]

Belshe RB, Newman FK, Wilkins K, et al. Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults. Vaccine. 2007 Sep 17;25(37–38):6755–63. doi: 10.1016/j.vaccine.2007.06.066. PMID: 17692438. Publication year [PMC free article: PMC2148502] [PubMed: 17692438] [CrossRef]

Belshe RB, Nichol KL, Black SB, et al. Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5–49 years. Clin Infect Dis. 2004 Oct 1;39(7):920–7. doi: CID33259 [pii] 10.1086/423001. PMID: 15472840. Publication year [PubMed: 15472840] [CrossRef]

Ben-Shimol S, Greenberg D, Givon-Lavi N, et al. Impact of PCV7/PCV13 introduction on invasive pneumococcal disease (IPD) in young children: Comparison between meningitis and non-meningitis IPD. Vaccine. 2016;34(38):4543–50. doi: 10.1016/j.vaccine.2016.07.038. Intervention [PubMed: 27475471] [CrossRef]

Bengtsson C, Kapetanovic MC, Kallberg H, et al. Common vaccinations among adults do not increase the risk of developing rheumatoid arthritis: results from the Swedish EIRA study. Ann Rheum Dis. 2010 Oct;69(10):1831–3. doi: ard.2010.129908 [pii] 10.1136/ard.2010.129908. PMID: 20603497. Publication year [PubMed: 20603497] [CrossRef]

Benjamin CM, Chew GC, Silman AJ. Joint and limb symptoms in children after immunisation with measles, mumps, and rubella vaccine. BMJ. 1992 Apr 25;304(6834):1075–8. PMID: 1586818. Publication year [PMC free article: PMC1881909] [PubMed: 1586818]

Benke G, Abramson M, Raven J, et al. Asthma and vaccination history in a young adult cohort. Australian & New Zealand Journal of Public Health. 2004 Aug;28(4):336–8. PMID: 15704697. Publication year [PubMed: 15704697]

Benn CS. Combining vitamin A and vaccines: convenience or conflict? Danish Medical Journal. 2012 Jan;59(1):B4378. PMID: 22239846. Study design [PubMed: 22239846]

Benn CS, Aaby P. Diphtheria-tetanus-pertussis vaccination administered after measles vaccine: Increased female mortality? SOURCE Pediatric Infectious Disease Journal (2012). Date of Publication: 7 Jun 2012. 2012. Study design [PubMed: 22683672]

Benn CS, Fisker AB, Whittle HC, et al. Revaccination with Live Attenuated Vaccines Confer Additional Beneficial Nonspecific Effects on Overall Survival: A Review. EBioMedicine. 2016;10:312–7. doi: 10.1016/j.ebiom.2016.07.016. Intervention [PMC free article: PMC5006692] [PubMed: 27498365] [CrossRef]

Benn CS, Lund S, Fisker A, et al. Should infant girls receive micronutrient supplements? International Journal of Epidemiology. 2009 2009;38(2):586–90. PMID: 2009174576 MEDLINE PMID 19147706 (http://www​.ncbi.nlm.nih​.gov/pubmed/19147706). Study design [PubMed: 19147706]

Bennett EM, Domachowske JB. Progress in adolescent immunization. Clinical Microbiology Newsletter. 2007 1;29(19):143–8. PMID: 2007450065. Outcome

Bennett JV, Fernandez de Castro J, Poblete RM, et al. A new, rapid, and promising approach to aerosol immunization: inflatable bags and valved masks. Vaccine. 2009 Jul 23;27(34):4571–5. doi: 10.1016/j.vaccine.2009.05.086. PMID: 19539584. Study design [PubMed: 19539584] [CrossRef]

Benoit B, Claire PN, Vincent M, et al. Safety and Efficacy of an Inactivated, Unadjuvanted Vaccine Against the Novel Influenza A Variant (H1N1v) in Renal Transplant Recipients (INSERM C09-32, Transfluvac Study). American Journal of Transplantation. 2011 Apr;11:78-. PMID: WOS:000289318400160. Publication type

Bensimon AG, Hernan MA, Gibson T, et al. COMPARATIVE EFFECTIVENESS OF HUMAN PAPILLOMAVIRUS VACCINATION AGAINST CERVICAL ABNORMALITIES BY DOSE LEVEL IN A COHORT OF PRIVATELY-INSURED US GIRLS. Value in Health. 2015 May;18(3):A192–A. doi: 10.1016/j.jval.2015.03.1113. PMID: WOS:000354498503135. Study design [CrossRef]

Benson CA, Andersen JW, Macatangay BJC, et al. Safety and Immunogenicity of Zoster Vaccine Live in Human Immunodeficiency Virus-Infected Adults With CD4(+) Cell Counts > 200 Cells/mL Virologically Suppressed on Antiretroviral Therapy. Clinical Infectious Diseases. 2018 Dec;67(11):1712–9. doi: 10.1093/cid/ciy242. PMID: WOS:000453367200010. Duplicate [PMC free article: PMC6233680] [PubMed: 29590326] [CrossRef]

Benson CA, Andersen JW, Macatangay BJC, et al. Safety and Immunogenicity of Zoster Vaccine Live in Human Immunodeficiency Virus-Infected Adults With CD4+ Cell Counts >200 Cells/mL Virologically Suppressed on Antiretroviral Therapy. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2018;67(11):1712–9. doi: 10.1093/cid/ciy242. Participants [PMC free article: PMC6233680] [PubMed: 29590326] [CrossRef]

Bentsi-Enchill AD, Zongo I, Khamassi S, et al. Monitoring of adverse events during the 2003 mass vaccination campaign with a trivalent meningococcal A/C/W135 polysaccharide vaccine in Burkina Faso. Vaccine. 2007 Sep 3;25 Suppl 1:A72–8. PMID: 17544552. Study design [PubMed: 17544552]

BenYishay A, Kranker K. All-cause mortality reductions from measles catchup campaigns in Africa. Journal of Human Resources. 2015;50(2):516–47. doi: 10.3368/jhr.50.2.516. Outcome [CrossRef]

Beran J, Abdel-Messih IA, Raupachova J, et al. A phase III, randomized, open-label study to assess the tolerability and immunogenicity of an H5N1 influenza vaccine administered to healthy adults with a 1-, 2-, 3-, or 6-week interval between first and second doses. Clinical Therapeutics. 2010 Dec;32(13):2186–97. PMID: 21316535. Intervention [PubMed: 21316535]

Beran J, Beutels M, Levie K, et al. A single dose, combined vaccine against typhoid fever and hepatitis A: consistency, immunogenicity and reactogenicity. Journal of Travel Medicine. 2000 Sep-Oct;7(5):246–52. PMID: 11231208. Study design [PubMed: 11231208]

Beran J, Hobzova L, Wertzova V, et al. Safety and immunogenicity of an investigational adjuvanted hepatitis B vaccine (HB-AS02(V)) in healthy adults. Human Vaccines. 2010 July;6(7):578–84. PMID: 2010520518 MEDLINE PMID 20523113 (http://www​.ncbi.nlm.nih​.gov/pubmed/20523113). Study design [PMC free article: PMC3322521] [PubMed: 20523113]

Beran J, Kervyn D, Wertzova V, et al. Comparison of long-term (10 years) immunogenicity of two- and three-dose regimens of a combined hepatitis A and B vaccine in adolescents. Vaccine. 2010 Aug 23;28(37):5993–7. PMID: 20637766. Study design [PubMed: 20637766]

Beran J, Lickliter JD, Schwarz TF, et al. Safety and Immunogenicity of 3 Formulations of an Investigational Respiratory Syncytial Virus Vaccine in Nonpregnant Women: Results From 2 Phase 2 Trials. The Journal of infectious diseases. 2018;217(10):1616–25. doi: 10.1093/infdis/jiy065. Intervention [PMC free article: PMC5913599] [PubMed: 29401325] [CrossRef]

Beran J, Lickliter JD, Schwarz TF, et al. Safety and Immunogenicity of 3 Formulations of an Investigational Respiratory Syncytial Virus Vaccine in Nonpregnant Women: Results From 2 Phase 2 Trials. Journal of Infectious Diseases. 2018 May;217(10):1616–25. doi: 10.1093/infdis/jiy065. PMID: WOS:000430729800016. Duplicate [PMC free article: PMC5913599] [PubMed: 29401325] [CrossRef]

Beran J, Peeters M, Dewe W, et al. Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults. BMC infectious diseases. 2013;13:224. doi: 10.1186/1471-2334-13-224. Duplicate [PMC free article: PMC3668902] [PubMed: 23688546] [CrossRef]

Beran J, Vesikari T, Wertzova V, et al. Efficacy of inactivated split-virus influenza vaccine against culture-confirmed influenza in healthy adults: a prospective, randomized, placebo-controlled trial. J Infect Dis. 2009 Dec 15;200(12):1861–9. doi: 10.1086/648406. PMID: 19909082. Outcome [PubMed: 19909082] [CrossRef]

Bergen R, Black S, Shinefield H, et al. Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents. Pediatr Infect Dis J. 2004 Feb;23(2):138–44. doi: 10.1097/01.inf.0000109392.96411.4f 00006454-200402000-00010 [pii]. PMID: 14872180. Publication year [PubMed: 14872180] [CrossRef]

Berger F, Njamkepo E, Minaberry S, et al. Investigation on a pertussis outbreak in a military school: risk factors and approach to vaccine efficacy. Vaccine. 2010 Jul 19;28(32):5147–52. PMID: 20541009. Outcome [PubMed: 20541009]

Bergfors E, Hermansson G, Nystrom Kronander U, et al. How common are long-lasting, intensely itching vaccination granulomas and contact allergy to aluminium induced by currently used pediatric vaccines? A prospective cohort study. European journal of pediatrics. 2014;173(10):1297–307. doi: 10.1007/s00431-014-2318-2. Intervention [PubMed: 24752308] [CrossRef]

Bergfors E, Trollfors B, Inerot A. Unexpectedly high incidence of persistent itching nodules and delayed hypersensitivity to aluminium in children after the use of adsorbed vaccines from a single manufacturer. Vaccine. 2003 8;22(1):64–9. PMID: 2003446835 MEDLINE PMID 14604572 (http://www​.ncbi.nlm.nih​.gov/pubmed/14604572). Study design [PubMed: 14604572]

Berglund J, Vink P, Da Silva FT, et al. Safety, immunogenicity, and antibody persistence following an investigational streptococcus pneumoniae and haemophilus influenzae triple-protein vaccine in a phase 1 randomized controlled study in healthy adults. Clinical and Vaccine Immunology. 2014;21(1):56–65. doi: 10.1128/CVI.00430-13. Duplicate [PMC free article: PMC3910926] [PubMed: 24173029] [CrossRef]

Berglund J, Vink P, Tavares Da Silva F, et al. Safety, immunogenicity, and antibody persistence following an investigational Streptococcus pneumoniae and Haemophilus influenzae triple-protein vaccine in a phase 1 randomized controlled study in healthy adults. Clinical and vaccine immunology : CVI. 2014;21(1):56–65. doi: 10.1128/CVI.00430-13. Intervention [PMC free article: PMC3910926] [PubMed: 24173029] [CrossRef]

Berhane Y, Worku A, Demissie M, et al. Children who received PCV-10 vaccine from a two-dose vial without preservative are not more likely to develop injection site abscess compared with those who received pentavalent (DPT-HepB-Hib) vaccine: a longitudinal multi-site study. PloS one. 2014;9(6):e97376. doi: 10.1371/journal.pone.0097376. Intervention [PMC free article: PMC4045572] [PubMed: 24896582] [CrossRef]

Berkowitz CD, Ward JI, Chiu CE, et al. Persistence of antibody and booster responses to reimmunization with Haemophilus influenzae type b polysaccharide and polysaccharide diphtheria toxoid conjugate vaccines in children initially immunized at 15 to 24 months of age. Pediatrics. 1990 Mar;85(3):288–93. PMID: 2304781. Intervention [PubMed: 2304781]

Berkowitz CD, Ward JI, Meier K, et al. Safety and immunogenicity of Haemophilus influenzae type b polysaccharide and polysaccharide diphtheria toxoid conjugate vaccines in children 15 to 24 months of age. Journal of Pediatrics. 1987 Apr;110(4):509–14. PMID: 3550021. Study design [PubMed: 3550021]

Berkowitz EM, Moyle G, Stellbrink H-J, et al. Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study. The Journal of infectious diseases. 2015;211(8):1279–87. doi: 10.1093/infdis/jiu606. Participants [PMC free article: PMC4371767] [PubMed: 25371534] [CrossRef]

Berkowitz EM, Moyle G, Stellbrink HJ, et al. Safety and Immunogenicity of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in HIV-Infected Adults: A Phase 1/2a Randomized, Placebo-Controlled Study. Journal of Infectious Diseases. 2015 Apr;211(8):1279–87. doi: 10.1093/infdis/jiu606. PMID: WOS:000354720900012. Duplicate [PMC free article: PMC4371767] [PubMed: 25371534] [CrossRef]

Bermal N, Alberto E, Hernandez M, et al. Safety and Reactogenicity of a 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D-Conjugate Vaccine (PHiD-CV) in Filipino Infants. International Journal of Infectious Diseases. 2008 Dec;12:E153–E. PMID: WOS:000263287800379. Publication type

Bermal N, Huang L-M, Dubey AP, et al. Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults. Human Vaccines. 2011 Feb;7(2):239–47. PMID: 21343698. Study design [PubMed: 21343698]

Bermal N, Szenborn L, Edison A, et al. Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine coadministered with DTPw-HBV/Hib and poliovirus vaccines. Pediatric Infectious Disease Journal. 2011 Jan;30(1):69–72. PMID: 20980933. Study design [PubMed: 20980933]

Berman-Rosa M, O’Donnell S, Barker M, et al. Efficacy and effectiveness of the PCV-10 and PCV-13 vaccines against invasive pneumococcal disease. Pediatrics. 2020;145(4). doi: 10.1542/peds.2019-0377. Outcome [PubMed: 32156773] [CrossRef]

Berner R, Boisnard F, Thomas S, et al. Safety and immunogenicity of fully liquid DTaP(5)-IPV-Hib pediatric combination vaccine (Pediacel((registered trademark))) compared to DTaP(3)-HBV-IPV/Hib (Infanrix((registered trademark)) Hexa) when coadministered with heptavalent pneumococcal conjugate vaccine (PCV7) as a booster at 11–18 months of age: A phase III, modified double-blind, randomized, controlled, multicenter study. Vaccine. 2012. Study design [PubMed: 22691430]

Berner R, Boisnard F, Thomas S, et al. Safety and immunogenicity of fully liquid DTaP(5)-IPV-Hib pediatric combination vaccine (Pediacel([REGISTERED])) compared to DTaP(3)-HBV-IPV/Hib (Infanrix([REGISTERED]) Hexa) when coadministered with heptavalent pneumococcal conjugate vaccine (PCV7) as a booster at 11–18 months of age: A phase III, modified double-blind, randomized, controlled, multicenter study. Vaccine. 2012 Jul 27;30(35):5270–7. PMID: 22691430. Study design [PubMed: 22691430]

Bernier RH, Frank Jr JA, Dondero Jr TJ, et al. Diphtheria-tetanus toxoids-pertussis vaccination and sudden infant deaths in Tennessee. Journal of Pediatrics. 1982 1982;101(3):419–21. PMID: 1982209354 MEDLINE PMID 7108666 (http://www​.ncbi.nlm.nih​.gov/pubmed/7108666). Study design [PubMed: 7108666]

Bernsen RM, van der Wouden JC. Is childhood immunisation associated with atopic disease from age 7 to 32 years? Thorax. 2007 Oct;62(10):925; author reply 6. PMID: 17909195. Study design [PMC free article: PMC2094236] [PubMed: 17909195]

Bernsen RMD, Koes BW, de Jongste JC, et al. Haemophilus influenzae type b vaccination and reported atopic disorders in 8–12-year-old children. Pediatric Pulmonology. 2006 May;41(5):463–9. PMID: 16547964. Duplicate [PubMed: 16547964]

Bernsen RMD, Nagelkerke NJD, Thijs C, et al. Reported pertussis infection and risk of atopy in 8- to 12-yr-old vaccinated and non-vaccinated children. Pediatric Allergy & Immunology. 2008 Feb;19(1):46–52. PMID: 18086216. Intervention [PubMed: 18086216]

Bernsen RMD, Van Der Wouden JC. Re: No epidemiological evidence for infant vaccinations to cause allergic disease. Vaccine. 2005 10;23(12):1427. PMID: 2005053523 MEDLINE PMID 15670875 (http://www​.ncbi.nlm.nih​.gov/pubmed/15670875). Study design [PubMed: 15670875]

Bernsen RMD, van der Wouden JC. Measles, mumps and rubella infections and atopic disorders in MMR-unvaccinated and MMR-vaccinated children. Pediatric Allergy & Immunology. 2008 Sep;19(6):544–51. PMID: 18266826. Publication year [PubMed: 18266826]

Bernstein D. Efficacy of the pentavalent rotavirus vaccine in subjects after 1 or 2 doses in the rotavirus efficacy and safety trial. Pediatrics. 2008 Jan;121(1):223; author reply -4. PMID: 18166579. Study design [PubMed: 18166579]

Bernstein DI, Atmar RL, Lyon GM, et al. Norovirus vaccine against experimental human GII.4 virus illness: a challenge study in healthy adults. Journal of infectious diseases. 2015;211(6):870–8. doi: 10.1093/infdis/jiu497. PMID: CN-01069605. Intervention [PMC free article: PMC5914500] [PubMed: 25210140] [CrossRef]

Bernstein DI, Glass RI, Rodgers G, et al. Evaluation of rhesus rotavirus monovalent and tetravalent reassortant vaccines in US children. US Rotavirus Vaccine Efficacy Group. JAMA. 1995 Apr 19;273(15):1191–6. PMID: 7707626. Study design [PubMed: 7707626]

Bernstein DI, Guptill J, Naficy A, et al. Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial. The Lancet. Infectious diseases. 2020;20(1):80–91. doi: 10.1016/S1473-3099(19)30393-7. Intervention [PMC free article: PMC6928577] [PubMed: 31630990] [CrossRef]

Bernstein DI, Guptill J, Naficy A, et al. Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial. The Lancet Infectious Diseases. 2020;20(1):80–91. doi: 10.1016/S1473-3099(19)30393-7. Duplicate [PMC free article: PMC6928577] [PubMed: 31630990] [CrossRef]

Bernstein DI, Guptill J, Naficy A, et al. Immunagenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial. Lancet Infectious Diseases. 2020 Jan;20(1):80–91. doi: 10.1016/s1473-3099(19)30393-7. PMID: WOS:000504005300044. Duplicate [PMC free article: PMC6928577] [PubMed: 31630990] [CrossRef]

Bernstein DI, Sack DA, Rothstein E, et al. Efficacy of live, attenuated, human rotavirus vaccine 89–12 in infants: a randomised placebo-controlled trial. Lancet. 1999 Jul 24;354(9175):287–90. PMID: 10440305. Intervention [PubMed: 10440305]

Bernstein DI, Smith VE, Sherwood JR, et al. Safety and immunogenicity of live, attenuated human rotavirus vaccine 89–12. Vaccine. 1998 Feb;16(4):381–7. PMID: 9607059. Intervention [PubMed: 9607059]

Bernstein DI, Smith VE, Sherwood JR, et al. Safety and immnnogenicity of live, attenuated human rotavirus vaccine 89–12. Vaccine. 1998 Feb;16(4):381–7. PMID: 1998005804. Study design [PubMed: 9607059]

Bernstein DI, Ward RL. Rotarix: development of a live attenuated monovalent human rotavirus vaccine. Pediatric Annals. 2006 Jan;35(1):38–43. PMID: 16466074. Study design [PubMed: 16466074]

Bernstein HH, Noriega F. Immunogenicity and safety of a combined diphtheria, tetanus, 5-component acellular pertussis, inactivated poliomyelitis, Haemophilus type b conjugate vaccine when administered concurrently with a pneumococcal conjugate vaccine: A randomized, open-label, phase 3 study. Vaccine. 2011 2011;29(11):2212–21. PMID: 2011104692 MEDLINE PMID 20609398 (http://www​.ncbi.nlm.nih​.gov/pubmed/20609398). Study design [PubMed: 20609398]

Berr C, Puel J, Clanet M, et al. Risk factors in multiple sclerosis: a population-based case-control study in Hautes-Pyrenees, France. Acta Neurol Scand. 1989 Jul;80(1):46–50. doi: 10.1111/j.1600-0404.1989.tb03841.x. PMID: 2782041. Publication year [PMC free article: PMC7159688] [PubMed: 2782041] [CrossRef]

Bettinger JA. Reassuring safety data from the UK multicomponent meningococcal group B vaccine (4CMenB) programme. The Lancet. Child & adolescent health. 2018;2(6):380–1. doi: 10.1016/S2352-4642(18)30135-4. Outcome [PubMed: 30169274] [CrossRef]

Bettoni da Cunha-Riehm C, Hildebrand V, Nathrath M, et al. Vaccination With Live Attenuated Vaccines in Four Children With Chronic Myeloid Leukemia While on Imatinib Treatment. Frontiers in Immunology. 2020;11. doi: 10.3389/fimmu.2020.00628. Comparator [PMC free article: PMC7181227] [PubMed: 32362894] [CrossRef]

Bewley KM, Schwab JG, Ballanco GA, et al. Interchangeability of Haemophilus influenzae type b vaccines in the primary series: evaluation of a two-dose mixed regimen. Pediatrics. 1996 Nov;98(5):898–904. PMID: 8909483. Study design [PubMed: 8909483]

Beyerlein A, Strobl AN, Winkler C, et al. Vaccinations in early life are not associated with development of islet autoimmunity in type 1 diabetes high-risk children: Results from prospective cohort data. Vaccine. 2017;35(14):1735–41. doi: 10.1016/j.vaccine.2017.02.049. Intervention [PubMed: 28268073] [CrossRef]

Beyerlein A, Strobl AN, Winkler C, et al. Vaccinations in early life are not associated with development of islet autoimmunity in type 1 diabetes high-risk children: Results from prospective cohort data. Vaccine. 2017;35(14):1735–41. doi: 10.1016/j.vaccine.2017.02.049. Duplicate [PubMed: 28268073] [CrossRef]

Beytout J, Launay O, Guiso N, et al. Safety of Tdap-IPV given one month after Td-IPV booster in healthy young adults: a placebo-controlled trial. Human Vaccines. 2009 May;5(5):315–21. PMID: 19011374. Intervention [PubMed: 19011374]

Bhaduri S, Roberts M, Williams N. Audit of hepatitis B vaccination in a semi- urban HIV-positive cohort. Hiv Medicine. 2014 Apr;15:134-. PMID: WOS:000333652300410. Study design

Bhandari N, Rongsen-Chandola T, Bavdekar A, et al. Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian children in the second year of life. Vaccine. 2014;32 Suppl 1:A110–6. doi: 10.1016/j.vaccine.2014.04.079. Intervention [PubMed: 25091663] [CrossRef]

Bhandari N, Rongsen-Chandola T, Bavdekar A, et al. Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2014;383(9935):2136–43. doi: 10.1016/S0140-6736(13)62630-6. Intervention [PMC free article: PMC4532697] [PubMed: 24629994] [CrossRef]

Bhandari N, Sharma P, Glass RI, et al. Safety and immunogenicity of two live attenuated human rotavirus vaccine candidates, 116E and I321, in infants: results of a randomised controlled trial. Vaccine. 2006 Jul 26;24(31–32):5817–23. PMID: 16735085. Intervention [PubMed: 16735085]

Bhandari N, Sharma P, Taneja S, et al. A dose-escalation safety and immunogenicity study of live attenuated oral rotavirus vaccine 116E in infants: a randomized, double-blind, placebo-controlled trial. Journal of Infectious Diseases. 2009 Aug 1;200(3):421–9. PMID: 19545211. Study design [PubMed: 19545211]

Bharadwaj AS, Rathod A, Badheka A, et al. Vaccination Serology Status (Non-Pneumococcal and Non-Influenza) and Cardiovascular Mortality: Insights from Nhanes Iii. Journal of the American College of Cardiology. 2011 Apr;57(14):E556–E. PMID: WOS:000291695100557. Publication type

Bhatla N, Suri V, Basu P, et al. Erratum: Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women (The Journal of Obstetrics and Gynaecology Research 36:1 (123–132)). Journal of Obstetrics and Gynaecology Research. 2010 April;36(2):466. PMID: 2010197269. Outcome [PubMed: 20178538]

Bhorat AaE, Madhi SA, Laudat F, et al. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination. AIDS (London, England). 2015;29(11):1345–54. doi: 10.1097/QAD.0000000000000689. Comparator [PMC free article: PMC4521829] [PubMed: 25888646] [CrossRef]

Bhorat AE, Madhi SA, Laudat F, et al. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination. AIDS. 2015;29(11):1345–54. doi: 10.1097/QAD.0000000000000689. Duplicate [PMC free article: PMC4521829] [PubMed: 25888646] [CrossRef]

Bhowmik E, Singh A, Sachan R. Profile of adverse events following immunization with measles rubella vaccine at a tertiary care hospital in East Delhi, India. Therapeutic Advances in Vaccines and Immunotherapy. 2020;8. doi: 10.1177/2515135520940131. Comparator [PMC free article: PMC7343355] [PubMed: 32685913] [CrossRef]

Bhutta ZA, Capeding MR, Bavdekar A, et al. lmmunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials. Lancet Infectious Diseases. 2014 Feb;14(2):119–29. doi: 10.1016/s1473-3099(13)70241-x. PMID: WOS:000330420400025. Intervention [PubMed: 24290843] [CrossRef]

Bi D, Apter D, Eriksson T, et al. Safety of the AS04-adjuvanted human papillomavirus (HPV)-16/18 vaccine in adolescents aged 12–15 years: end-of-study results from a community-randomized study up to 6.5 years. Human vaccines & immunotherapeutics. 2019:1–12. doi: 10.1080/21645515.2019.1692557. Intervention [PMC free article: PMC7482795] [PubMed: 31829767] [CrossRef]

Bi D, Apter D, Eriksson T, et al. Safety of the AS04-adjuvanted human papillomavirus (HPV)-16/18 vaccine in adolescents aged 12–15 years: end-of-study results from a community-randomized study up to 6.5 years. Human Vaccines and Immunotherapeutics. 2019. doi: 10.1080/21645515.2019.1692557. Duplicate [PMC free article: PMC7482795] [PubMed: 31829767] [CrossRef]

Biai S, Rodrigues A, Nielsen J, et al. Vaccination status and sequence of vaccinations as risk factors for hospitalisation among outpatients in a high mortality country. Vaccine. 2011 May;29(20):3662–9. PMID: WOS:000290977700007. Study design [PubMed: 21440640]

Bianchini S, Orabona C, Camilloni B, et al. Effects of probiotic administration on immune responses of children and adolescents with type 1 diabetes to a quadrivalent inactivated influenza vaccine. Human Vaccines and Immunotherapeutics. 2020;16(1):86–94. doi: 10.1080/21645515.2019.1633877. Comparator [PMC free article: PMC7012143] [PubMed: 31210557] [CrossRef]

Billal DS, Hotomi M, Yamanaka N. Rotavirus vaccine for developing countries. The Lancet. 2008 20080809/15;372(9637):444. PMID: 2008373042. Study design [PubMed: 18692705]

Binenbaum G, Christian CW, Guttmann K, et al. Evaluation of Temporal Association Between Vaccinations and Retinal Hemorrhage in Children. Jama Ophthalmology. 2015 Nov;133(11):1261–5. doi: 10.1001/jamaophthalmol.2015.2868. PMID: WOS:000365034000009. Intervention [PMC free article: PMC4910821] [PubMed: 26335082] [CrossRef]

Bines J. Intussusception and rotavirus vaccines. Vaccine. 2006 May 1;24(18):3772–6. PMID: 16099078. Study design [PubMed: 16099078]

Bines JE. Rotavirus vaccines and intussusception risk. Current Opinion in Gastroenterology. 2005 Jan;21(1):20–5. PMID: 15687880. Study design [PubMed: 15687880]

Bines JE, At Thobari J, Satria CD, et al. Human Neonatal Rotavirus Vaccine (RV3-BB) to Target Rotavirus from Birth. The New England journal of medicine. 2018;378(8):719–30. doi: 10.1056/NEJMoa1706804. Intervention [PMC free article: PMC5774175] [PubMed: 29466164] [CrossRef]

Bines JE, Danchin M, Jackson P, et al. Safety and immunogenicity of RV3-BB human neonatal rotavirus vaccine administered at birth or in infancy: A randomised, double-blind, placebo-controlled trial. The Lancet Infectious Diseases. 2015;15(12):1389–97. doi: 10.1016/S1473-3099(15)00227-3. Duplicate [PubMed: 26318715] [CrossRef]

Bines JE, Danchin M, Jackson P, et al. Safety and immunogenicity of RV3-BB human neonatal rotavirus vaccine administered at birth or in infancy: a randomised, double-blind, placebo-controlled trial. Lancet Infectious Diseases. 2015 Dec;15(12):1389–97. doi: 10.1016/s1473-3099(15)00227-3. PMID: WOS:000365144800025. Duplicate [PubMed: 26318715] [CrossRef]

Bingham CO, 3rd, Looney RJ, Deodhar A, et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis & Rheumatism. 2010 Jan;62(1):64–74. PMID: 20039397. Study design [PubMed: 20039397]

Bingham ICO, Rizzo W, Kivitz A, et al. Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: Results of a randomised controlled trial (VISARA). Annals of the Rheumatic Diseases. 2014. doi: 10.1136/annrheumdis-2013-204427. Intervention [PMC free article: PMC4392200] [PubMed: 24448345] [CrossRef]

Bird SM. Febrile convulsions after seasonal influenza immunisation in UK. Lancet. 2011 Jul 30;378(9789):399–400; author reply PMID: 21803201. Study design [PubMed: 21803201]

Bischoff AL, Folsgaard NV, Carson CG, et al. Altered response to A(H1N1)pnd09 vaccination in pregnant women: a single blinded randomized controlled trial. PLoS ONE [Electronic Resource]. 2013;8(4):e56700. doi: 10.1371/journal.pone.0056700. PMID: 23637733. Intervention [PMC free article: PMC3630160] [PubMed: 23637733] [CrossRef]

Bissantz N, Jenke AC, Trampisch M, et al. Hospital-based, prospective, multicentre surveillance to determine the incidence of intussusception in children aged below 15 years in Germany. Bmc Gastroenterology. 2011;11:26. PMID: 21435207. Study design [PMC free article: PMC3079686] [PubMed: 21435207]

Bjune G, Closs O, Froholm LO, et al. Design of clinical trials with an outer membrane vesicle vaccine against systemic serogroup B meningococcal disease in Norway. NIPH Annals. 1991 Dec;14(2):81–91; discussion -3. PMID: 1812439. Study design [PubMed: 1812439]

Black C, Kaye JA, Jick H. MMR vaccine and idiopathic thrombocytopaenic purpura. Br J Clin Pharmacol. 2003 Jan;55(1):107–11. PMID: 12534647. Publication year [PMC free article: PMC1884189] [PubMed: 12534647]

Black S. The clinical impact of pneumococcal conjugate vaccines. American Journal of Managed Care. 1999 Nov;5(SUPPL. 17):S1010–S7. PMID: 2000000365. Study design

Black S. The costs and effectiveness of large Phase III pre-licensure vaccine clinical trials. Expert Review of Vaccines. 2015 Dec;14(12):1543–8. doi: 10.1586/14760584.2015.1091733. PMID: WOS:000364493400001. Outcome [PubMed: 26414015] [CrossRef]

Black S, Friedland LR, Ensor K, et al. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4–6 years of age. Pediatric Infectious Disease Journal. 2008 Apr;27(4):341–6. PMID: 18316985. Study design [PubMed: 18316985]

Black S, Shinefield H. Safety and efficacy of the seven-valent pneumococcal conjugate vaccine: evidence from Northern California. European Journal of Pediatrics. 2002 Dec;161 Suppl 2:S127–31. PMID: 12494258. Study design [PubMed: 12494258]

Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatric Infectious Disease Journal. 2000 Mar;19(3):187–95. PMID: 10749457. Study design [PubMed: 10749457]

Black S, Shinefield H, Ray P, et al. Risk of hospitalization because of aseptic meningitis after measles-mumps-rubella vaccination in one- to two-year-old children: an analysis of the Vaccine Safety Datalink (VSD) Project. Pediatr Infect Dis J. 1997 May;16(5):500–3. PMID: 9154545. Publication year [PubMed: 9154545]

Black S, Shinefield H, Ray P, et al. Postmarketing evaluation of the safety and effectiveness of varicella vaccine. Pediatric Infectious Disease Journal. 1999 December;18(12):1041–6. PMID: 1999436773 MEDLINE PMID 10608621 (http://www​.ncbi.nlm.nih​.gov/pubmed/10608621). Study design [PubMed: 10608621]

Black S, Shinefield H, Ray P, et al. Safety and immunogenicity of heptavalent pneumococcal conjugate vaccine (Wyeth-Lederle) in infancy. Pediatric Research. 1996 Apr;39(4):986-. PMID: WOS:A1996UD23800986. Publication type

Black SB, Cimino CO, Hansen J, et al. Immunogenicity and safety of measles-mumps-rubella, varicella and Haemophilus influenzae type b vaccines administered concurrently with a fourth dose of heptavalent pneumococcal conjugate vaccine compared with the vaccines administered without heptavalent pneumococcal conjugate vaccine. Pediatric Infectious Disease Journal. 2006 Apr;25(4):306–11. PMID: 16567981. Study design [PubMed: 16567981]

Black SB, Shinefield HR. b-CAPSA I Haemophilus influenzae, type b, capsular polysaccharide vaccine safety. Pediatrics. 1987 Mar;79(3):321–5. PMID: 3822630. Study design [PubMed: 3822630]

Black SB, Shinefield HR, Fireman B, et al. Safety, immunogenicity, and efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b vaccine in a United States population: possible implications for optimal use. Journal of Infectious Diseases. 1992 Jun;165 Suppl 1:S139–43. PMID: 1588149. Study design [PubMed: 1588149]

Black SB, Shinefield HR, France EK, et al. Effectiveness of influenza vaccine during pregnancy in preventing hospitalizations and outpatient visits for respiratory illness in pregnant women and their infants. American Journal of Perinatology. 2004 Aug;21(6):333–9. PMID: 15311370. Publication year [PubMed: 15311370]

Black SB, Shinefield HR, Hiatt RH, et al. Safety and Efficacy of Hboc Conjugate Haemophilus Influenzae Type-B Vaccine in 61,000 Infants. Pediatric Research. 1991 Jan;29(1):116-. PMID: WOS:A1991EP11000024. Publication type

Black SB, Shinefield HR, Lampert D, et al. Safety and immunogenicity of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in infancy. The Northern California Kaiser Permanente Vaccine Study Center Pediatrics Group. Pediatric Infectious Disease Journal. 1991 Feb;10(2):92–6. PMID: 2062620. Intervention [PubMed: 2062620]

Black SB, Shinefield HR, Ray P, et al. Safety of combined oligosaccharide conjugate Haemophilus influenzae type b (HbOC) and whole cell diphtheria-tetanus toxoids-pertussis vaccine in infancy. The Kaiser Permanente Pediatric Vaccine Study Group. Pediatric Infectious Disease Journal. 1993 Dec;12(12):981–5. PMID: 8108224. Study design [PubMed: 8108224]

Blanchard Rohner G, Chatzis O, Chinwangso P, et al. Boosting Teenagers With Acellular Pertussis Vaccines Containing Recombinant or Chemically Inactivated Pertussis Toxin: A Randomized Clinical Trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2019;68(7):1213–22. doi: 10.1093/cid/ciy594. Intervention [PubMed: 30759183] [CrossRef]

Blasco GP, Perez-Aramendia MJB. A cost-benefit analysis of varicella vaccination in Aragon. Archivos Argentinos De Pediatria. 2017 Oct;115(5):432–8. doi: 10.5546/aap.2017.eng.432. PMID: WOS:000417562100006. Outcome [PubMed: 28895689] [CrossRef]

Blatter M, Friedland LR, Weston WM, et al. Immunogenicity and safety of a tetanus toxoid, reduced diphtheria toxoid and three-component acellular pertussis vaccine in adults 19–64 years of age. Vaccine. 2009 Jan 29;27(5):765–72. doi: 10.1016/j.vaccine.2008.11.028. PMID: 19041352. Study design [PubMed: 19041352] [CrossRef]

Blatter MM, Klein NP, Shepard JS, et al. Immunogenicity and Safety of two tetravalent (measles, mumps, rubella, varicella) vaccines coadministered with hepatitis a and pneumococcal conjugate vaccines to children twelve to fourteen months of age. Pediatric Infectious Disease Journal. 2012 August;31(8):e133–e40. PMID: 2012419784. Study design [PubMed: 22622699]

Blitshteyn S. Postural tachycardia syndrome after vaccination with Gardasil. European Journal of Neurology. 2010 July;17(7):e52. PMID: 2010352058 MEDLINE PMID 20402758 (http://www​.ncbi.nlm.nih​.gov/pubmed/20402758). Study design [PubMed: 20402758]

Blitshteyn S, Brook J. Postural tachycardia syndrome (POTS) with anti-NMDA receptor antibodies after human papillomavirus vaccination. Immunol Res. 2017 Feb;65(1):282–4. doi: 10.1007/s12026-016-8855-1. PMID: 27561785. Comparator [PubMed: 27561785] [CrossRef]

Block SL, Busman TA, Paris MM, et al. Comparison of five-day cefdinir treatment with ten-day low dose amoxicillin/clavulanate treatment for acute otitis media. Pediatric Infectious Disease Journal. 2004 Sep;23(9):834–8. PMID: 15361722. Outcome [PubMed: 15361722]

Block SL, Nolan T, Sattler C, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics. 2006 Nov;118(5):2135–45. doi: 10.1542/peds.2006-0461. PMID: 17079588. Publication year [PubMed: 17079588] [CrossRef]

Block SL, Ruiz-Palacios GM, Guerrero ML, et al. Dose-range Study of MF59-adjuvanted Versus Nonadjuvanted Monovalent A/H1N1 Pandemic Influenza Vaccine in Six- to Less Than Thirty-Six-month-old Children. Pediatric Infectious Disease Journal. 2012 Jul;31(7):e92–8. PMID: 22481427. Study design [PubMed: 22481427]

Block SL, Shepard J, Garfield H, et al. Immunogenicity and Safety of a 3- and 4-dose Vaccination Series of a Meningococcal ACWY Conjugate Vaccine in Infants: Results of a Phase 3b, Randomized, Open-label Trial. The Pediatric infectious disease journal. 2016;35(2):e48–59. doi: 10.1097/INF.0000000000000965. Comparator [PubMed: 26479973] [CrossRef]

Block SL, Szenborn L, Daly W, et al. A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: Results of a phase 2 randomized, controlled trial. Vaccine. 2015;33(21):2500–10. doi: 10.1016/j.vaccine.2015.03.001. Intervention [PubMed: 25795256] [CrossRef]

Blok BA, de Bree LCJ, Diavatopoulos DA, et al. INTERACTING NON-SPECIFIC IMMUNOLOGICAL EFFECTS OF BCG AND Tdapf VACCINATIONS: AN EXPLORATIVE RANDOMIZED TRIAL. Clinical infectious diseases. 2019. doi: 10.1093/cid/ciz246. PMID: CN-01937019. Duplicate [PubMed: 30919883] [CrossRef]

Blok BA, de Bree LCJ, Diavatopoulos DA, et al. Interacting, Nonspecific, Immunological Effects of Bacille Calmette-Guérin and Tetanus-diphtheria-pertussis Inactivated Polio Vaccinations: An Explorative, Randomized Trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2020;70(3):455–63. doi: 10.1093/cid/ciz246. Intervention [PubMed: 30919883] [CrossRef]

Blom K, Yin L, Arnheim-Dahlstrom L. Effectiveness of the herpes zoster vaccine Zostavax in Stockholm County, Sweden. Vaccine. 2019;37(31):4401–6. doi: 10.1016/j.vaccine.2019.06.008. Outcome [PubMed: 31230884] [CrossRef]

Blom L, Nystrom L, Dahlquist G. The Swedish childhood diabetes study. Vaccinations and infections as risk determinants for diabetes in childhood. Diabetologia. 1991 Mar;34(3):176–81. PMID: 1884889. Publication year [PubMed: 1884889]

Blomberg M, Dehlendorff C, Sand C, et al. Dose-Related Differences in Effectiveness of Human Papillomavirus Vaccination Against Genital Warts: A Nationwide Study of 550,000 Young Girls. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2015;61(5):676–82. doi: 10.1093/cid/civ364. Outcome [PubMed: 25944340] [CrossRef]

Bloom DE, Canning D, Shenoy ES. The effect of vaccination on children’s physical and cognitive development in the Philippines. Applied Economics. 2012;44(21):2777–83. PMID: WOS:000301540200010. Outcome

Bluestone CD. Pneumococcal conjugate vaccine - Impact on otitis media and otolaryngology. Archives of Otolaryngology-Head & Neck Surgery. 2001 Apr;127(4):464–7. PMID: WOS:000167936100022. Outcome [PubMed: 11296063]

Blum MD, Dagan R, Mendelman PM, et al. A comparison of multiple regimens of pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine and pneumococcal polysaccharide vaccine in toddlers. Vaccine. 2000 May 8;18(22):2359–67. PMID: 10738092. Outcome [PubMed: 10738092]

Blyth CC, Cheng AC, Crawford NW, et al. The impact of new universal child influenza programs in Australia: Vaccine coverage, effectiveness and disease epidemiology in hospitalised children in 2018. Vaccine. 2020;38(13):2779–87. doi: 10.1016/j.vaccine.2020.02.031. Outcome [PubMed: 32107062] [CrossRef]

Boccara F, Benhaiem-Sigaux N, Cohen A. Acute myopericarditis after diphtheria, tetanus, and polio vaccination. Chest. 2001 2001;120(2):671–2. PMID: 2001332118 MEDLINE PMID 11502677 (http://www​.ncbi.nlm.nih​.gov/pubmed/11502677). Study design [PubMed: 11502677]

Bocchini Jr JA. Efficacy of the pentavalent rotavirus vaccine in subjects after 1 or 2 doses in the rotavirus efficacy and safety trial: In reply [6]. Pediatrics. 2008 January;121(1):223–4. PMID: 2008022043. Study design [PubMed: 18166579]

Boen M, DeLeon D, Bennett CL, et al. Gardasil: A false sense of immunity? Journal of Clinical Oncology. 2010;28(15):2010–06. Publication type

Bogaards JA, Coupe VMH, Xiridou M, et al. Long-term impact of human papillomavirus vaccination on infection rates, cervical abnormalities, and cancer incidence. Epidemiology. 2011 July;22(4):505–15. PMID: 2011438768 MEDLINE PMID 21540743 (http://www​.ncbi.nlm.nih​.gov/pubmed/21540743). Outcome [PubMed: 21540743]

Boghani DC, Ali QK. Patient with probable side effect of hepatitis vaccination. CME Journal Ophthalmology. 2000 2000;4(3):86–7. PMID: 2001103434. Study design

Bohn-Goldbaum E, Lee VY, Skinner SR, et al. Acute exercise does not improve immune response to HPV vaccination series in adolescents. Papillomavirus Research. 2019;8. doi: 10.1016/j.pvr.2019.100178. Comparator [PMC free article: PMC6658927] [PubMed: 31319174] [CrossRef]

Boikos C, De Serres G, Lands LC, et al. Safety of live-attenuated influenza vaccination in cystic fibrosis. Pediatrics. 2014;134(4):e983–91. doi: 10.1542/peds.2014-0887. Intervention [PubMed: 25225145] [CrossRef]

Boikos C, Joseph L, Scheifele D, et al. Adverse events following live-attenuated intranasal influenza vaccination of children with cystic fibrosis: Results from two influenza seasons. Vaccine. 2017;35(37):5019–26. doi: 10.1016/j.vaccine.2017.07.068. Intervention [PubMed: 28774563] [CrossRef]

Boikos C, Sylvester GC, Sampalis JS, et al. Relative Effectiveness of the Cell-Cultured Quadrivalent Influenza Vaccine Compared to Standard, Egg-Derived Quadrivalent Influenza Vaccines in Preventing Influenza-Like Illness in 2017–2018. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2020. doi: 10.1093/cid/ciaa371. Outcome [PMC free article: PMC7745007] [PubMed: 32253431] [CrossRef]

Boiron L, Joura E, Largeron N, et al. Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria. BMC Infectious Diseases. 2016;16(1). doi: 10.1186/s12879-016-1483-5. Outcome [PMC free article: PMC4833954] [PubMed: 27084683] [CrossRef]

Bol KF, van den Bosch T, Schreibelt G, et al. Adjuvant Dendritic Cell Vaccination in High-Risk Uveal Melanoma. Ophthalmology. 2016;123(10):2265–7. doi: 10.1016/j.ophtha.2016.06.027. Intervention [PubMed: 27476772] [CrossRef]

Bolgiano B, Mawas F, Burkin K, et al. A retrospective study on the quality of Haemophilus influenzae type b vaccines used in the UK between 1996 and 2004. Human Vaccines. 2007 Sep-Oct;3(5):176–82. PMID: 17786035. Outcome [PubMed: 17786035]

Bollaerts K, Shinde V, Dos Santos G, et al. Application of Probabilistic Multiple-Bias Analyses to a Cohort- and a Case-Control Study on the Association between PandemrixTM and Narcolepsy. PloS one. 2016;11(2):e0149289. doi: 10.1371/journal.pone.0149289. Intervention [PMC free article: PMC4762678] [PubMed: 26901063] [CrossRef]

Bomprezzi R, Wildemann B. Acute disseminated encephalomyelitis following vaccination against human papilloma virus. Neurology. 2010 Mar 9;74(10):864; author reply -5. PMID: 20211914. Outcome [PubMed: 20211914]

Bona G, Castiglia P, Zoppi G, et al. Safety and immunogenicity of a CRM or TT conjugated meningococcal vaccine in healthy toddlers. Vaccine. 2016;34(29):3363–70. doi: 10.1016/j.vaccine.2016.05.009. Intervention [PubMed: 27181507] [CrossRef]

Bona G, Castiglia P, Zoppi G, et al. Safety and immunogenicity of a CRM or TT conjugated meningococcal vaccine in healthy toddlers. Vaccine. 2016 Jun;34(29):3363–70. doi: 10.1016/j.vaccine.2016.05.009. PMID: WOS:000378668000006. Duplicate [PubMed: 27181507] [CrossRef]

Bonaldo G, Montanaro N, Vaccheri A, et al. Human papilloma virus vaccination in males: A pharmacovigilance study on the Vaccine Adverse Event Reporting System. British journal of clinical pharmacology. 2020. doi: 10.1111/bcp.14584. Study design [PubMed: 33145777] [CrossRef]

Bonvehi P, Boutriau D, Casellas J, et al. Three doses of an experimental detoxified L3-derived lipooligosaccharide meningococcal vaccine offer good safety but low immunogenicity in healthy young adults. Clinical & Vaccine Immunology: CVI. 2010 Sep;17(9):1460–6. PMID: 20660140. Intervention [PMC free article: PMC2944444] [PubMed: 20660140]

Boonnak K, Dhitavat J, Thantamnu N, et al. Immune responses to intradermal and intramuscular inactivated influenza vaccine among older age group. Vaccine. 2017;35(52):7339–46. doi: 10.1016/j.vaccine.2017.10.106. Intervention [PubMed: 29157960] [CrossRef]

Booy R, Hodgson SA, Slack MPE, et al. Invasive Haemophilus-Influenzae Type-B Disease in the Oxford Region (1985–91). Archives of Disease in Childhood. 1993 Aug;69(2):225–8. PMID: WOS:A1993LQ09400014. Outcome [PMC free article: PMC1029463] [PubMed: 8215526]

Booy R, Nolan T, Reynolds G, et al. Five-year Antibody Persistence and Safety After a Single Dose of Combined Haemophilus influenzae Type B Neisseria meningitidis Serogroup C-Tetanus Toxoid Conjugate Vaccine in Haemophilus influenzae Type B-primed Toddlers. The Pediatric infectious disease journal. 2015;34(12):1379–84. doi: 10.1097/INF.0000000000000898. Intervention [PubMed: 26372451] [CrossRef]

Booy R, Richmond P, Nolan T, et al. Immediate and longer term immunogenicity of a single dose of the combined Haemophilus influenzae type b-Neisseria meningitidis serogroup c-tetanus toxoid conjugate vaccine in primed toddlers 12 to 18 months of age. Pediatric Infectious Disease Journal. 2011 April;30(4):340–2. PMID: 2011214242 MEDLINE PMID 21068692 (http://www​.ncbi.nlm.nih​.gov/pubmed/21068692). Study design [PubMed: 21068692]

Booy R, Taylor SA, Dobson SRM, et al. Immunogenicity and Safety of Prp-T Conjugate Vaccine Given According to the British Accelerated Immunization Schedule. Archives of Disease in Childhood. 1992 Apr;67(4):475–8. PMID: WOS:A1992HR68500002. Study design [PMC free article: PMC1793337] [PubMed: 1580674]

Borba EF, Saad CGS, Calich ALG, et al. The novel pandemic influenza A (H1N1) 2009 vaccine: Low rate of Seroconversion after vaccination in systemic lupus erythematosus. Arthritis and Rheumatism. 2010 2010;62 SUPPL. 10:481. Publication type

Borba EF, Saad CGS, Pasoto SG, et al. Influenza A/H1N1 vaccination of patients with SLE: can antimalarial drugs restore diminished response under immunosuppressive therapy? Rheumatology. 2012 Jun;51(6):1061–9. PMID: 22298793. Study design [PubMed: 22298793]

Borcic B, Dobrovsak-Sourek V, Kaic B, et al. A comparative study of reactogenicity and immunogenicity of an oral and an inactivated polio vaccine. Acta Medica Croatica. 1998;52(3):155–8. PMID: 9818437. Publication year [PubMed: 9818437]

Borja-Tabora C, Montalban C, Memish ZA, et al. Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study. BMC Infectious Diseases. 2013;13:116. doi: 10.1186/1471-2334-13-116. PMID: 23510357. Intervention [PMC free article: PMC3599520] [PubMed: 23510357] [CrossRef]

Borja-Tabora CFC, Montalban C, Memish ZA, et al. Long-term immunogenicity and safety after a single dose of the quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine in adolescents and adults: 5-year follow-up of an open, randomized trial. BMC infectious diseases. 2015;15:409. doi: 10.1186/s12879-015-1138-y. Intervention [PMC free article: PMC4595195] [PubMed: 26437712] [CrossRef]

Borja-Tabora CFC, Peyrani P, Webber C, et al. A phase 2b/3b MenACWY-TT study of long-term antibody persistence after primary vaccination and immunogenicity and safety of a booster dose in individuals aged 11 through 55 years. BMC Infectious Diseases. 2020;20(1). doi: 10.1186/s12879-020-05104-5. Intervention [PMC free article: PMC7301505] [PubMed: 32552685] [CrossRef]

Borner N, Muhlberger N, Jelinek T. Tolerability of multiple vaccinations in travel medicine. Journal of Travel Medicine. 2003 March/April;10(2):112–6. PMID: 2003138738 MEDLINE PMID 12650655 (http://www​.ncbi.nlm.nih​.gov/pubmed/12650655). Study design [PubMed: 12650655]

Borràs E, Urbiztondo L, Carmona G, et al. Effectiveness and impact of the hepatitis B vaccination program in preadolescents in Catalonia 21 years after its introduction. Vaccine. 2019;37(9):1137–41. doi: 10.1016/j.vaccine.2019.01.024. Outcome [PubMed: 30709729] [CrossRef]

Botet Asensi FI, Veronese A, Del Carmen Otero M, et al. Immunogenicity and safety in infants of a DTwPHib full liquid vaccine. Acta Paediatrica. 2003 May;92(5):541–5. PMID: 12839281. Study design [PubMed: 12839281]

Botham SJ, Isaacs D. Incidence of apnoea and bradycardia in preterm infants following triple antigen immunization. J Paediatr Child Health. 1994 Dec;30(6):533–5. PMID: 7865269. Study design [PubMed: 7865269]

Botham SJ, Isaacs D, Henderson-Smart DJ. Incidence of apnoea and bradycardia in preterm infants following DTP(w) and Hib immunization: A prospective study. Journal of Paediatrics and Child Health. 1997 1997;33(5):418–21. PMID: 1997331261 MEDLINE PMID 9401886 (http://www​.ncbi.nlm.nih​.gov/pubmed/9401886). Study design [PubMed: 9401886]

Boudes PF. An Analysis of US Food and Drug Administration Clinical Hold Orders for Drugs and Biologics: A Prospective Study Between 2008 and 2014. Pharmaceutical Medicine. 2015;29(4):203–9. doi: 10.1007/s40290-015-0105-7. Intervention [CrossRef]

Boudville IC, Phua KB, Quak SH, et al. The epidemiology of paediatric intussusception in Singapore: 1997 to 2004. Annals of the Academy of Medicine, Singapore. 2006 Oct;35(10):674–9. PMID: 17102889. Study design [PubMed: 17102889]

Boulagnon C, Leveque N, Renois F, et al. Influenza A/H1N1 (2009) infection as a cause of unexpected out-of-hospital death in the young. Journal of Forensic Sciences. 2012 Nov;57(6):1650–5. doi: 10.1111/j.1556-4029.2012.02180.x. PMID: 22583168. Intervention [PMC free article: PMC7194258] [PubMed: 22583168] [CrossRef]

Bouree P. Immunity and immunization in elderly. Pathologie Biologie. 2003 Dec;51(10):581–5. PMID: 14622949. Study design [PubMed: 14622949]

Boussageon R, Riva C, Michal-Teitelbaum C, et al. VIVIANE study of HPV vaccination. Lancet Infectious Diseases. 2019 Dec;19(12):1281–2. doi: 10.1016/s1473-3099(19)30619-x. PMID: WOS:000499641600020. Publication type [CrossRef]

Bradley SF. Influenza in the elderly: Prevention is the best strategy in high-risk populations. Postgraduate Medicine. 1996 1996;99(2):138–44+46–49. PMID: 1996056403 MEDLINE PMID 8632963 (http://www​.ncbi.nlm.nih​.gov/pubmed/8632963). Study design [PubMed: 8632963]

Brady RC, Hu W, Houchin VG, et al. Randomized trial to compare the safety and immunogenicity of CSL Limited’s 2009 trivalent inactivated influenza vaccine to an established vaccine in United States children. Vaccine. 2014;32(52):7141–7. doi: 10.1016/j.vaccine.2014.10.024. Intervention [PubMed: 25454878] [CrossRef]

Brady RC, Jackson LA, Frey SE, et al. Randomized trial comparing the safety and antibody responses to live attenuated versus inactivated influenza vaccine when administered to breastfeeding women. Vaccine. 2018;36(31):4663–71. doi: 10.1016/j.vaccine.2018.06.036. Intervention [PMC free article: PMC8785652] [PubMed: 29961606] [CrossRef]

Braeckman T, Van Herck K, Raes M, et al. Rotavirus Vaccines in Belgium Policy and Impact. Pediatric Infectious Disease Journal. 2011 Jan;30(1):S21–S4. PMID: WOS:000285795900005. Outcome [PubMed: 21183836]

Brakemeier S, Schweiger B, Lachmann N, et al. Immune response to an adjuvanted influenza A H1N1 vaccine (Pandemrix(registered trademark)) in renal transplant recipients. Nephrology Dialysis Transplantation. 2012 January;27(1):423–8. PMID: 2012075978 MEDLINE PMID 21613386 (http://www​.ncbi.nlm.nih​.gov/pubmed/21613386). Study design [PubMed: 21613386]

Branagan A, Duffy E, Foster C, et al. Two dose series of high-dose influenza vaccine is associated with longer duration of serologic immunity in patients with plasma cell disorders. Blood. 2017;130. PMID: CN-01453301. Outcome

Branagan A, Duffy E, Foster C, et al. Two dose series of high-dose influenza vaccine is associated with longer duration of serologic immunity in patients with plasma cell disorders. Haematologica. 2018;103:41-. PMID: CN-01612549. Participants

Branagan AR, Duffy E, Parker TL, et al. Lower Rates of Influenza Infection Following Two Dose Series of High Dose Vaccination in Plasma Cell Disorders: Results of a Randomized, Double-Blind, Placebo-Assisted Clinical Trial. Blood. 2016 Dec;128(22):5. doi: 10.1182/blood.V128.22.2139.2139. PMID: WOS:000394452504161. Outcome [CrossRef]

Branch H. Results announced from largest double-blind, placebo-controlled vaccine efficacy trial to date. Future Microbiology. 2014 Apr;9(4):437–8. doi: 10.2217/fmb.14.26. PMID: WOS:000335954700003. Study design [CrossRef]

Brandon D, Kimmel M, Kuriyakose SO, et al. Antibody persistence and safety and immunogenicity of a second booster dose nine years after a first booster vaccination with a reduced antigen diphtheria-tetanus-acellular pertussis vaccine (Tdap) in adults. Vaccine. 2018;36(42):6325–33. doi: 10.1016/j.vaccine.2018.08.051. Comparator [PubMed: 30197282] [CrossRef]

Brauner S, Folkersen L, Kvarnstrom M, et al. H1N1 vaccination in Sjogren’s syndrome triggers polyclonal B cell activation and promotes autoantibody production. Annals of the Rheumatic Diseases. 2017 Oct;76(10):1755–63. doi: 10.1136/annrheumdis-2016-210509. PMID: WOS:000410939600028. Intervention [PMC free article: PMC5629946] [PubMed: 28760805] [CrossRef]

Brauner S, Kvarnstom M, Gorgen S, et al. Vaccination of patients with primary Sjogren’s syndrome reveals hyperreactive B cell compartment with a skewed maturation pattern. Annals of the Rheumatic Diseases. 2011 March;70 SUPPL. 2:A67. Publication type

Bravo L, Chitkara A, Liu A, et al. Reactogenicity and safety of the human rotavirus vaccine, Rotarix™ in the Philippines, Sri Lanka, and India: A post-marketing surveillance study. Human Vaccines and Immunotherapeutics. 2014;10(8):2276–83. doi: 10.4161/hv.29280. Duplicate [PMC free article: PMC4896787] [PubMed: 25424932] [CrossRef]

Bravo L, Chitkara A, Liu AX, et al. Reactogenicity and safety of the human rotavirus vaccine, Rotarix (TM) in The Philippines, Sri Lanka, and India A post-marketing surveillance study. Human Vaccines & Immunotherapeutics. 2014;10(8):2276–83. doi: 10.4161/hv.29280. PMID: WOS:000344318300024. Duplicate [PMC free article: PMC4896787] [PubMed: 25424932] [CrossRef]

Bravo L, Chitraka A, Liu A, et al. Reactogenicity and safety of the human rotavirus vaccine, RotarixTM in The Philippines, Sri Lanka, and India: a post-marketing surveillance study. Human vaccines & immunotherapeutics. 2014;10(8):2276–83. doi: 10.4161/hv.29280. Comparator [PMC free article: PMC4896787] [PubMed: 25424932] [CrossRef]

Bravo LC, Carlos JC, Gatchalian SR, et al. Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, compared to standard IPV: A phase 3 observer-blinded, randomised, controlled trial in infants vaccinated at 6, 10, 14 weeks and 9 months of age. Vaccine. 2020 Jan;38(3):530–8. doi: 10.1016/j.vaccine.2019.10.064. PMID: WOS:000509816900014. Duplicate [PMC free article: PMC6983932] [PubMed: 31703934] [CrossRef]

Bravo LC, Carlos JC, Gatchalian SR, et al. Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, compared to standard IPV: A phase 3 observer-blinded, randomised, controlled trial in infants vaccinated at 6, 10, 14weeks and 9months of age. Vaccine. 2019. doi: 10.1016/j.vaccine.2019.10.064. Intervention [PMC free article: PMC6983932] [PubMed: 31703934] [CrossRef]

Bravo LC, Carlos JC, Gatchalian SR, et al. Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, compared to standard IPV: A phase 3 observer-blinded, randomised, controlled trial in infants vaccinated at 6, 10, 14 weeks and 9 months of age. Vaccine. 2020;38(3):530–8. doi: 10.1016/j.vaccine.2019.10.064. Duplicate [PMC free article: PMC6983932] [PubMed: 31703934] [CrossRef]

Bravo-Alcantara P, Perez-Vilar S, Molina-Leon HF, et al. Building capacity for active surveillance of vaccine adverse events in the Americas: A hospital-based multi-country network. Vaccine. 2018;36(3):363–70. doi: 10.1016/j.vaccine.2017.04.069. Intervention [PubMed: 28803714] [CrossRef]

Breiman RF, Brooks WA, Goswami D, et al. A multinational, randomized, placebo-controlled trial to assess the immunogenicity, safety, and tolerability of live attenuated influenza vaccine coadministered with oral poliovirus vaccine in healthy young children. Vaccine. 2009 Sep 4;27(40):5472–9. PMID: 19616493. Study design [PubMed: 19616493]

Breiman RF, Zaman K, Armah G, et al. Analyses of health outcomes from the 5 sites participating in the Africa and Asia clinical efficacy trials of the oral pentavalent rotavirus vaccine. Vaccine. 2012 27;30(SUPPL. 1):A24–A9. PMID: 2012230571 MEDLINE PMID 22520132 (http://www​.ncbi.nlm.nih​.gov/pubmed/22520132). Outcome [PubMed: 22520132]

Bresee JS, El Arifeen S, Azim T, et al. Safety and immunogenicity of tetravalent rhesus-based rotavirus vaccine in Bangladesh. Pediatric Infectious Disease Journal. 2001 Dec;20(12):1136–43. PMID: 11740320. Intervention [PubMed: 11740320]

Brickley EB, Wieland-Alter W, Connor RI, et al. VACCINE-INDUCED MUCOSAL IMMUNITY FROM IPV-BOPV AND IPV-ONLY IMMUNIZATION SCHEDULES: ANALYSIS OF AN OPEN-LABEL, RANDOMIZED CONTROLLED TRIAL IN CHILEAN INFANTS. American Journal of Tropical Medicine and Hygiene. 2017;97(5):234-. PMID: WOS:000423215203119. Study design

Bricks LF, Berezin E. Impact of pneumococcal conjugate vaccine on the prevention of invasive pneumococcal diseases. Jornal de Pediatria. 2006 July/August;82(SUPPL. 1):S67–S74. PMID: 2006533782 MEDLINE PMID 16721440 (http://www​.ncbi.nlm.nih​.gov/pubmed/16721440). Outcome [PubMed: 16721440]

Bricout H, Chabanon AL, Souverain A, et al. Passive enhanced safety surveillance for Vaxigrip and Intanza 15 micro g in the United Kingdom and Finland during the northern hemisphere influenza season 2015/16. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 2017;22(18). doi: 10.2807/1560-7917.ES.2017.22.18.30527. Intervention [PMC free article: PMC5434878] [PubMed: 28494843] [CrossRef]

Bricout H, Chabanon AL, Souverain A, et al. Passive enhanced safety surveillance for vaxigrip and intanza 15 μg in the United Kingdom and Finland during the northern hemisphere influenza season 2015/16. Eurosurveillance. 2017;22(18):1–9. doi: 10.2807/1560-7917.ES.2017.22.18.30527. Duplicate [PMC free article: PMC5434878] [PubMed: 28494843] [CrossRef]

Bridy-Pappas AE, Margolis MB, Center KJ, et al. Streptococcus pneumoniae: description of the pathogen, disease epidemiology, treatment, and prevention. Pharmacotherapy:The Journal of Human Pharmacology & Drug Therapy. 2005 Sep;25(9):1193–212. PMID: 16164394. Study design [PubMed: 16164394]

Brillanti S, Laterza L, Cecinato P, et al. Loss and seroconversion of hepatitis B surface antigen after vaccine therapy in chronic hepatitis B patients treated with nucleoside/nucleotide analogues. Hepatology international. 2013;7:S169–S70. doi: 10.1007/s12072-013-9429-0. PMID: CN-01063466. Publication type [CrossRef]

Brinth L, Theibel AC, Pors K, et al. Suspected side effects to the quadrivalent human papilloma vaccine. Danish medical journal. 2015;62(4):A5064. Intervention [PubMed: 25872549]

Brinth LS, Pors K, Theibel AC, et al. Orthostatic intolerance and postural tachycardia syndrome as suspected adverse effects of vaccination against human papilloma virus. Vaccine. 2015 May 21;33(22):2602–5. doi: 10.1016/j.vaccine.2015.03.098. PMID: 25882168. Comparator [PubMed: 25882168] [CrossRef]

Brisson M, Laprise JF, Chesson HW, et al. Health and Economic Impact of Switching from a 4-Valent to a 9-Valent HPV Vaccination Program in the United States. Journal of the National Cancer Institute. 2016;108(1). doi: 10.1093/jnci/djv282. Outcome [PMC free article: PMC6745694] [PubMed: 26438574] [CrossRef]

Brito MG, Thompson A, Girgenti D, et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in Mexico. Revista Panamericana de Salud Publica/Pan American Journal of Public Health. 2013;33(6):414–21. Duplicate [PubMed: 23939366]

Broder K, Haber P, Miller E, et al. Detecting signals in the vaccine adverse event reporting system. Pharmacoepidemiology and Drug Safety. 2011 August;20 SUPPL. 1:S358. Publication type

Broeders NE, Hombrouck A, Lemy A, et al. Influenza A/H1N1 vaccine in patients treated by kidney transplant or dialysis: a cohort study. Clinical Journal of The American Society of Nephrology: CJASN. 2011 Nov;6(11):2573–8. PMID: 21921153. Study design [PMC free article: PMC3359578] [PubMed: 21921153]

Brond M, Martins CL, Byberg S, et al. Randomized Trial of 2 Versus 1 Dose of Measles Vaccine: Effect on Hospital Admission of Children After 9 Months of Age. Journal of the Pediatric Infectious Diseases Society. 2018;7(3):226–33. doi: 10.1093/jpids/pix042. Intervention [PubMed: 28992261] [CrossRef]

Brønd M, Martins CL, Byberg S, et al. Randomized Trial of 2 Versus 1 Dose of Measles Vaccine: Effect on Hospital Admission of Children After 9 Months of Age. Journal of the Pediatric Infectious Diseases Society. 2018;7(3):226–33. doi: 10.1093/jpids/pix042. Duplicate [PubMed: 28992261] [CrossRef]

Bronowski C, Parker EPK, Sindhu KNC, et al. IMPACT OF THE GUT MICROBIOTA ON ROTAVIRUS VACCINE RESPONSE IN INDIAN, AFRICAN AND EUROPEAN INFANTS: A PROSPECTIVE COHORT STUDY. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2019 Sep;113:S65–S6. PMID: WOS:000493064400164. Study design

Brookhart MA, Walker AM, Lu Y, et al. Characterizing vaccine-associated risks using cubic smoothing splines. American Journal of Epidemiology. 2012 Nov 15;176(10):949–57. doi: 10.1093/aje/kws158. PMID: 23100246. Study design [PubMed: 23100246] [CrossRef]

Brookhart SMA, Li J, Paeglow C, et al. Characterizing vaccine-associated risk using natural smoothing. Pharmacoepidemiology and Drug Safety. 2011 August;20 SUPPL. 1:S260–S1. Publication type

Brooks WA, Chang L-J, Sheng X, et al. Safety and immunogenicity of a trivalent recombinant PcpA, PhtD, and PlyD1 pneumococcal protein vaccine in adults, toddlers, and infants: A phase I randomized controlled study. Vaccine. 2015;33(36):4610–7. doi: 10.1016/j.vaccine.2015.06.078. Intervention [PubMed: 26143615] [CrossRef]

Brooks WA, Chang LJ, Sheng X, et al. Safety and immunogenicity of a trivalent recombinant PcpA, PhtD, and PlyD1 pneumococcal protein vaccine in adults, toddlers, and infants: A phase I randomized controlled study. Vaccine. 2015;33(36):4610–7. doi: 10.1016/j.vaccine.2015.06.078. Duplicate [PubMed: 26143615] [CrossRef]

Brooks WA, Chang LJ, Sheng XH, et al. Safety and immunogenicity of a trivalent recombinant PcpA, PhtD, and PlyD1 pneumococcal protein vaccine in adults, toddlers, and infants: A phase I randomized controlled study. Vaccine. 2015 Aug;33(36):4610–7. doi: 10.1016/j.vaccine.2015.06.078. PMID: WOS:000360867500037. Duplicate [PubMed: 26143615] [CrossRef]

Brooks WA, Zaman K, Lewis KDC, et al. Efficacy of a Russian-backbone live attenuated influenza vaccine among young children in Bangladesh: a randomised, double-blind, placebo-controlled trial. The Lancet. Global health. 2016;4(12):e946–e54. doi: 10.1016/S2214-109X(16)30200-5. Intervention [PMC free article: PMC5118223] [PubMed: 27746226] [CrossRef]

Brophy J, Bitnun A, Alimenti A, et al. Immunogenicity and Safety of the Quadrivalent Human Papillomavirus Vaccine in Girls Living With HIV. The Pediatric infectious disease journal. 2018;37(6):595–7. doi: 10.1097/INF.0000000000001874. Comparator [PubMed: 29278613] [CrossRef]

Brophy J, Bitnun A, Alimenti A, et al. Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in girls living with HIV. Pediatric Infectious Disease Journal. 2018;37(6):595–7. doi: 10.1097/INF.0000000000001874. Duplicate [PubMed: 29278613] [CrossRef]

Brophy JC, Ward BJ, Samson L, et al. Immunogenicity of AS03-adjuvanted H1N1 pandemic influenza vaccine in HIV-infected children. Canadian Journal of Infectious Diseases and Medical Microbiology. 2011 Spring;22 SUPPL. SB:36B. Study design

Brown B, Blas M, Cabral A, et al. Randomized trial of HPV4 vaccine assessing the response to HPV4 vaccine in two schedules among Peruvian female sex workers. Vaccine. 2012 16;30(13):2309–14. PMID: 2012130238 MEDLINE PMID 22306855 (http://www​.ncbi.nlm.nih​.gov/pubmed/22306855). Outcome [PMC free article: PMC3296898] [PubMed: 22306855]

Brown VB, Oluwatosin OA, Akinyemi JO, et al. Effects of Community Health Nurse-Led Intervention on Childhood Routine Immunization Completion in Primary Health Care Centers in Ibadan, Nigeria. Journal of Community Health. 2016 Apr;41(2):265–73. doi: 10.1007/s10900-015-0092-3. PMID: WOS:000371793700009. Intervention [PubMed: 26395786] [CrossRef]

Brückner S, Agnandji ST, Berberich S, et al. Effect of antihelminthic treatment on vaccine immunogenicity to a seasonal influenza vaccine in primary school children in Gabon: A randomized placebo-controlled trial. PLoS Neglected Tropical Diseases. 2015;9(6). doi: 10.1371/journal.pntd.0003768. Intervention [PMC free article: PMC4459874] [PubMed: 26053679] [CrossRef]

Bruun T, Watle SSV, Tveteraas IH, et al. Intussusception among Norwegian children: What to expect after introduction of rotavirus vaccination? Vaccine. 2019;37(38):5717–23. doi: 10.1016/j.vaccine.2019.06.058. Study design [PubMed: 31255303] [CrossRef]

Bryan P, Seabroke S. No increased risk of febrile convulsions after seasonal influenza immunisation in UK. Lancet. 2011 Mar 12;377(9769):904. PMID: 21397766. Study design [PubMed: 21397766]

Bryan P, Seabroke S, Wong J, et al. Safety of multicomponent meningococcal group B vaccine (4CMenB) in routine infant immunisation in the UK: a prospective surveillance study. The Lancet. Child & adolescent health. 2018;2(6):395–403. doi: 10.1016/S2352-4642(18)30103-2. Participants [PubMed: 30169281] [CrossRef]

Bryant KA, Block SL, Baker SA, et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine. Pediatrics. 2010 May;125(5):866–75. PMID: 20435707. Study design [PubMed: 20435707]

Bryant KA, Frenck R, Gurtman A, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 18–49 years of age, naive to 23-valent pneumococcal polysaccharide vaccine. Vaccine. 2015;33(43):5854–60. doi: 10.1016/j.vaccine.2015.08.080. Comparator [PubMed: 26362099] [CrossRef]

Bryant KA, Frenck R, Gurtman A, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 18–49 years of age, naive to 23-valent pneumococcal polysaccharide vaccine. Vaccine. 2015;33(43):5854–60. doi: 10.1016/j.vaccine.2015.08.080. PMID: CN-01169918. Duplicate [PubMed: 26362099] [CrossRef]

Bryant KA, Marshall GS, Marchant CD, et al. Immunogenicity and safety of H influenzae type b-N meningitidis C/Y conjugate vaccine in infants. Pediatrics. 2011 June;127(6):e1375–e85. PMID: 2011303443 MEDLINE PMID 21624883 (http://www​.ncbi.nlm.nih​.gov/pubmed/21624883). Study design [PubMed: 21624883]

Bucardo F, Rippinger CM, Svensson L, et al. Vaccine-derived NSP2 segment in rotaviruses from vaccinated children with gastroenteritis in Nicaragua. Infection, Genetics and Evolution. 2012 August;12(6):1282–94. PMID: 2012327099. Participants [PMC free article: PMC3372771] [PubMed: 22487061]

Bucher J, Boelle PY, Hubert D, et al. Lessons from a French collaborative case-control study in cystic fibrosis patients during the 2009 A/H1N1 influenza pandemy. BMC Infectious Diseases. 2016;16(1). doi: 10.1186/s12879-016-1352-2. Intervention [PMC free article: PMC4736161] [PubMed: 26830335] [CrossRef]

Buchwald UK. Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine. Journal of the american geriatrics society. 2017;65:S48–S9. doi: 10.1111/(ISSN)1445-5994. PMID: CN-01376940. Comparator [CrossRef]

Bucsa C, Bulik N, Farcas A, et al. Reactogenicity and Safety of the Measles-Mumps-Rubella Vaccine: A Prospective Observational Real World Study. Drug Safety. 2018 Nov;41(11):1199-. PMID: WOS:000446470800199. Comparator

Bucșa C, Bulik N, Farcaș A, et al. Adverse events following measles-mumps-rubella vaccination. A prospective observational study. Farmacia. 2020;68(2):219–24. doi: 10.31925/farmacia.2020.2.5. Comparator [CrossRef]

Buettcher M, Baer G, Bonhoeffer J, et al. Three-year surveillance of intussusception in children in Switzerland. Pediatrics. 2007 September;120(3):473–80. PMID: 2007433961 MEDLINE PMID 17766518 (http://www​.ncbi.nlm.nih​.gov/pubmed/17766518). Outcome [PubMed: 17766518]

Buettcher M, Heininger U, Braun M, et al. Hypotonic-hyporesponsive episode (HHE) as an adverse event following immunization in early childhood: Case definition and guidelines for data collection, analysis, and presentation. Vaccine. 2007 1;25(31):5875–81. PMID: 2007335610. Study design [PubMed: 17537554]

Bueving HJ, Bernsen RM, de Jongste JC, et al. Does influenza vaccination exacerbate asthma in children? Vaccine. 2004 Nov 15;23(1):91–6. doi: S0264-410X(04)00411-6 [pii] 10.1016/j.vaccine.2004.03.067. PMID: 15519712. Publication year [PubMed: 15519712] [CrossRef]

Buhler S, Ciurea A, Eperon G, et al. Immunogenicity and safety of tetanus/diphtheria booster vaccine and hepatitis A vaccine in patients with rheumatoid arthritis, spondyloarthritis and vasculitis - a cohort study in 6 Swiss rheumatology centres and 4 travel clinics. Tropical Medicine & International Health. 2015 Sep;20:293-. PMID: WOS:000360758801314. Study design

Buhler S, Jaeger VK, Adler S, et al. Safety and immunogenicity of tetanus/diphtheria vaccination in patients with rheumatic diseases-a prospective multi-centre cohort study. Rheumatology (Oxford, England). 2019;58(9):1585–96. doi: 10.1093/rheumatology/kez045. Comparator [PubMed: 30877773] [CrossRef]

Bühler S, Jaeger VK, Adler S, et al. Safety and immunogenicity of tetanus/diphtheria vaccination in patients with rheumatic diseases-a prospective multi-centre cohort study. Rheumatology (United Kingdom). 2019;58(9):1585–96. doi: 10.1093/rheumatology/kez045. Duplicate [PubMed: 30877773] [CrossRef]

Bulik NB, Bucșa C, Leucuța D, et al. Reactogenicity and medically attended adverse events following hexavalent vaccination: An observational prospective study. Farmacia. 2019;67(6):1018–24. doi: 10.31925/farmacia.2019.6.12. Participants [CrossRef]

Bulkow LR, McMahon BJ, Wainwright RB, et al. Safety and immunogenicity of a combined hepatitis B virus-Haemophilus influenzae type B vaccine formulation in healthy adults. Arctic Medical Research. 1993 Jul;52(3):118–26. PMID: 8397580. Study design [PubMed: 8397580]

Bults M, Kemmeren JM, van der Maas NAT. Adverse events following booster doses of diphtheria-tetanus-inactivated poliovirus and acellular pertussis vaccines for 4-year-old children in The Netherlands. Vaccine. 2007 Jul 20;25(29):5272–7. PMID: 17573165. Study design [PubMed: 17573165]

Bunupuradah T, Ananworanich J, Pancharoen C, et al. Randomized study of intradermal compared to intramuscular hepatitis B vaccination in HIV-infected children without severe immunosuppression. Vaccine. 2011 Apr;29(16):2962–7. PMID: WOS:000290062700021. Study design [PubMed: 21329776]

Burmester GR, Landewe R, Genovese MC, et al. Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis. Annals of the rheumatic diseases. 2017;76(2):414–7. doi: 10.1136/annrheumdis-2016-209322. Intervention [PMC free article: PMC5284339] [PubMed: 27338778] [CrossRef]

Burwen DR, Ball R, Bryan WW, et al. Evaluation of Guillain-Barre Syndrome among recipients of influenza vaccine in 2000 and 2001. Am J Prev Med. 2010 Oct;39(4):296–304. doi: S0749-3797(10)00410-1 [pii] 10.1016/j.amepre.2010.05.022. PMID: 20837279. Publication year [PubMed: 20837279] [CrossRef]

Burwen DR, La Voie L, Braun MM, et al. Evaluating adverse events after vaccination in the Medicare population. Pharmacoepidemiology & Drug Safety. 2007 Jul;16(7):753–61. PMID: 17385786. Outcome [PubMed: 17385786]

Burwen DR, Sandhu SK, MaCurdy TE, et al. Surveillance for Guillain-Barre syndrome after influenza vaccination among the Medicare population, 2009–2010. American Journal of Public Health. 2012 Oct;102(10):1921–7. PMID: 22970693. Study design [PMC free article: PMC3490645] [PubMed: 22970693]

Busse WW, Peters SP, Fenton MJ, et al. Vaccination of patients with mild and severe asthma with a 2009 pandemic H1N1 influenza virus vaccine. Journal of Allergy & Clinical Immunology. 2011 Jan;127(1):130–7, 7.e1–3. PMID: 21145578. Study design [PMC free article: PMC3017653] [PubMed: 21145578]

Butler JC, Breiman RF, Campbell JF, et al. Pneumococcal Polysaccharide Vaccine Efficacy - an Evaluation of Current Recommendations. Jama-Journal of the American Medical Association. 1993 Oct;270(15):1826–31. PMID: WOS:A1993MB46400025. Outcome [PubMed: 8411526]

Butt M, Symington A, Janes M, et al. Respiratory syncytial virus prophylaxis in children with cardiac disease: a retrospective single-centre study. Cardiology in the Young. 2014 Apr;24(2):337–43. doi: 10.1017/s1047951113000401. PMID: WOS:000339484700019. Intervention [PubMed: 23628233] [CrossRef]

Buttery J. A rotavirus vaccine for infants prevented rotavirus gastroenteritis with no increase in risk of intussusception. Evidence-Based Medicine. 2006 Aug;11(4):113. PMID: 2006385636. Duplicate [PubMed: 17213126]

Buttmann M. [Quadrivalent HPV vaccination does not increase MS risk]. Quadrivalente HPV-Impfung erhoht nicht das MS-Risiko. 2015;157(8):33. doi: 10.1007/s15006-015-3024-3. Not in English [PubMed: 26012676] [CrossRef]

Butts C, Socinski MA, Mitchell PL, et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): A randomised, double-blind, phase 3 trial. The Lancet Oncology. 2014;15(1):59–68. doi: 10.1016/S1470-2045(13)70510-2. Intervention [PubMed: 24331154] [CrossRef]

Cachay ER, Mathews Wm C. Use of human papillomavirus vaccine in HIV-infected men for the prevention of anal dysplasia and cancer. AIDS Reviews. 2014;16(2):90–100. Comparator [PubMed: 24818632]

Cadorna-Carlos J, Vidor E, Bonnet MC. Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines. International Journal of Infectious Diseases. 2012 February;16(2):e110–e6. PMID: 2012044276. Study design [PubMed: 22153001]

Cadorna-Carlos JB, Nolan T, Borja-Tabora CF, et al. Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial. Vaccine. 2015;33(21):2485–92. doi: 10.1016/j.vaccine.2015.03.065. Intervention [PubMed: 25843270] [CrossRef]

Cadoz M, Armand J, Arminjon F, et al. A new 23 valent pneumococcal vaccine: immunogenicity and reactogenicity in adults. Journal of Biological Standardization. 1985 Jul;13(3):261–5. PMID: 4030796. Study design [PubMed: 4030796]

Cadranel S, Zeglache S, Jonckheer T, et al. Factors affecting antibody response of newborns to repeated administrations of the rotavirus vaccine RIT 4237. Journal of Pediatric Gastroenterology & Nutrition. 1987 Jul-Aug;6(4):525–8. PMID: 3430259. Intervention [PubMed: 3430259]

Caesar NM, Myers KA, Fan X. Neisseria meningitidis serogroup B vaccine development. Microbial Pathogenesis. 2013 Apr;57:33–40. doi: 10.1016/j.micpath.2013.02.003. PMID: 23416222. Intervention [PubMed: 23416222] [CrossRef]

Cai Y, Rodriguez S, Rameswaran R, et al. Production of pharmaceutical-grade plasmids at high concentration and high supercoiled percentage. Vaccine. 2010 23;28(8):2046–52. PMID: 2010119217 MEDLINE PMID 19896448 (http://www​.ncbi.nlm.nih​.gov/pubmed/19896448). Outcome [PubMed: 19896448]

Caillet C, Durrieu G, Jacquet A, et al. Safety surveillance of influenza A(H1N1)v monovalent vaccines during the 2009–2010 mass vaccination campaign in France. European Journal of Clinical Pharmacology. 2011 Jun;67(6):649–51. PMID: 21153631. Study design [PubMed: 21153631]

Cakir FB, Timur C, Yoruk A, et al. Seroconversion status after single dose and double doses of varicella vaccination in children with leukemia. Pediatric Hematology & Oncology. 2012 Mar;29(2):191–4. PMID: 21787125. Study design [PubMed: 21787125]

Calabrese LH, Abud-Mendoza C, Lindsey S, et al. Evaluation of Live Zoster Vaccine in a Subset of Patients with Rheumatoid Arthritis Treated with Tofacitinib with or without Methotrexate, and Adalimumab with Methotrexate: Results from a Phase 3b/4 Randomized Trial. Arthritis & Rheumatology. 2017 Oct;69:2. PMID: WOS:000411824105235. Comparator

Calabrese LH, Abud-Mendoza C, Lindsey S, et al. EVALUATION OF LIVE ZOSTER VACCINE IN A SUBSET OF PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH TOFACITINIB WITH OR WITHOUT METHOTREXATE, AND ADALIMUMAB WITH METHOTREXATE: RESULTS FROM A PHASE 3B/4 RANDOMISED TRIAL. Annals of the Rheumatic Diseases. 2018 Jun;77:971-. doi: 10.1136/annrheumdis-2018-eular.1469. PMID: WOS:000444351002582. Intervention [CrossRef]

Calabrese LH, Abud-Mendoza C, Lindsey SM, et al. Live Zoster Vaccine in Patients with Rheumatoid Arthritis Treated with Tofacitinib with or without Methotrexate, or Adalimumab with Methotrexate. Arthritis care & research. 2019. doi: 10.1002/acr.24010. PMID: CN-01959798. Participants [PMC free article: PMC7064887] [PubMed: 31207152] [CrossRef]

Calabrese LH, Abud-Mendoza C, Lindsey SM, et al. Live Zoster Vaccine in Patients With Rheumatoid Arthritis Treated With Tofacitinib With or Without Methotrexate, or Adalimumab With Methotrexate: A Post Hoc Analysis of Data From a Phase IIIb/IV Randomized Study. Arthritis Care and Research. 2020;72(3):353–9. doi: 10.1002/acr.24010. Participants [PMC free article: PMC7064887] [PubMed: 31207152] [CrossRef]

Calbo F, Dal-Re R, Diez-Delgado J, et al. Comparative trial to assess the reactogenicity of the diphtheria-tetanusacellular pertussis (DTPa) vaccine plus Haemophilus influenza type b (Hib) conjugate vaccine and that of the diphtheria-tetanus-whole cell pertussis (DTPw) vaccine plus Hib conjugate vaccine, administered in single injection as a booster dose to 14–20 months-old children. Medicina Clinica. 2002 19;118(1):1–4. PMID: 2002064432 MEDLINE PMID 11803003 (http://www​.ncbi.nlm.nih​.gov/pubmed/11803003). Study design [PubMed: 11803003]

Calder P, Miles E, Ramjee M, et al. Effects of scFOS on modulation of immune response in elderly people. Annals of nutrition and metabolism. Conference: 12th european nutrition conference, FENS 2015. Berlin germany. Conference start: 20151020. Conference end: 20151023. Conference publication: (var.pagings). 2015;67:337. doi: 10.1159/000440895. PMID: CN-01267161. Participants [CrossRef]

Caldera F, Hillman L, Saha S, et al. Immunogenicity of High Dose Influenza Vaccine for Patients with Inflammatory Bowel Disease on Anti-TNF Monotherapy: A Randomized Clinical Trial. Inflammatory bowel diseases. 2019. doi: 10.1093/ibd/izz164. Intervention [PubMed: 31504526] [CrossRef]

Caldera F, Saha S, Wald A, et al. RANDOMIZED TRIAL EVALUATING THE IMMUNOGENICITY OF HIGH DOSE VS. STANDARD DOSE INFLUENZA VACCINE IN IBD PATIENTS ON ANTI-TNF MONOTHERAPY. Gastroenterology. 2018 May;154(6):S69–S. PMID: WOS:000450011100197. Intervention

Caldera F, Zhang Y, Megna B, et al. Sustained immune response to measles, mumps and rubella in immunosuppressed inflammatory bowel disease patients. American journal of gastroenterology. Conference: 82nd annual scientific meeting of the american college of gastroenterology. United states. 2017;112(Supplement 1):S406. doi: 10.1038/ajg.2017.303. PMID: CN-01463071. Outcome [CrossRef]

Cale CM, Klein NJ. The link between rotavirus vaccination and intussusception: implications for vaccine strategies. Gut. 2002 Jan;50(1):11–2. PMID: 11772959. Study design [PMC free article: PMC1773072] [PubMed: 11772959]

Callaway E. Smart shots bring Nigeria to brink of polio eradication. Nature. 2015 Jul;523(7560):263–4. doi: 10.1038/523263a. PMID: WOS:000357950900005. Study design [PubMed: 26178940] [CrossRef]

Callejo D, Lopez-Polin A, Blasco JA. Cost utility of human papiloma virus vaccine in Spain. Value in Health. 2010 November;13(7):A258. Publication type

Calmy A, Bel M, Nguyen A, et al. Strong serological responses and HIV RNA increase following AS03-adjuvanted pandemic immunization in HIV-infected patients. HIV Medicine. 2012 April;13(4):207–18. PMID: 2012139702 MEDLINE PMID 22093373 (http://www​.ncbi.nlm.nih​.gov/pubmed/22093373). Study design [PubMed: 22093373]

Calnan M, Krishnarajah G, Duh MS, et al. Rotavirus vaccination in a Medicaid infant population from four US states: compliance, vaccination completion rate, and predictors of compliance. Human Vaccines & Immunotherapeutics. 2016;12(5):1235–43. doi: 10.1080/21645515.2015.1136041. PMID: WOS:000379259100031. Outcome [PMC free article: PMC4963051] [PubMed: 26900728] [CrossRef]

Camacho LH, Betts RF, Wertheim MS, et al. Safety and immunogenicity of heat-treated zoster vaccine (ZV(HT)) in adults with hematologic malignancy (HM). Blood. 2010;116(21):2010–12. Publication type

Camacho-Lovillo MS, Bulnes-Ramos A, Goycochea-Valdivia W, et al. Immunogenicity and safety of influenza vaccination in patients with juvenile idiopathic arthritis on biological therapy using the microneutralization assay. Pediatric rheumatology online journal. 2017;15(1):62. doi: 10.1186/s12969-017-0190-0. Comparator [PMC free article: PMC5547451] [PubMed: 28784185] [CrossRef]

Camerino M, Jackson S, Chinnakotla S, et al. Effects of the influenza vaccine on pediatric kidney transplant outcomes. Pediatric transplantation. 2019;23(2):e13354. doi: 10.1111/petr.13354. Intervention [PubMed: 30714274] [CrossRef]

Cameron E, Ruth L. Safety and effectiveness of human papillomavirus vaccines: umbrella review of systematic reviews. 2019. PMID: CRD42019118971. Study design [PubMed: 31983391]

Cameron RL, Ahmed S, Pollock KGJ. Adverse event monitoring of the human papillomavirus vaccines in Scotland. Internal medicine journal. 2016;46(4):452–7. doi: 10.1111/imj.13005. Intervention [PubMed: 26765074] [CrossRef]

Campagne G, Garba A, Fabre P, et al. Safety and immunogenicity of three doses of a Neisseria meningitidis A + C diphtheria conjugate vaccine in infants from Niger. Pediatric Infectious Disease Journal. 2000 Feb;19(2):144–50. PMID: 10694002. Study design [PubMed: 10694002]

Campbell AL, Bryant KA. Routine childhood immunizations. Primary Care; Clinics in Office Practice. 2001 Dec;28(4):713–38, vi. PMID: 11739027. Study design [PubMed: 11739027]

Campbell H, Byass P, Ahonkhai VI, et al. Serologic responses to an Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine in very young Gambian infants. Pediatrics. 1990 Jul;86(1):102–7. PMID: 2113671. Study design [PubMed: 2113671]

Campbell JD, Chambers CV, Brady RC, et al. Immunologic non-inferiority of a newly licensed inactivated trivalent influenza vaccine versus an established vaccine: a randomized study in US adults. Human Vaccines. 2011 Jan 1;7(1):81–8. PMID: 21285532. Study design [PMC free article: PMC3062242] [PubMed: 21285532]

Campbell WN, Hendrix E, Cryz S, Jr., et al. Immunogenicity of a 24-valent Klebsiella capsular polysaccharide vaccine and an eight-valent Pseudomonas O-polysaccharide conjugate vaccine administered to victims of acute trauma. Clinical Infectious Diseases. 1996 Jul;23(1):179–81. PMID: 8816151. Study design [PubMed: 8816151]

Campitelli MA, Rosella LC, Stukel TA, et al. Influenza vaccination and all-cause mortality in community-dwelling elderly in Ontario, Canada, a cohort study. Vaccine. 2010 Dec 16;29(2):240–6. PMID: 21044667. Outcome [PubMed: 21044667]

Canaday D, Oswald D, Hoffman S, et al. Frailty correlates with age and inflammatory markers but not flu vaccine response in an older veteran cohort. Journal of Immunology. 2014 May;192:1. PMID: WOS:000209765002126. Outcome

Candela S, Pergolizzi S, Ragni P, et al. An early (3–6 weeks) active surveillance study to assess the safety of pandemic influenza vaccine Focetria in a province of Emilia-Romagna region, Italy - part one. Vaccine. 2013 Feb 27;31(10):1431–7. doi: 10.1016/j.vaccine.2012.06.030. PMID: 22766247. Intervention [PubMed: 22766247] [CrossRef]

Canelle Q, Dewe W, Innis BL, et al. Evaluation of potential immunogenicity differences between Pandemrix and Arepanrix. Human Vaccines & Immunotherapeutics. 2016;12(9):2289–98. doi: 10.1080/21645515.2016.1168954. PMID: WOS:000384217200023. Intervention [PMC free article: PMC5027709] [PubMed: 27105343] [CrossRef]

Caniza MA, Hunger SP, Schrauder A, et al. The controversy of varicella vaccination in children with acute lymphoblastic leukemia. Pediatric Blood & Cancer. 2012 Jan;58(1):12–6. doi: 10.1002/pbc.22759. PMID: 20848637. Study design [PMC free article: PMC3004985] [PubMed: 20848637] [CrossRef]

Caniza MA, Hunger SP, Schrauder A, et al. The controversy of varicella vaccination in children with acute lymphoblastic leukemia. Pediatric Blood and Cancer. 2012 January;58(1):12–6. PMID: 2011629669 MEDLINE PMID 20848637 (http://www​.ncbi.nlm.nih​.gov/pubmed/20848637). Study design [PMC free article: PMC3004985] [PubMed: 20848637]

Cantelli CP, Fumian TM, Malta FC, et al. Norovirus infection and HBGA host genetic susceptibility in a birth community-cohort, Rio de Janeiro, Brazil. Infection, Genetics and Evolution. 2020;82. doi: 10.1016/j.meegid.2020.104280. Comparator [PubMed: 32165242] [CrossRef]

Cantu J, Biggio J, Jauk V, et al. Selective uptake of influenza vaccine and pregnancy outcomes. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians. 2013;26(12):1207–11. doi: 10.3109/14767058.2013.775419. Intervention [PubMed: 23406444] [CrossRef]

Cao H, Lavange LM, Heyse JF, et al. Medical records-based postmarketing safety evaluation of rare events with uncertain status. Journal of Biopharmaceutical Statistics. 2013 Jul 4;23(4):744–55. doi: 10.1080/10543406.2013.789886. PMID: 23786578. Study design [PMC free article: PMC4491986] [PubMed: 23786578] [CrossRef]

Cao M, Wu Y, Wen S, et al. 20 μg hepatitis B vaccination reduced the risk of low responsiveness in infants with HLA-II risk genotype of HBsAg positive mothers. Infection, Genetics and Evolution. 2018;63:243–8. doi: 10.1016/j.meegid.2018.06.006. Outcome [PubMed: 29883771] [CrossRef]

Capeding MR, Alberto E, Feser J, et al. Safety and immunogenicity of measles, mumps, and rubella vaccine co-administered with live attenuated SA 14-14-2 Japanese encephalitis vaccine [CD.Jevax, Chengdu institute of biological products]. American journal of tropical medicine and hygiene. 2018;99(4):293-. PMID: CN-01934488. Participants

Capeding MR, Cadorna-Carlos J, Book-Montellano M, et al. Immunogenicity and safety of a DTaP-IPV//PRP approximately T combination vaccine given with hepatitis B vaccine: a randomized open-label trial. Bulletin of the World Health Organization. 2008 Jun;86(6):443–51. PMID: 18568273. Study design [PMC free article: PMC2647469] [PubMed: 18568273]

Capeding MRZ, Alberto E, Versteilen A, et al. Comparison of the immunogenicity and safety of pentavalent vaccine Quinvaxem in a compact prefilled auto-disabled (cPAD) injection system versus single-dose vials in healthy infants: a phase 3, open-label, randomized, parallel-group, non-inferiority study. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2016;46:71–8. doi: 10.1016/j.ijid.2016.02.015. Intervention [PubMed: 26923083] [CrossRef]

Capeding MRZ, Jica C, Macura-Biegun A, et al. Interchangeability of Quinvaxem during primary vaccination schedules: results from a phase IV, single-blind, randomized, controlled, single-center, non-inferiority study. Vaccine. 2014;32(7):888–94. doi: 10.1016/j.vaccine.2013.10.059. Intervention [PubMed: 24176498] [CrossRef]

Capeding MZR, Puumalainen T, Gepanayao CP, et al. Safety and immunogenicity of three doses of an eleven-valent diphtheria toxoid and tetanus protein--conjugated pneumococcal vaccine in Filipino infants. BMC Infectious Diseases. 2003 Aug 10;3:17. PMID: 12908876. Study design [PMC free article: PMC184484] [PubMed: 12908876]

Cappelletti M, Taddeo A, Colombo E, et al. Immunogenicity and Safety of Seasonal Influenza Vaccination in Patients with Classic Kaposi’s Sarcoma. Journal of Investigative Dermatology. 2012;24. Study design [PubMed: 22622418]

Carbone T, McEntire B, Kissin D, et al. Absence of an increase in cardiorespiratory events after diphtheria-tetanus-acellular pertussis immunization in preterm infants: a randomized, multicenter study. Pediatrics. 2008 May;121(5):e1085–90. doi: 10.1542/peds.2007-2059. PMID: 18450851. Publication year [PubMed: 18450851] [CrossRef]

Carcione D, Blyth CC, Richmond PC, et al. Safety surveillance of influenza vaccine in pregnant women. Australian & New Zealand Journal of Obstetrics & Gynaecology. 2013 Feb;53(1):98–9. doi: 10.1111/ajo.12034. PMID: 23406000. Study design [PubMed: 23406000] [CrossRef]

Cardellino A, Khawaja S, Cruz ES, et al. Effectiveness of vaccination with the pentavalent rotavirus vaccine in Nicaragua as determined using the screening method. Human Vaccines & Immunotherapeutics. 2013 Jul;9(7):1449–53. doi: 10.4161/hv.24338. PMID: WOS:000328572700018. Outcome [PubMed: 23571175] [CrossRef]

Carlsson RM, Claesson BA, Selstam U, et al. Safety and immunogenicity of a combined diphtheria-tetanus-acellular pertussis-inactivated polio vaccine-Haemophilus influenzae type b vaccine administered at 2-4-6-13 or 3-5-12 months of age. Pediatric Infectious Disease Journal. 1998 Nov;17(11):1026–33. PMID: 9849987. Study design [PubMed: 9849987]

Carlsson RM, Gustafsson L, Hallander HO, et al. Two consecutive randomized controlled pertussis booster trials in children initially vaccinated in infancy with an acellular vaccine: The first with a five-component Tdap vaccine to 5-year olds and the second with five- or monocomponent Tdap vaccines at age 14–15 years. Vaccine. 2015;33(31):3717–25. doi: 10.1016/j.vaccine.2015.05.079. Comparator [PubMed: 26057135] [CrossRef]

Carmo GMID, Yen C, Cortes J, et al. Decline in diarrhea mortality and admissions after routine childhood rotavirus immunization in Brazil: A time-series analysis. PLoS Medicine. 2011;8(4):11. PMID: 2011240140. Outcome [PMC free article: PMC3079643] [PubMed: 21526228]

Carmona A, Miranda M, Barrio F, et al. Reactogenicity and immunogenicity of combined haemophilus influenzae type B-meningococcal serogroup C conjugate vaccine booster dose coadministered with measles, mumps, and rubella vaccinehib-menc-TT booster with routine MMR vaccine. Pediatric Infectious Disease Journal. 2010 March;29(3):269–71. PMID: 2010145503 MEDLINE PMID 19952860 (http://www​.ncbi.nlm.nih​.gov/pubmed/19952860). Study design [PubMed: 19952860]

Carmona A, Omenaca F, Tejedor JC, et al. Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6–35 months. Vaccine. 2010 Aug 16;28(36):5837–44. PMID: 20600478. Study design [PubMed: 20600478]

Carmona Martinez A, Prymula R, Miranda Valdivieso M, et al. Immunogenicity and safety of 11- and 12-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccines (11vPHiD-CV, 12vPHiD-CV) in infants: Results from a phase II, randomised, multicentre study. Vaccine. 2019;37(1):176–86. doi: 10.1016/j.vaccine.2018.07.023. Intervention [PubMed: 30054160] [CrossRef]

Carmona Martinez A, Prymula R, Miranda Valdivieso M, et al. Immunogenicity and safety of 11- and 12-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccines (11vPHiD-CV, 12vPHiD-CV) in infants: results from a phase II, randomised, multicentre study. Vaccine. 2019;37(1):176–86. doi: 10.1016/j.vaccine.2018.07.023. PMID: CN-01944147. Duplicate [PubMed: 30054160] [CrossRef]

Carmona Martinez A, Salamanca de la Cueva I, Boutet P, et al. A phase 1, open-label safety and immunogenicity study of an AS03-adjuvanted trivalent inactivated influenza vaccine in children aged 6 to 35 months. Human vaccines & immunotherapeutics. 2014;10(7):1959–68. doi: 10.4161/hv.28743. Intervention [PMC free article: PMC4186022] [PubMed: 25424805] [CrossRef]

Carniel EF, Antonio MARGM, Zanolli ML, et al. Clinical trials field strategies with novel vaccines produced in Brazil ORIGINAL (NON-ENGLISH) TITLE Estrategias de campo em ensaios clinicos com novas vacinas produzidas no Brasil. Revista Paulista de Pediatria. 2012 June;30(2):202–9. PMID: 2012438939. Study design

Caroline G, Fernando N, Luís L-J, et al. Safety, efficacy and immunogenicity of therapeutic vaccines in the treatment of patients with high-grade cervical intraepithelial neoplasia (CIN 2/3) associated with human papillomavirus (HPV): a systematic review. 2017. PMID: CRD42017077428. Study design

Caroline Q-T, Fazia T, Shannon M, et al. Is there a difference in the immune response, efficacy, and safety of seasonal influenza vaccine in males and females? A meta-analysis protocol. 2018. PMID: CRD42018112260. Study design [PubMed: 31711676]

Carpenter SL, Soucie JM, Presley RJ, et al. Hepatitis B vaccination is effective by subcutaneous route in children with bleeding disorders: A universal data collection database analysis. Haemophilia. 2015;21(1):e39–e43. doi: 10.1111/hae.12569. Comparator [PMC free article: PMC4467876] [PubMed: 25381731] [CrossRef]

Carr S, Allison KJ, Van De Velde L-A, et al. Safety and immunogenicity of live attenuated and inactivated influenza vaccines in children with cancer. Journal of Infectious Diseases. 2011 Nov 15;204(10):1475–82. PMID: 21949042. Study design [PubMed: 21949042]

Carraro G, Naso A, Montomoli E, et al. Thymosin-alpha 1 (Zadaxin) enhances the immunogenicity of an adjuvated pandemic H1N1v influenza vaccine (Focetria) in hemodialyzed patients: a pilot study. Vaccine. 2012 Feb 1;30(6):1170–80. PMID: 22178096. Study design [PubMed: 22178096]

Carreras-Abado C, Cocheto M, Hallo T, et al. Developing a serocorrelate of protection against invasive group B streptococcus disease in pregnant women: a feasibility study. Health Technology Assessment. 2019 Dec;23(67):1-+. doi: 10.3310/hta23670. PMID: WOS:000503987200001. Intervention [PMC free article: PMC6936166] [PubMed: 31855555] [CrossRef]

Carter C, Houser KV, Yamshchikov GV, et al. Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial. PLoS ONE. 2019;14(9). doi: 10.1371/journal.pone.0222178. Duplicate [PMC free article: PMC6750650] [PubMed: 31532789] [CrossRef]

Carter C, Houser KV, Yamshchikov GV, et al. Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial. PloS one. 2019;14(9):e0222178. doi: 10.1371/journal.pone.0222178. Intervention [PMC free article: PMC6750650] [PubMed: 31532789] [CrossRef]

Cartwright K, Morris R, Rumke H, et al. Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins. Vaccine. 1999 4;17(20 21):2612–9. PMID: 1999235600 MEDLINE PMID 10418910 (http://www​.ncbi.nlm.nih​.gov/pubmed/10418910). Study design [PubMed: 10418910]

Carty CL, Heagerty P, Nakayama K, et al. Inflammatory response after influenza vaccination in men with and without carotid artery disease. Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2738–44. doi: 10.1161/01.ATV.0000248534.30057.b5. PMID: 17023683. Outcome [PubMed: 17023683] [CrossRef]

Carvajal A, Ortega PG, Sainz M, et al. Adverse events associated with pandemic influenza vaccines: comparison of the results of a follow-up study with those coming from spontaneous reporting. Vaccine. 2011 Jan 10;29(3):519–22. PMID: 21112311. Study design [PubMed: 21112311]

Casado I, Domínguez A, Toledo D, et al. Effect of influenza vaccination on the prognosis of hospitalized influenza patients. Expert Review of Vaccines. 2016;15(3):425–32. doi: 10.1586/14760584.2016.1134328. Outcome [PubMed: 26690376] [CrossRef]

Casetta I, Granieri E, Malagu S, et al. Environmental risk factors and multiple sclerosis: a community-based, case-control study in the province of Ferrara, Italy. Neuroepidemiology. 1994;13(3):120–8. doi: 10.1159/000110369. PMID: 8015665. Intervention [PubMed: 8015665] [CrossRef]

Cashman P, Moberley S, Chee K, et al. Participant centred safety surveillance of health care workers receiving influenza vaccination. Vaccine. 2019;37(18):2427–9. doi: 10.1016/j.vaccine.2019.02.082. Comparator [PubMed: 30930006] [CrossRef]

Caso F, Ramonda R, Del Puente A, et al. Influenza vaccine with adjuvant on disease activity in psoriatic arthritis patients under anti-TNF-alpha therapy. Clinical and experimental rheumatology. 2016;34(3):507–12. Intervention [PubMed: 26967009]

Caspard H, Wise RP, Steffey A, et al. Incidence of live-attenuated influenza vaccine administration beyond expiry date in children and adolescents aged 2–17 years in the UK: a population-based cohort study. Bmj Open. 2017 Jul;7(7):6. doi: 10.1136/bmjopen-2017-016520. PMID: WOS:000410203700183. Intervention [PMC free article: PMC5726133] [PubMed: 28716794] [CrossRef]

Cassidy C, MacDonald NE, Steenbeek A, et al. A global survey of adverse event following immunization surveillance systems for pregnant women and their infants. Human Vaccines and Immunotherapeutics. 2016;12(8):2010–6. doi: 10.1080/21645515.2016.1175697. Comparator [PMC free article: PMC4994761] [PubMed: 27159639] [CrossRef]

Cassisi G, Sarzi-Puttini P, Cazzola M. Chronic widespread pain and fibromyalgia: Could there be some relationship with infections and vaccinations? Clinical and Experimental Rheumatology. 2011 2011;29(6 SUPPL. 69):S118–S26. PMID: 2012228348. Intervention [PubMed: 22243559]

Castellanos M, Cinza Z, Dorta Z, et al. Immunization with a DNA vaccine candidate in chronic hepatitis C patients is safe, well tolerated and does not impair immune response induction after anti-hepatitis B vaccination. Journal of Gene Medicine. 2010 January;12(1):107–16. PMID: 2010075090 MEDLINE PMID 19866482 (http://www​.ncbi.nlm.nih​.gov/pubmed/19866482). Intervention [PubMed: 19866482]

Castellsagué X, Giuliano AR, Goldstone S, et al. Immunogenicity and safety of the 9-valent HPV vaccine in men. Vaccine. 2015;33(48):6892–901. doi: 10.1016/j.vaccine.2015.06.088. Intervention [PubMed: 26144901] [CrossRef]

Castellsague X, Giuliano AR, Goldstone S, et al. Immunogenicity and safety of the 9-valent HPV vaccine in men. Vaccine. 2015;33(48):6892–901. doi: 10.1016/j.vaccine.2015.06.088. PMID: CN-01125165. Duplicate [PubMed: 26144901] [CrossRef]

Castellsague X, Munoz N, Pitisuttithum P, et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age. British Journal of Cancer. 2011 Jun 28;105(1):28–37. doi: 10.1038/bjc.2011.185. PMID: 21629249. Duplicate [PMC free article: PMC3137403] [PubMed: 21629249] [CrossRef]

Castellsagué X, Paavonen J, Jaisamrarn U, et al. Risk of first cervical HPV infection and pre-cancerous lesions after onset of sexual activity: Analysis of women in the control arm of the randomized, controlled PATRICIA trial. BMC Infectious Diseases. 2014;14(1). doi: 10.1186/s12879-014-0551-y. Intervention [PMC free article: PMC4251672] [PubMed: 25927224] [CrossRef]

Castilla J, Beristain X, Martinez-Artola V, et al. Effectiveness of rotavirus vaccines in preventing cases and hospitalizations due to rotavirus gastroenteritis in Navarre, Spain. Vaccine. 2012 Jan;30(3):539–43. PMID: WOS:000301812300007. Outcome [PubMed: 22122860]

Castilla J, Moran J, Martinez-Artola V, et al. Effectiveness of the monovalent influenza A(H1N1)2009 vaccine in Navarre, Spain, 2009–2010: Cohort and case-control study. Vaccine. 2011 11;29(35):5919–24. PMID: 2011409529 MEDLINE PMID 21723358 (http://www​.ncbi.nlm.nih​.gov/pubmed/21723358). Outcome [PubMed: 21723358]

Castillo E, Poliquin V. No. 357-Immunization in Pregnancy. Journal of Obstetrics and Gynaecology Canada. 2018 Apr;40(4):478–89. doi: 10.1016/j.jogc.2017.11.010. PMID: WOS:000435071200025. Study design [PubMed: 29503251] [CrossRef]

Castillo-Solorzano C, Reef SE, Morice A, et al. Rubella vaccination of unknowingly pregnant women during mass campaigns for rubella and congenital rubella syndrome elimination, the Americas 2001–2008. Journal of Infectious Diseases. 2011 Sep 1;204 Suppl 2:S713–7. PMID: 21954271. Intervention [PubMed: 21954271]

Castro JF, Bennett JV, Rincon HG, et al. Evaluation of immunogenicity and side effects of triple viral vaccine (MMR) in adults, given by two routes: subcutaneous and respiratory (aerosol). Vaccine. 2005 Jan 11;23(8):1079–84. doi: 10.1016/j.vaccine.2004.08.018. PMID: 15620482. Study design [PubMed: 15620482] [CrossRef]

Castro M, Dozor A, Fish J, et al. The safety of inactivated influenza vaccine in adults and children with asthma. New England Journal of Medicine. 2001;245(21):1529–36. Intervention [PubMed: 11794219]

Cavenaugh JS, Awi D, Mendy M, et al. Partially Randomized, Non-Blinded Trial of DNA and MVA Therapeutic Vaccines Based on Hepatitis B Virus Surface Protein for Chronic HBV Infection. PLoS ONE. 2011 Feb;6(2). PMID: WOS:000287369200001. Outcome [PMC free article: PMC3039644] [PubMed: 21347224]

Celik A, Orscelik O. Effects of influenza vaccination in patients with heart failure. Herz. 2017 May;42(3):325–6. doi: 10.1007/s00059-016-4484-7. PMID: WOS:000400680200012. Study design [PubMed: 27796407] [CrossRef]

Center HLMC, Institute R, Sharp M, et al. Study of Gardasil in Mid-Adult Males (MAM). https:​//ClinicalTrials​.gov/show/NCT01432574; 2012. Intervention

Center HLMC, Research I. Exploration of Immune Response to Early PCV13 Vaccination in Conjunction With Autologous Transplant. 2015. Participants

Center KJ, Hansen JR, Lewis E, et al. Lack of association of Kawasaki disease after immunization in a cohort of infants followed for multiple autoimmune diagnoses in a large, phase-4 observational database safety study of 7-valent pneumococcal conjugate vaccine: lack of association between Kawasaki disease and seven-valent pneumococcal conjugate vaccine. Pediatric Infectious Disease Journal. 2009 May;28(5):438–40. PMID: 19319016. Study design [PubMed: 19319016]

Center KJ, Strauss A. Safety experience with heptavalent pneumococcal CRM197-conjugate vaccine (Prevenar) since vaccine introduction. Vaccine. 2009 May 26;27(25–26):3281–4. PMID: 19200818. Study design [PubMed: 19200818]

Centers for Disease C, Prevention. Suspension of rotavirus vaccine after reports of intussusception--United States, 1999.[Erratum appears in MMWR Morb Mortal Wkly Rep. 2004 Sep 24;53(37):879]. MMWR - Morbidity & Mortality Weekly Report. 2004 Sep 3;53(34):786–9. PMID: 15343145. Study design [PubMed: 15343145]

Centers for Disease C, Prevention. Postmarketing monitoring of intussusception after RotaTeq vaccination--United States, February 1, 2006–February 15, 2007. MMWR - Morbidity & Mortality Weekly Report. 2007 Mar 16;56(10):218–22. PMID: 17363890. Study design [PubMed: 17363890]

Centers for Disease C, Prevention. Addition of history of intussusception as a contraindication for rotavirus vaccination. MMWR - Morbidity & Mortality Weekly Report. 2011 Oct 21;60(41):1427. PMID: 22012117. Duplicate [PubMed: 22012117]

Centers for Disease C, Prevention. Licensure of 13-valent pneumococcal conjugate vaccine for adults aged 50 years and older. MMWR - Morbidity & Mortality Weekly Report. 2012 Jun;61(21):394–5. PMID: 22647745. Study design [PubMed: 22647745]

Centers for Disease C, Prevention, Advisory Committee on Immunization P. Update: recommendations from the Advisory Committee on Immunization Practices (ACIP) regarding administration of combination MMRV vaccine. MMWR Morb Mortal Wkly Rep. 2008 Mar 14;57(10):258–60. PMID: 18340332. Study design [PubMed: 18340332]

Centers for Disease Control and Prevention (CDC). Syncope After Vaccination --- United States, January 2005--July 2007. Available at: http://www​.cdc.gov/mmwr​/preview/mmwrhtml/mm5717a2.htm. MMWR. 2008;57(17):457–60. Study design [PubMed: 18451756]

Cerami C, Corbo M, Piccolo G, et al. Autoimmune neuromyotonia following human papilloma virus vaccination. Muscle Nerve. 2013 Mar;47(3):466–7. doi: 10.1002/mus.23648. PMID: 23364906. Comparator [PubMed: 23364906] [CrossRef]

Cerbino-Neto J, Santos AT, Gouvea MI, et al. Comparison of adverse events following immunization with pandemic influenza A (H1N1)pdm09 vaccine with or without adjuvant among health professionals in Rio de Janeiro, Brazil. Memorias do Instituto Oswaldo Cruz. 2012 Nov;107(7):923–7. PMID: 23147150. Study design [PubMed: 23147150]

Cérbulo-Vázquez A, Arriaga-Pizano L, Cruz-Cureño G, et al. Medical outcomes in women who became pregnant after vaccination with a virus-like particle experimental vaccine against influenza A (H1N1) 2009 virus tested during 2009 pandemic outbreak. Viruses. 2019;11(9). doi: 10.3390/v11090868. Intervention [PMC free article: PMC6783846] [PubMed: 31533277] [CrossRef]

Cerpa-Cruz S, Paredes-Casillas P, Landeros Navarro E, et al. Adverse events following immunization with vaccines containing adjuvants. Immunol Res. 2013 Jul;56(2–3):299–303. doi: 10.1007/s12026-013-8400-4. PMID: 23576057. Comparator [PubMed: 23576057] [CrossRef]

Cervantes-Torres J, Gracia-Mora I, Segura-Velazquez R, et al. Preclinical evidences of safety of a new synthetic adjuvant to formulate with the influenza human vaccine: absence of subchronic toxicity and mutagenicity. Immunopharmacology and Immunotoxicology. 2019 Jan;41(1):140–9. doi: 10.1080/08923973.2019.1566359. PMID: WOS:000472033500018. Intervention [PubMed: 30714433] [CrossRef]

Ceschi A, Ingram K, Curkovic I, et al. Adverse drug reactions: The most commonly involved drugs and organ systems in pharmacovigilance reports at the University Hospital Zurich. British Journal of Clinical Pharmacology. 2009 October;68 SUPPL. 1:50. Publication type

Ceyhan M, Yildirim I, Tezer H, et al. A fully liquid DTaP-IPV-HB-PRP-T hexavalent vaccine for primary and booster vaccination of healthy Turkish infants and toddlers. Turkish journal of medical sciences. 2017;47(4):1247–56. doi: 10.3906/sag-1609-62. Intervention [PubMed: 29156870] [CrossRef]

Ceylan B, Demir B, Dursun HK, et al. Evaluation of Hepatitis A immunization in chronic Hepatitis B infected cases: A retrospective study. Clinical and Investigative Medicine. 2015;38(4):E192–E5. Intervention

Cha S-H, Shin S-H, Lee T-J, et al. Immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine: an open-labeled, randomized trial in healthy Korean children. Clinical and experimental vaccine research. 2014;3(1):91–9. doi: 10.7774/cevr.2014.3.1.91. Intervention [PMC free article: PMC3890454] [PubMed: 24427766] [CrossRef]

Chabanon AL, Bricout H, Ballandras C, et al. Report from enhanced safety surveillance of two influenza vaccines (Vaxigrip and Intanza 15 mug) in two European countries during influenza season 2016/17 and comparison with 2015/16 season. Human vaccines & immunotherapeutics. 2018;14(2):378–85. doi: 10.1080/21645515.2017.1405882. Intervention [PMC free article: PMC5806654] [PubMed: 29148911] [CrossRef]

Chabanon AL, Bricout H, Ballandras C, et al. Report from enhanced safety surveillance of two influenza vaccines (Vaxigrip and Intanza 15 μg) in two European countries during influenza season 2016/17 and comparison with 2015/16 season. Human Vaccines and Immunotherapeutics. 2018;14(2):378–85. doi: 10.1080/21645515.2017.1405882. Duplicate [PMC free article: PMC5806654] [PubMed: 29148911] [CrossRef]

Chaibou MS, Bako H, Salisou L, et al. Monitoring adverse events following immunization with a new conjugate vaccine against group A meningococcus in Niger, September 2010. Vaccine. 2012 Jul 27;30(35):5229–34. PMID: 22709955. Study design [PubMed: 22709955]

Chaiklang K, Wipasa J, Chaiwarith R, et al. Comparison of immunogenicity and safety of four doses and four double doses vs. standard doses of hepatitis B vaccination in HIV-infected adults: a randomized, controlled trial. PloS one. 2013;8(11):e80409. doi: 10.1371/journal.pone.0080409. Intervention [PMC free article: PMC3827227] [PubMed: 24265819] [CrossRef]

Chambers C, Johnson D, Xu RH, et al. Lessons Learned from Implementation of a Prospective, Observational Cohort Study to Assess Risk of Spontaneous Abortion (SA) Following Administration of Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Vaccine around Conception. Pharmacoepidemiology and Drug Safety. 2013 Oct;22:140–1. PMID: WOS:000334876100270. Study design

Chambers CD, Johnson D, Xu R, et al. Risks and safety of pandemic h1n1 influenza vaccine in pregnancy: Birth defects, spontaneous abortion, preterm delivery, and small for gestational age infants. Vaccine. 2013;31(44):5026–32. doi: 10.1016/j.vaccine.2013.08.097. Duplicate [PubMed: 24016809] [CrossRef]

Chambers CD, Johnson DL, Xu R, et al. Safety of the 2010–11, 2011–12, 2012–13, and 2013–14 seasonal influenza vaccines in pregnancy: Birth defects, spontaneous abortion, preterm delivery, and small for gestational age infants, a study from the cohort arm of VAMPSS. Vaccine. 2016;34(37):4443–9. doi: 10.1016/j.vaccine.2016.06.054. Duplicate [PubMed: 27449682] [CrossRef]

Chambers CD, Johnson DL, Xu R, et al. Safety of the 2010–11, 2011–12, 2012–13, and 2013–14 seasonal influenza vaccines in pregnancy: Birth defects, spontaneous abortion, preterm delivery, and small for gestational age infants, a study from the cohort arm of VAMPSS. Vaccine. 2016;34(37):4443–9. doi: 10.1016/j.vaccine.2016.06.054. Intervention [PubMed: 27449682] [CrossRef]

Chambers CD, Johnson DL, Xu R, et al. Challenges and design of a prospective, observational cohort study to assess the risk of spontaneous abortion following administration of human papillomavirus (HPV) bivalent (Types 16 and 18) recombinant vaccine. Pharmacoepidemiology and Drug Safety. 2011 August;20 SUPPL. 1:S358. Publication type

Chambers CD, Johnson DL, Xu RH, et al. Safety of the 2010–11, 2011–12, 2012–13, and 2013–14 seasonal influenza vaccines in pregnancy: Birth defects, spontaneous abortion, preterm delivery, and small for gestational age infants, a study from the cohort arm of VAMPSS. Vaccine. 2016 Aug;34(37):4443–9. doi: 10.1016/j.vaccine.2016.06.054. PMID: WOS:000381542800015. Duplicate [PubMed: 27449682] [CrossRef]

Chambers CD, Schatz M, Mitchell AA, et al. The vaccines and medications in pregnancy surveillance system (VAMPSS): Launch of a new system for post-marketing surveillance. Birth Defects Research Part A - Clinical and Molecular Teratology. 2010 May;88(5):406. Publication type

Chan SSC, Leung DYP, Leung AYM, et al. A nurse-delivered brief health education intervention to improve pneumococcal vaccination rate among older patients with chronic diseases: A cluster randomized controlled trial. International Journal of Nursing Studies. 2015;52(1):317–24. doi: 10.1016/j.ijnurstu.2014.06.008. Intervention [PMC free article: PMC7094619] [PubMed: 25012957] [CrossRef]

Chan T-C, Fan-Ngai Hung I, Ka-Hay Luk J, et al. Efficacy of trivalent seasonal influenza vaccination in reducing mortality and hospitalization in Chinese nursing home older adults. Journal of the American Medical Directors Association. 2013;14(12):889–94. doi: 10.1016/j.jamda.2013.04.004. Outcome [PubMed: 23702605] [CrossRef]

Chan T-C, Hung IF-N, Chan K-H, et al. Immunogenicity and safety of intradermal trivalent influenza vaccination in nursing home older adults: a randomized controlled trial. Journal of the American Medical Directors Association. 2014;15(8):607.e5–12. doi: 10.1016/j.jamda.2014.05.002. Intervention [PubMed: 24957950] [CrossRef]

Chan TC, Hung IF, Chan KH, et al. Immunogenicity and safety of intradermal trivalent influenza vaccination in nursing home older adults: a randomized controlled trial. Journal of the American Medical Directors Association. 2014;15(8):607.e5–12. doi: 10.1016/j.jamda.2014.05.002. PMID: CN-01115671. Duplicate [PubMed: 24957950] [CrossRef]

Chan TC, Hung IFN, Luk JKH, et al. Efficacy of dual vaccination of pandemic H1N1 2009 influenza and seasonal influenza on institutionalized elderly: A one-year prospective cohort study. Vaccine. 2011 13;29(44):7773–8. PMID: 2011557539 MEDLINE PMID 21821084 (http://www​.ncbi.nlm.nih​.gov/pubmed/21821084). Outcome [PubMed: 21821084]

Chan TC, Hung IFN, Luk JKH, et al. Prevention of Mortality and Pneumonia Among Nursing Home Older Adults by Dual Pneumococcal and Seasonal Influenza Vaccination During a Pandemic Caused by Novel Pandemic Influenza A (H1N1). Journal of the American Medical Directors Association. 2012. Outcome [PubMed: 22722051]

Chan TC, Hung IFN, Luk JKH, et al. Functional status of older nursing home residents can affect the efficacy of influenza vaccination. Journals of Gerontology - Series A Biological Sciences and Medical Sciences. 2013;68(3):324–30. doi: 10.1093/gerona/gls175. Intervention [PubMed: 22967458] [CrossRef]

Chandola TR, Taneja S, Goyal N, et al. ROTAVAC does not interfere with the immune response to childhood vaccines in Indian infants: A randomized placebo controlled trial. Heliyon. 2017;3(5):e00302. doi: 10.1016/j.heliyon.2017.e00302. Intervention [PMC free article: PMC5435614] [PubMed: 28560356] [CrossRef]

Chandola TR, Taneja S, Goyal N, et al. ROTAVAC® does not interfere with the immune response to childhood vaccines in Indian infants: A randomized placebo controlled trial. Heliyon. 2017;3(5). doi: 10.1016/j.heliyon.2017.e00302. Duplicate [PMC free article: PMC5435614] [PubMed: 28560356] [CrossRef]

Chandramohan D, Hodgson A, Coleman P, et al. An evaluation of the immunogenicity and safety of a new trivalent meningococcal polysaccharide vaccine. Vaccine. 2007 Sep 3;25 Suppl 1:A83–91. PMID: 17521782. Study design [PubMed: 17521782]

Chandran A, Santosham M. RotaTeq: a three-dose oral pentavalent reassortant rotavirus vaccine. Expert Review of Vaccines. 2008 Dec;7(10):1475–80. PMID: 19053204. Study design [PubMed: 19053204]

Chandwani S, Beeler J, Li H, et al. Safety and immunogenicity of early measles vaccination in children born to HIV-infected mothers in the United States: results of Pediatric AIDS Clinical Trials Group (PACTG) protocol 225. Journal of Infectious Diseases. 2011 Jul;204 Suppl 1:S179–89. PMID: 21666159. Study design [PMC free article: PMC3143449] [PubMed: 21666159]

Chang C-C, Chang Y-S, Chen W-S, et al. Effects of annual influenza vaccination on morbidity and mortality in patients with Systemic Lupus Erythematosus: A Nationwide Cohort Study. Scientific reports. 2016;6:37817. doi: 10.1038/srep37817. Duplicate [PMC free article: PMC5133584] [PubMed: 27910867] [CrossRef]

Chang CC, Chang YS, Chen WS, et al. Effects of annual influenza vaccination on morbidity and mortality in patients with Systemic Lupus Erythematosus: A Nationwide Cohort Study. Scientific Reports. 2016;6. doi: 10.1038/srep37817. Comparator [PMC free article: PMC5133584] [PubMed: 27910867] [CrossRef]

Chang CY, Cho CY, Lai CC, et al. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in healthy subjects aged 3 to 17 years old: A phase III, open label, single-arm study. Vaccine. 2020;38(22):3839–46. doi: 10.1016/j.vaccine.2020.03.048. Comparator [PubMed: 32284272] [CrossRef]

Chang EJ, Zangwill KM, Lee H, et al. Lack of association between rotavirus infection and intussusception: implications for use of attenuated rotavirus vaccines. Pediatric Infectious Disease Journal. 2002 Feb;21(2):97–102. PMID: 11840074. Intervention [PubMed: 11840074]

Chang HG, Smith PF, Ackelsberg J, et al. Intussusception, rotavirus diarrhea, and rotavirus vaccine use among children in New York state. Pediatrics. 2001 Jul;108(1):54–60. PMID: 11433054. Study design [PubMed: 11433054]

Chang JY, Jung SA, Moon CM, et al. Response to hepatitis B vaccination in patients with inflammatory bowel disease: A prospective observational study in Korea. Intestinal Research. 2018;16(4):599–608. doi: 10.5217/ir.2018.00012. Intervention [PMC free article: PMC6223458] [PubMed: 30301330] [CrossRef]

Chang JY, Jung SA, Moon CM, et al. Response of hepatitis B vaccination in patients with inflammatory bowel disease; prospective observational study in Korea. Journal of Crohns & Colitis. 2018 Feb;12:S362–S. PMID: WOS:000427318901285. Study design

Chang K-H, Lyu R-K, Lin W-T, et al. Gulllain-Barre Syndrome After Trivalent Influenza Vaccination in Adults. Frontiers in neurology. 2019;10:768. doi: 10.3389/fneur.2019.00768. Intervention [PMC free article: PMC6667925] [PubMed: 31396144] [CrossRef]

Chang LJ, Meng Y, Janosczyk H, et al. Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults ≥65years of age: A phase 3 randomized clinical trial. Vaccine. 2019;37(39):5825–34. doi: 10.1016/j.vaccine.2019.08.016. Duplicate [PubMed: 31431411] [CrossRef]

Chang LJ, Meng Y, Janosczyk H, et al. Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults >= 65 years of age: A phase 3 randomized clinical trial. Vaccine. 2019 Sep;37(39):5825–34. doi: 10.1016/j.vaccine.2019.08.016. PMID: WOS:000487175700004. Duplicate [PubMed: 31431411] [CrossRef]

Chang LJ, Meng Y, Janosczyk H, et al. Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults ≥65 years of age: A phase 3 randomized clinical trial. Vaccine. 2019;37(39):5825–34. doi: 10.1016/j.vaccine.2019.08.016. Duplicate [PubMed: 31431411] [CrossRef]

Chang MH, You SL, Chen CJ, et al. Long-term Effects of Hepatitis B Immunization of Infants in Preventing Liver Cancer. Gastroenterology. 2016;151(3):472–80.e1. doi: 10.1053/j.gastro.2016.05.048. Outcome [PubMed: 27269245] [CrossRef]

Chang S, Ball R, Braun MM. Elective termination of pregnancy after vaccination reported to the Vaccine Adverse Event Reporting System (VAERS): 1990–2006. Vaccine. 2008 2;26(19):2428–32. PMID: 2008210701 MEDLINE PMID 18406499 (http://www​.ncbi.nlm.nih​.gov/pubmed/18406499). Study design [PubMed: 18406499]

Chang S, O’Connor PM, Slade BA, et al. U.S. Postlicensure safety surveillance for adolescent and adult tetanus, diphtheria and acellular pertussis vaccines: 2005–2007. Vaccine. 2013 Feb 27;31(10):1447–52. doi: 10.1016/j.vaccine.2012.10.097. PMID: 23142308. Study design [PubMed: 23142308] [CrossRef]

Chang SJ, O’Connor PM, Slade BA, et al. U.S. Postlicensure safety surveillance for adolescent and adult tetanus, diphtheria and acellular pertussis vaccines: 2005–2007. Vaccine. 2013 Feb;31(10):1447–52. doi: 10.1016/j.vaccine.2012.10.097. PMID: WOS:000315540000016. Duplicate [PubMed: 23142308] [CrossRef]

Chang Y-C, Tung H-J, Huang Y-T, et al. Effect of Influenza Vaccination on Mortality and Risk of Hospitalization in Elderly Individuals with and without Disabilities: A Nationwide, Population-Based Cohort Study. Vaccines. 2020;8(1). doi: 10.3390/vaccines8010112. Intervention [PMC free article: PMC7157235] [PubMed: 32121645] [CrossRef]

Chang Y-T, Guo C-Y, Tsai M-S, et al. Poor immune response to a standard single dose non-adjuvanted vaccination against 2009 pandemic H1N1 influenza virus A in the adult and elder hemodialysis patients. Vaccine. 2012 Jul 13;30(33):5009–18. PMID: 22658967. Study design [PubMed: 22658967]

Chang YC, Tung HJ, Huang YT, et al. Effect of influenza vaccination on mortality and risk of hospitalization in elderly individuals with and without disabilities: A nationwide, population-based cohort study. Vaccines. 2020;8(1). doi: 10.3390/vaccines8010112. Outcome [PMC free article: PMC7157235] [PubMed: 32121645] [CrossRef]

Chang YC, Wang JH, Chen YS, et al. Hepatitis B virus vaccination booster does not provide additional protection in adolescents: a cross-sectional school-based study. BMC public health. 2014;14:991. doi: 10.1186/1471-2458-14-991. Intervention [PMC free article: PMC4246462] [PubMed: 25248369] [CrossRef]

Chang YT, Wang JR, Lin MT, et al. Changes of immunogenic profiles between a single dose and one booster influenza vaccination in hemodialysis patients-an 18-week, open-label trial. Scientific Reports. 2016;6. doi: 10.1038/srep20725. Intervention [PMC free article: PMC4751607] [PubMed: 26869526] [CrossRef]

Chantelle G, Candyce H, Dianna W, et al. Safety and Effectiveness of Influenza Vaccines During Pregnancy for Women and Newborns: a Systematic Review Protocol. 2020. PMID: CRD42020159030. Study design

Chanthavanich P, Anderson E, Kerdpanich P, et al. Safety, Tolerability and Immunogenicity of an MF59-adjuvanted, Cell Culture-derived, A/H5N1, Subunit Influenza Virus Vaccine: Results From a Dose-finding Clinical Trial in Healthy Pediatric Subjects. The Pediatric infectious disease journal. 2019;38(7):757–64. doi: 10.1097/INF.0000000000002345. Intervention [PubMed: 31194712] [CrossRef]

Chao AS, Chang YL, Chao A, et al. Seropositivity of influenza A H1NI in mothers and infants following maternal vaccination with trivalent seasonal influenza vaccine after the 2009 pandemic. Taiwanese Journal of Obstetrics & Gynecology. 2017 Feb;56(1):37–40. doi: 10.1016/j.tjog.2016.08.007. PMID: WOS:000400956600007. Intervention [PubMed: 28254223] [CrossRef]

Chaparro M, Gordillo J, Domenech E, et al. Prospective, randomized clinical trial comparing the efficacy of two vaccines against hepatitis B virus (HBV) in inflammatory bowel disease (IBD) patients. Journal of crohn’s and colitis. 2015;9:S299. doi: 10.1093/ecco-jcc/jju027.557. PMID: CN-01130628. Intervention [CrossRef]

Chaparro M, Gordillo J, Domenech E, et al. Prospective, Randomized Clinical Trial Comparing the Efficacy of Two Vaccines Against Hepatitis B Virus (HBV) in Inflammatory Bowel Disease (IBD) Patients. Gastroenterology. 2014 May;146(5):S648–S9. PMID: WOS:000371236403179. Intervention

Chaparro M, Gordillo J, Domenech E, et al. Prospective, randomized clincal trial comparing the efficacy of two vaccines against hepatis B virus (HBV) in inflamatory bowel disease (IBD) patients. Gastroenterology. 2015;148(4 SUPPL. 1):S276. PMID: CN-01089136. Intervention

Chaparro M, Gordillo J, Domenech E, et al. Prospective, randomized clinical trial comparing the efficacy of two vaccines against hepatitis B virus (HBV) in inflammatory bowel disease (IBD) patients. United european gastroenterology journal. 2019;7(8):610-. doi: 10.1177/205064061985467. PMID: CN-02138265. Comparator [CrossRef]

Chaparro M, Gordillo J, Domenech E, et al. Prospective, randomized clinical trial comparing the efficacy of two vaccines against hepatitis B virus (HBV) in inflammatory bowel disease (IBD) patients. Journal of Crohns & Colitis. 2014 Feb;8:S220–S1. doi: 10.1016/s1873-9946(14)60492-x. PMID: WOS:000359377600488. Study design [CrossRef]

Chaparro M, Gordillo J, Domenech E, et al. Prospective, randomized clinical trial comparing the efficacy of two vaccines against hepatitis B virus (HBV) in inflammatory bowel disease (IBD) patients. Journal of Crohns & Colitis. 2015 Feb;9:S299–S. PMID: WOS:000353811200554. Study design

Charkoudian LD, Kaiser GM, Steinmetz RL, et al. Acute retinal necrosis after herpes zoster vaccination. Archives of Ophthalmology. 2011 Nov;129(11):1495–7. PMID: 22084222. Study design [PubMed: 22084222]

Charman T. The highs and lows of counting autism. American Journal of Psychiatry. 2011 September;168(9):873–5. PMID: 2011496939 MEDLINE PMID 21890797 (http://www​.ncbi.nlm.nih​.gov/pubmed/21890797). Study design [PubMed: 21890797]

Chatham W, Chadha A, Fettiplace J, et al. A phase 4, multicenter, randomized, open-label study to evaluate the effect of belimumab on vaccine responses in patients with systemic lupus erythematosus. Arthritis & rheumatology. 2016;68:997–8. doi: 10.1002/art.39977. PMID: CN-01293005. Participants [CrossRef]

Chatkittikunwong G, Khawcharoenporn T. Hepatitis B revaccination in HIV-infected vaccine non-responders: is double dosing always necessary? International journal of STD & AIDS. 2016;27(10):850–5. doi: 10.1177/0956462415596498. Outcome [PubMed: 26185040] [CrossRef]

Chatterjee A, O’Keefe C, Varman M, et al. Comparative immunogenicity and safety of different multivalent component pertussis vaccine formulations and a 5-component acellular pertussis vaccine in infants and toddlers: A randomized, controlled, open-label, multicenter study. Vaccine. 2012 14;30(23):3360–8. PMID: 2012222630. Study design [PubMed: 22475857]

Chatterjee S, Rego SJ, D’Souza F, et al. The immunogenicity and safety of a reduced PRP-content DTPw-HBV/Hib vaccine when administered according to the accelerated EPI schedule. BMC Infectious Diseases. 2010;10:298. PMID: 20950457. Study design [PMC free article: PMC2973939] [PubMed: 20950457]

Chattha KS, Vlasova AN, Kandasamy S, et al. Probiotics and colostrum/milk differentially affect neonatal humoral immune responses to oral rotavirus vaccine. Vaccine. 2013 Apr;31(15):1916–23. doi: 10.1016/j.vaccine.2013.02.020. PMID: WOS:000317557600006. Participants [PMC free article: PMC3606660] [PubMed: 23453730] [CrossRef]

Chavant F, Favreliere S, Lafay-Chebassier C, et al. Memory disorders associated with consumption of drugs: Updating through a case/noncase study in the French PharmacoVigilance Database. British Journal of Clinical Pharmacology. 2011 December;72(6):898–904. PMID: 2011622723 MEDLINE PMID 21557759 (http://www​.ncbi.nlm.nih​.gov/pubmed/21557759). Study design [PMC free article: PMC3244635] [PubMed: 21557759]

Chavant F, Ingrand I, Jonville-Bera AP, et al. The PREGVAXGRIP Study: a Cohort Study to Assess Foetal and Neonatal Consequences of In Utero Exposure to Vaccination Against A(H1N1)v2009 Influenza. Drug Safety. 2013 Jun;36(6):455–65. doi: 10.1007/s40264-013-0030-1. PMID: 23516007. Study design [PubMed: 23516007] [CrossRef]

Chawansuntati K, Chaiklang K, Chaiwarith R, et al. Hepatitis B vaccination induced TNF-α- and IL-2-producing T cell responses in HIV. Healthy individuals higher than in HIV+ individuals who received the same vaccination regimen. Journal of Immunology Research. 2018;2018. doi: 10.1155/2018/8350862. Outcome [PMC free article: PMC5848135] [PubMed: 29682590] [CrossRef]

Chazono M, Hirota T, Yoshida I, et al. Safety follow-up in a cohort of Biken acellular DPT vaccine recipients in Japan. Developments in Biological Standardization. 1991;73:323–7. PMID: 1778326. Study design [PubMed: 1778326]

Cheetham TC, Marcy SM, Tseng HF, et al. Risk of Herpes Zoster and Disseminated Varicella Zoster in Patients Taking Immunosuppressant Drugs at the Time of Zoster Vaccination. Mayo Clinic Proceedings. 2015;90(7):865–73. doi: 10.1016/j.mayocp.2015.04.021. Intervention [PubMed: 26051268] [CrossRef]

Chen C-M, Chen H-J, Chen W-S, et al. Clinical effectiveness of influenza vaccination in patients with rheumatoid arthritis. International journal of rheumatic diseases. 2018;21(6):1246–53. doi: 10.1111/1756-185X.13322. Outcome [PubMed: 29879317] [CrossRef]

Chen CI, Kao PF, Wu MY, et al. Influenza vaccination is associated with lower risk of acute coronary syndrome in elderly patients with chronic kidney disease. Medicine (United States). 2016;95(5). doi: 10.1097/MD.0000000000002588. Intervention [PMC free article: PMC4748883] [PubMed: 26844466] [CrossRef]

Chen E, Grimwood K, Beasley S. Operative rates for acute intussusception in New Zealand [2]. New Zealand Medical Journal. 2004;117(1202). PMID: 2005483071. Intervention [PubMed: 15477916]

Chen J, Heyse JF, Heaton P. Erratum: Age dependence of the risk of intussusception following tetravalent rhesus-human reassortant rotavirus tetravalent vaccine: Is it beyond doubt? (American Journal of Epidemiology (2010) 171: 9 (1046–1054)). American Journal of Epidemiology. 2010 1-jul-2012;172(1):125. PMID: 2012350024. Study design [PubMed: 20400464]

Chen J, Heyse JF, Heaton P, et al. Age dependence of the risk of intussusception following [corrected] rhesus-human reassortant rotavirus tetravalent vaccine: is it beyond doubt?.[Erratum appears in Am J Epidemiol. 2010 Jul 1;172(1):125]. American Journal of Epidemiology. 2010 May 1;171(9):1046–54. PMID: 20400464. Study design [PubMed: 20400464]

Chen J, Heyse JF, Heaton P, et al. Re: “Age Dependence of the Risk of Intussusception Following Tetravalent Rhesus-Human Reassortant Rotavirus Tetravalent Vaccine: Is It Beyond Doubt?” Reply. American Journal of Epidemiology. 2010 Oct;172(7). PMID: WOS:000282166900019. Study design [PubMed: 20682522]

Chen RT. Evaluation of vaccine safety after the events of 11 September 2001: Role of cohort and case-control studies. Vaccine. 2004 7;22(15 16):2047–53. PMID: 2004198046 MEDLINE PMID 15121321 (http://www​.ncbi.nlm.nih​.gov/pubmed/15121321). Study design [PubMed: 15121321]

Chen RT, Glasser JW, Rhodes PH, et al. Vaccine Safety Datalink project: a new tool for improving vaccine safety monitoring in the United States. The Vaccine Safety Datalink Team. Pediatrics. 1997 Jun;99(6):765–73. PMID: 9164767. Study design [PubMed: 9164767]

Chen RT, Moses JM, Markowitz LE, et al. Adverse events following measles-mumps-rubella and measles vaccinations in college students. Vaccine. 1991 May;9(5):297–9. PMID: 1872012. Publication year [PubMed: 1872012]

Chen RT, Pool V, Takahashi H, et al. Combination vaccines: Postlicensure safety evaluation. Clinical Infectious Diseases. 2001 15;33(SUPPL. 4):S327–S33. PMID: 2001441953 MEDLINE PMID 11709768 (http://www​.ncbi.nlm.nih​.gov/pubmed/11709768). Study design [PubMed: 11709768]

Chen RT, Rastogi SC, Mullen JR, et al. The vaccine adverse event reporting system (VAERS). Vaccine. 1994 1994;12(6):542–50. PMID: 1994117962 MEDLINE PMID 8036829 (http://www​.ncbi.nlm.nih​.gov/pubmed/8036829). Outcome [PubMed: 8036829]

Chen W, Zhao Y, Xie X, et al. Safety of a quadrivalent human papillomavirus vaccine in a Phase 3, randomized, double-blind, placebo-controlled clinical trial among Chinese women during 90months of follow-up. Vaccine. 2019;37(6):889–97. doi: 10.1016/j.vaccine.2018.12.030. Intervention [PubMed: 30638797] [CrossRef]

Chen W, Zhao Y, Xie X, et al. Safety of a quadrivalent human papillomavirus vaccine in a Phase 3, randomized, double-blind, placebo-controlled clinical trial among Chinese women during 90 months of follow-up. Vaccine. 2019 Feb;37(6):889–97. doi: 10.1016/j.vaccine.2018.12.030. PMID: WOS:000458343100018. Duplicate [PubMed: 30638797] [CrossRef]

Chen WH, El-Kamary SS. Vaccines for enteric infections. Current Opinion in Gastroenterology. 2012 January;28(1):18–23. PMID: 2012089077 MEDLINE PMID 22080824 (http://www​.ncbi.nlm.nih​.gov/pubmed/22080824). Outcome [PubMed: 22080824]

Chen WH, Jackson LA, Edwards KM, et al. Safety, Reactogenicity, and Immunogenicity of Inactivated Monovalent Influenza A(H5N1) Virus Vaccine Administered With or Without AS03 Adjuvant. Open forum infectious diseases. 2014;1(3):ofu091. doi: 10.1093/ofid/ofu091. Intervention [PMC free article: PMC4324222] [PubMed: 25734159] [CrossRef]

Chen WH, Neuzil KM, Boyce CR, et al. Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled study. The Lancet. Infectious diseases. 2018;18(10):1088–96. doi: 10.1016/S1473-3099(18)30400-6. Intervention [PubMed: 30120069] [CrossRef]

Chen WH, Neuzil KM, Boyce CR, et al. Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled study. The lancet. Infectious diseases. 2018;18(10):1088–96. doi: 10.1016/S1473-3099(18)30400-6. PMID: CN-01650992. Duplicate [PubMed: 30120069] [CrossRef]

Chen WH, Winokur PL, Edwards KM, et al. Phase 2 assessment of the safety and immunogenicity of two inactivated pandemic monovalent H1N1 vaccines in adults as a component of the U.S. pandemic preparedness plan in 2009. Vaccine. 2012 13;30(28):4240–8. PMID: 2012314753. Study design [PMC free article: PMC3490194] [PubMed: 22537984]

Chen WH, Winokur PL, Edwards KM, et al. Phase 2 assessment of the safety and immunogenicity of two inactivated pandemic monovalent H1N1 vaccines in adults as a component of the U.S. pandemic preparedness plan in 2009. Vaccine. 2012 Jun 13;30(28):4240–8. doi: 10.1016/j.vaccine.2012.04.044. PMID: 22537984. Study design [PMC free article: PMC3490194] [PubMed: 22537984] [CrossRef]

Chen Y, Ma F, Xu Y, et al. Vaccines and the risk of acute disseminated encephalomyelitis. Vaccine. 2018;36(26):3733–9. doi: 10.1016/j.vaccine.2018.05.063. Intervention [PubMed: 29784468] [CrossRef]

Chen Y, Zhang J, Chu X, et al. Vaccines and the risk of Guillain-Barre syndrome. European journal of epidemiology. 2019. doi: 10.1007/s10654-019-00596-1. Intervention [PubMed: 31858323] [CrossRef]

Chen YE, Beasley S, Grimwood K. Intussusception and rotavirus associated hospitalisation in New Zealand. Archives of Disease in Childhood. 2005 October;90(10):1077–81. PMID: 2005448132 MEDLINE PMID 15964860 (http://www​.ncbi.nlm.nih​.gov/pubmed/15964860). Outcome [PMC free article: PMC1720128] [PubMed: 15964860]

Chen YS, Chu CH, Wang JH, et al. Predictors of Booster Response to Hepatitis B Vaccine at 15 years of age: A Cross-Sectional School-Based Study. Pediatrics and Neonatology. 2016;57(4):302–9. doi: 10.1016/j.pedneo.2015.09.006. Outcome [PubMed: 26750404] [CrossRef]

Chen Z, Zeng M, Liu D, et al. Antenatal administration of hepatitis B immunoglobulin and hepatitis B vaccine to prevent mother to child transmission in hepatitis B virus surface antigen positive pregnant women: A systematic review and meta-analysis. Medicine. 2020;99(16):e19886. doi: 10.1097/MD.0000000000019886. Intervention [PMC free article: PMC7220666] [PubMed: 32312015] [CrossRef]

Chenaf C, Zenut M, Eschalier A. Thrombocytopenic Purpura and vaccination: Where do we stand? Fundamental and Clinical Pharmacology. 2010 April;24 SUPPL. 1:73. Publication type

Cheng A, Chang SY, Tsai MS, et al. Long-term immune responses and comparative effectiveness of one or two doses of 7-valent pneumococcal conjugate vaccine (PCV7) in HIV-positive adults in the era of combination antiretroviral therapy. Journal of the International AIDS Society. 2016;19(1). doi: 10.7448/IAS.19.1.20631. Intervention [PMC free article: PMC4733944] [PubMed: 26829360] [CrossRef]

Cheng A, Fung C-P, Liu C-C, et al. A Phase I, randomized, open-label study to evaluate the safety and immunogenicity of an enterovirus 71 vaccine. Vaccine. 2013;31(20):2471–6. doi: 10.1016/j.vaccine.2013.03.015. Intervention [PubMed: 23541623] [CrossRef]

Cheng A, Hsieh S-M, Pan S-C, et al. The safety and immunogenicity of a cell-derived adjuvanted H5N1 vaccine - A phase I randomized clinical trial. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi. 2019;52(5):685–92. doi: 10.1016/j.jmii.2019.03.009. Intervention [PubMed: 31255574] [CrossRef]

Cheng A, Hsieh SM, Pan SC, et al. The safety and immunogenicity of a cell-derived adjuvanted H5N1 vaccine – A phase I randomized clinical trial. Journal of Microbiology, Immunology and Infection. 2019;52(5):685–92. doi: 10.1016/j.jmii.2019.03.009. Duplicate [PubMed: 31255574] [CrossRef]

Cheng AC, Holmes M, Irving LB, et al. Influenza Vaccine Effectiveness against Hospitalisation with Confirmed Influenza in the 2010–11 Seasons: A Test-negative Observational Study. Plos One. 2013 Jul;8(7):8. doi: 10.1371/journal.pone.0068760. PMID: WOS:000322064300070. Outcome [PMC free article: PMC3712933] [PubMed: 23874754] [CrossRef]

Cheng DR, Perrett KP, Choo S, et al. Pediatric anaphylactic adverse events following immunization in Victoria, Australia from 2007 to 2013. Vaccine. 2015;33(13):1602–7. doi: 10.1016/j.vaccine.2015.02.008. Intervention [PubMed: 25698493] [CrossRef]

Cheng HK, Rajadurai VS, Amin Z, et al. Immunogenicity and reactogenicity of two regimens of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio and Haemophilus influenzae type b vaccines administered to infants primed at birth with hepatitis B vaccine. Southeast Asian Journal of Tropical Medicine & Public Health. 2004 Sep;35(3):685–92. PMID: 15689088. Study design [PubMed: 15689088]

Cheng MP, Pandit A, Antin JH, et al. Safety and immunogenicity of conjugate quadrivalent meningococcal vaccination after hematopoietic cell transplantation. Blood advances. 2018;2(11):1272–6. doi: 10.1182/bloodadvances.2018018911. Intervention [PMC free article: PMC5998919] [PubMed: 29871892] [CrossRef]

Cheong HJ, Song JY, Heo JY, et al. Immunogenicity and safety of influenza A (H1N1) 2009 monovalent inactivated split vaccine in Korea. Vaccine. 2011 Jan 10;29(3):523–7. PMID: 21055502. Study design [PubMed: 21055502]

Cheong HJ, Song JY, Heo JY, et al. Immunogenicity and safety of the influenza A/H1N1 2009 inactivated split-virus vaccine in young and older adults: MF59-adjuvanted vaccine versus nonadjuvanted vaccine. Clinical & Vaccine Immunology: CVI. 2011 Aug;18(8):1358–64. PMID: 21715575. Study design [PMC free article: PMC3147346] [PubMed: 21715575]

Cherian MP, Al-Kanani KA, Al Qahtani SS, et al. The rising incidence of type 1 diabetes mellitus and the role of environmental factors - Three decade experience in a primary care health center in Saudi Arabia. Journal of Pediatric Endocrinology and Metabolism. 2010 2010;23(7):685–95. PMID: 2010493713 MEDLINE PMID 20857841 (http://www​.ncbi.nlm.nih​.gov/pubmed/20857841). Outcome [PubMed: 20857841]

Cherian T, Thomas N, Raghupathy P, et al. Safety and immunogenicity of Haemophilus influenzae type B vaccine given in combination with DTwP at 6, 10 and 14 weeks of age. Indian Pediatrics. 2002 May;39(5):427–36. PMID: 12037271. Study design [PubMed: 12037271]

Cherif H, Hoglund M, Pauksens K. Adjuvanted influenza a (H1N1) 2009 vaccine in patients with hematological diseases: good safety and immunogenicity even in chemotherapy-treated patients. European Journal of Haematology. 2013 May;90(5):413–9. doi: 10.1111/ejh.12094. PMID: 23444982. Intervention [PubMed: 23444982] [CrossRef]

Chernin LR, Swender D, Hostoffer RW, Jr. Cracking the shell on egg-hypersensitive patients and egg-containing vaccines. Journal of the American Osteopathic Association. 2011 Oct;111(10 Suppl 6):S5–6. PMID: 22086894. Outcome [PubMed: 22086894]

Cherry JD. Tetanus-Diphtheria-Pertussis Immunization in Pregnant Women and the Prevention of Pertussis in Young Infants. Clinical Infectious Diseases. 2015 Feb;60(3):338–40. doi: 10.1093/cid/ciu823. PMID: WOS:000349761600010. Study design [PubMed: 25332079] [CrossRef]

Chevallier B, Vesikari T, Brzostek J, et al. Safety and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with routine childhood vaccines. Pediatric Infectious Disease Journal. 2009 Apr;28(4 Suppl):S109–18. PMID: 19325447. Study design [PubMed: 19325447]

Chhatwal J, Lalwani S, Vidor E. Immunogenicity and Safety of a Liquid Hexavalent Vaccine in Indian Infants. Indian pediatrics. 2017;54(1):15–20. Intervention [PubMed: 27889711]

Chi CI. A Randomized, Blind, active-controlled trials to evaluate the safety and immunogenicity of Quadrivalent influenza vaccine (Split Virion) for Human use in the healthy subjects among 6-months to 3 years old. http://www​.who.int/trialsearch/Trial2​.aspx?TrialID​=ChiCTR-IIR-16008507. 2016. PMID: CN-01812276. Intervention

Chi CI. The Phase I Clinical Trial of Recombinant (hansenula polymorpha) hepatitis B vaccine with CpG ODN adjuvant. http://www​.who.int/trialsearch/Trial2​.aspx?TrialID​=ChiCTR-IIR-16009836. 2016. PMID: CN-01807653. Intervention

Chi CI. A Randomized, double-blind, positive vaccine-controlled phase II clinical trial of mumps attenuated live vaccine (human diploid cells) in Healthy infants and young children aged 8 months to 24 months. http://www​.who.int/trialsearch/Trial2​.aspx?TrialID​=ChiCTR-IIR-17011282. 2017. PMID: CN-01892863. Intervention

Chi CP. Immunogenicity and safety of two doses live attenuated varicella vaccine with different intervals schedule in children. http://www​.who.int/trialsearch/Trial2​.aspx?TrialID​=ChiCTR-PNRC-13003527. 2013. PMID: CN-01802761. Comparator

Chi CP. A Randomized, Blind, parallel controlled trials to evaluate the safety and immunogenicity of freeze-dried group ACYW135 meningococcal conjugate vaccine. http://www​.who.int/trialsearch/Trial2​.aspx?TrialID​=ChiCTR-PPR-15006591. 2015. PMID: CN-01846800. Intervention

Chi CP. The post-marketing clinical study of Influenza vaccine(split virion). http://www​.who.int/trialsearch/Trial2​.aspx?TrialID​=ChiCTR-PPR-15007470. 2015. PMID: CN-01880818. Intervention

Chi CP. A Randomized, Blind, active-controlled trials to evaluate the safety and immunogenicity of Quadrivalent influenza vaccine (Split Virion) for Human use in the healthy subjects among 6-months to 3 years old. http://www​.who.int/trialsearch/Trial2​.aspx?TrialID​=ChiCTR-PIR-16008224. 2016. PMID: CN-01854201. Intervention

Chi CP. A Phase ?study for the Hexavalent BRV Vaccine. http://www​.who.int/trialsearch/Trial2​.aspx?TrialID​=ChiCTR-PIR-16008824. 2016. PMID: CN-01854410. Participants

Chi CP. Evaluating the Immunogenicity and Safety of Sequential Inoculation of Type I & III Live Attenuated OPV (Human Diploid Cells) and IPV Vaccine for Infants Aged 2 Months. http://www​.who.int/trialsearch/Trial2​.aspx?TrialID​=ChiCTR-PIR-16009000. 2016. PMID: CN-01808701. Intervention

Chi CT. Safety and efficacy of a therapeutic hepatitis B vaccine. http://www​.who.int/trialsearch/Trial2​.aspx?TrialID​=ChiCTR-TRC-13003441. 2013. PMID: CN-01822053. Intervention

Chi R-C, Reiber GE, Neuzil KM. Influenza and pneumococcal vaccination in older veterans: results from the behavioral risk factor surveillance system. Journal of the American Geriatrics Society. 2006 Feb;54(2):217–23. PMID: 16460371. Outcome [PubMed: 16460371]

Chi R-C, Rock MT, Neuzil KM. Immunogenicity and safety of intradermal influenza vaccination in healthy older adults. Clinical Infectious Diseases. 2010 May 15;50(10):1331–8. PMID: 20377407. Study design [PubMed: 20377407]

Chiang M-H, Wu H-H, Shih C-J, et al. Association between influenza vaccination and reduced risks of major adverse cardiovascular events in elderly patients. American heart journal. 2017;193:1–7. doi: 10.1016/j.ahj.2017.07.020. Intervention [PubMed: 29129247] [CrossRef]

ChiCtr. A multi-center, randomised, double-blind, placebo-controlled phase III clinical trial to evaluate the protective efficacy, safety and immunogenicity of Recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine (Hansenulapolymorpha) in healthy Chinese woman aged 18–45 years. http://www​.who.int/trialsearch/Trial2​.aspx?TrialID​=ChiCTR1800016432. 2018. PMID: CN-01900611. Intervention

ChiCtr. A randomized, multi-center, control trial for Sabin-IPV replacement vaccination. http://www​.who.int/trialsearch/Trial2​.aspx?TrialID​=ChiCTR1800016767. 2018. PMID: CN-01908929. Intervention

ChiCtr. Relationship between immune status and hepatitis B vaccination active immune reconstitution after liver transplantation in patients with hepatitis B related liver disease. http://www​.who.int/trialsearch/Trial2​.aspx?TrialID​=ChiCTR1800018209. 2018. PMID: CN-01908561. Intervention

ChiCtr. The preventive effect of different potency HPV vaccines on secondary diseases after cervical intraepithelial neoplasia after surgery. http://www​.who.int/trialsearch/Trial2​.aspx?TrialID​=ChiCTR1800019008. 2018. PMID: CN-01910075. Outcome

ChiCtr. Phase III clinical trial for live attenuated varicella vaccine. http://www​.who.int/trialsearch/Trial2​.aspx?TrialID​=ChiCTR1900020665. 2019. PMID: CN-01949204. Outcome

ChiCtr. Evaluate the Recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine (Hansenulapolymorpha) in the Chinese women at the age of 18 to 45 in the protective efficacy, safety and immunogenicity of multicenter, randomized, double-blind, placebo-controlled phase III clinical trials. http://www​.who.int/trialsearch/Trial2​.aspx?TrialID​=ChiCTR1900025470. 2019. PMID: CN-01975413. Intervention

ChiCtr. Phase I Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed (DTcP). http://www​.who.int/trialsearch/Trial2​.aspx?TrialID​=ChiCTR2000031510. 2020. PMID: CN-02165891. Intervention

ChiCtr. Phase III clinical study of 23-Valent Pneumococcal Polysaccharide Vaccine. http://www​.who.int/trialsearch/Trial2​.aspx?TrialID​=ChiCTR2000030009. 2020. PMID: CN-02165644. Comparator

Chioato A, Noseda E, Felix SD, et al. Influenza and meningococcal vaccinations are effective in healthy subjects treated with the interleukin-1 beta-blocking antibody canakinumab: results of an open-label, parallel group, randomized, single-center study. Clinical & Vaccine Immunology: CVI. 2010 Dec;17(12):1952–7. PMID: 20962212. Study design [PMC free article: PMC3008193] [PubMed: 20962212]

Chioato A, Noseda E, Stevens M, et al. Efficacy of influenza and meningococcal vaccinations in healthy subjects exposed to secukinumab 150 mg: Preliminary study results. Arthritis and Rheumatism. 2011;63(10):1822. Publication type

Chiou WY, Hung SK, Lai CL, et al. Effect of 23-valent pneumococcal polysaccharide vaccine inoculated during anti-cancer treatment period in elderly lung cancer patients on community-acquired pneumonia hospitalization: A nationwide population-based cohort study. Medicine (United States). 2015;94(26). doi: 10.1097/MD.0000000000001022. Outcome [PMC free article: PMC4504648] [PubMed: 26131806] [CrossRef]

Chiou WY, Hung SK, Lin HY, et al. Effectiveness of 23-valent pneumococcal polysaccharide vaccine on elderly patients with colorectal cancer: A population-based propensity score-matched cohort study. Medicine (United States). 2019;98(50). doi: 10.1097/MD.0000000000018380. Outcome [PMC free article: PMC6922596] [PubMed: 31852152] [CrossRef]

Chippaux JP, Garba A, Ethevenaux C, et al. Immunogenicity, safety, and memory of different schedules of Neisseria meningitidis A/C-diphtheria toxoid conjugate vaccine in infants in Niger. Vaccine. 2004 3;22(25 26):3303–11. PMID: 2004349307 MEDLINE PMID 15308353 (http://www​.ncbi.nlm.nih​.gov/pubmed/15308353). Study design [PubMed: 15308353]

Chiu HH, Huang LM, Lee PI, et al. Diphtheria, tetanus and whole cell pertussis vaccine combined with hepatitis B vaccines: A comparison of two doses (10 (mu)g and 5 (mu)g). Pediatric Infectious Disease Journal. 1998 March;17(3):206–11. PMID: 1998106916 MEDLINE PMID 9535247 (http://www​.ncbi.nlm.nih​.gov/pubmed/9535247). Study design [PubMed: 9535247]

Chiu N-C, Huang L-M, Willemsen A, et al. Safety and immunogenicity of a meningococcal B recombinant vaccine when administered with routine vaccines to healthy infants in Taiwan: A phase 3, open-label, randomized study. Human vaccines & immunotherapeutics. 2018;14(5):1075–83. doi: 10.1080/21645515.2018.1425659. Participants [PMC free article: PMC5989895] [PubMed: 29337653] [CrossRef]

Chiu NC, Clifford R, Huang LM, et al. A second dose of a measles-mumps-rubella vaccine administered to healthy four-to-six-year-old children: a phase III, observer-blind, randomized, safety and immunogenicity study comparing GSK MMR and MMR II with and without DTaP-IPV and varicella vaccines co-administration. Human Vaccines & Immunotherapeutics. 2019 Apr;15(4):786–99. doi: 10.1080/21645515.2018.1554971. PMID: WOS:000467847400006. Duplicate [PMC free article: PMC6605865] [PubMed: 30785357] [CrossRef]

Chiu NC, Huang LM, Willemsen A, et al. Safety and immunogenicity of a meningococcal B recombinant vaccine when administered with routine vaccines to healthy infants in Taiwan: A phase 3, open-label, randomized study. Human Vaccines & Immunotherapeutics. 2018;14(5):1075–83. doi: 10.1080/21645515.2018.1425659. PMID: WOS:000433960500018. Duplicate [PMC free article: PMC5989895] [PubMed: 29337653] [CrossRef]

Chiu NC, Huang LM, Willemsen A, et al. Safety and immunogenicity of a meningococcal B recombinant vaccine when administered with routine vaccines to healthy infants in Taiwan: A phase 3, open-label, randomized study. Human Vaccines and Immunotherapeutics. 2018;14(5):1075–83. doi: 10.1080/21645515.2018.1425659. Duplicate [PMC free article: PMC5989895] [PubMed: 29337653] [CrossRef]

Chiu SS, Peiris JS, Chan KH, et al. Immunogenicity and safety of intradermal influenza immunization at a reduced dose in healthy children. Pediatrics. 2007 Jun;119(6):1076–82. doi: 10.1542/peds.2006-3176. PMID: 17545373. Publication year [PubMed: 17545373] [CrossRef]

Chlebna-Sokol D, Szynczewska E. Immunogenicity and Safety of Heptavalent Pneumococcal Conjugate Vaccine in Very Preterm Infants - Draft Report. Acta Paediatrica. 2009 Oct;98:101–2. PMID: WOS:000269862100263. Publication type

Chlibek R, Pauksens K, Rombo L, et al. Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults. Vaccine. 2016;34(6):863–8. doi: 10.1016/j.vaccine.2015.09.073. Participants [PubMed: 26432913] [CrossRef]

Chlibek R, Smetana J, Pauksens K, et al. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vaccine. 2014;32(15):1745–53. doi: 10.1016/j.vaccine.2014.01.019. Comparator [PubMed: 24508036] [CrossRef]

Choe YJ, Cho H, Bae G-R, et al. Guillain-Barre syndrome following receipt of influenza A (H1N1) 2009 monovalent vaccine in Korea with an emphasis on Brighton Collaboration case definition. Vaccine. 2011 Mar 3;29(11):2066–70. PMID: 21255684. Study design [PubMed: 21255684]

Choe YJ, Cho H, Kim SN, et al. Serious adverse events following receipt of trivalent inactivated influenza vaccine in Korea, 2003–2010. Vaccine. 2011 Oct 13;29(44):7727–32. PMID: 21827815. Study design [PubMed: 21827815]

Choe YJ, Cho H, Song KM, et al. Active surveillance of adverse events following immunization against pandemic influenza A (H1N1) in Korea. Japanese Journal of Infectious Diseases. 2011;64(4):297–303. PMID: 21788704. Study design [PubMed: 21788704]

Choe YJ, Eom HS, Bae GR. Vaccine-associated measles in the low-incidence country of Korea over a 10-year period. Japanese Journal of Infectious Diseases. 2014;67(3):180–3. doi: 10.7883/yoken.67.180. Comparator [PubMed: 24858606] [CrossRef]

Choi CH, Choi HJ, Lee JW, et al. Phase I study of a B cell-based and monocyte-based immunotherapeutic vaccine, BVAC-C in human papillomavirus type 16-or 18-positive recurrent cervical cancer. Journal of Clinical Medicine. 2020;9(1). doi: 10.3390/jcm9010147. Intervention [PMC free article: PMC7019768] [PubMed: 31948126] [CrossRef]

Choi J-H, Choo EJ, Huh A, et al. Immunogenicity and safety of diphtheria-tetanus vaccine in adults. Journal of Korean Medical Science. 2010 Dec;25(12):1727–32. PMID: 21165286. Study design [PMC free article: PMC2995225] [PubMed: 21165286]

Choi JY, Kang MG, Park KU, et al. Immunogenicity of the varicella-zoster vaccine in community-dwelling non-robust elderly individuals compared to robust elderly individuals: A prospective cohort study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences. 2019;74(8):1225–30. doi: 10.1093/gerona/gly287. Outcome [PubMed: 30576411] [CrossRef]

Choi NW, Estes MK, Langridge WHR. Mucosal immunization with a ricin toxin B subunit-rotavirus NSP4 fusion protein stimulates a Th1 lymphocyte response. Journal of Biotechnology. 2006 24;121(2):272–83. PMID: 2006012524 MEDLINE PMID 16181698 (http://www​.ncbi.nlm.nih​.gov/pubmed/16181698). Participants [PubMed: 16181698]

Choi U, Lee SY, Kwak GY, et al. Immunogenicity and safety of primary and secondary DTaP booster vaccination. Journal of the Korean Medical Association. 2011 September;54(9):979–87. PMID: 2011560263. Study design

Choi W, Kim JG, Beom S-H, et al. Immunogenicity and Optimal Timing of 13-Valent Pneumococcal Conjugate Vaccination during Adjuvant Chemotherapy in Gastric and Colorectal Cancer: A Randomized Controlled Trial. Cancer research and treatment : official journal of Korean Cancer Association. 2019. doi: 10.4143/crt.2019.189. Comparator [PMC free article: PMC6962463] [PubMed: 31291710] [CrossRef]

Choi W, Kim JG, Beom SH, et al. Immunogenicity and optimal timing of 13-valent pneumococcal conjugate vaccination during adjuvant chemotherapy in gastric and colorectal cancer: A randomized controlled trial. Cancer Research and Treatment. 2020;52(1):246–53. doi: 10.4143/crt.2019.189. Duplicate [PMC free article: PMC6962463] [PubMed: 31291710] [CrossRef]

Choi WS, Choi J-H, Choi JY, et al. Immunogenicity and Safety of a Live Attenuated Zoster Vaccine (ZOSTAVAXTM) in Korean Adults. Journal of Korean medical science. 2016;31(1):13–7. doi: 10.3346/jkms.2016.31.1.13. Comparator [PMC free article: PMC4712571] [PubMed: 26770032] [CrossRef]

Choi WS, Choi JH, Choi JY, et al. Immunogenicity and safety of a live attenuated zoster vaccine (ZOSTAVAX™) in Korean adults. Journal of Korean Medical Science. 2016;31(1):13–7. doi: 10.3346/jkms.2016.31.1.13. Duplicate [PMC free article: PMC4712571] [PubMed: 26770032] [CrossRef]

Choi WS, Choi JH, Jung DS, et al. Immunogenicity and safety of a new live attenuated herpes zoster vaccine (NBP608) compared to Zostavax in healthy adults aged 50 years and older. Vaccine. 2019;37(27):3605–10. doi: 10.1016/j.vaccine.2019.04.046. Intervention [PubMed: 31122860] [CrossRef]

Choi WS, Choi JH, Jung DS, et al. Immunogenicity and safety of a new live attenuated herpes zoster vaccine (NBP608) compared to Zostavax (R) in healthy adults aged 50 years and older. Vaccine. 2019 Jun;37(27):3605–10. doi: 10.1016/j.vaccine.2019.04.046. PMID: WOS:000474325600013. Duplicate [PubMed: 31122860] [CrossRef]

Choi WS, Choi JH, Jung DS, et al. Immunogenicity and safety of a new live attenuated herpes zoster vaccine (NBP608) compared to Zostavax® in healthy adults aged 50 years and older. Vaccine. 2019;37(27):3605–10. doi: 10.1016/j.vaccine.2019.04.046. Duplicate [PubMed: 31122860] [CrossRef]

Choi WS, Choi JH, Jung DS, et al. Immunogenicity and safety of a new live attenuated herpes zoster vaccine (NBP608) compared to Zostavax® in healthy adults aged 50 years and older. Vaccine. 2019;37(27):3605–10. doi: 10.1016/j.vaccine.2019.04.046. PMID: CN-01937498. Duplicate [PubMed: 31122860] [CrossRef]

Choi WS, Noh JY, Lee J, et al. Immunogenicity and safety of a split-virion quadrivalent influenza vaccine in adults 18–60 years of age in the Republic of Korea. Human vaccines & immunotherapeutics. 2018;14(3):587–92. doi: 10.1080/21645515.2017.1381808. Intervention [PMC free article: PMC5861787] [PubMed: 28933625] [CrossRef]

Choi WS, Noh JY, Lee J, et al. Immunogenicity and safety of a split-virion quadrivalent influenza vaccine in adults 18–60 years of age in the Republic of Korea. Human Vaccines and Immunotherapeutics. 2018;14(3):587–92. doi: 10.1080/21645515.2017.1381808. Duplicate [PMC free article: PMC5861787] [PubMed: 28933625] [CrossRef]

Choi WS, Noh JY, Lee J, et al. Immunogenicity and safety of a split-virion quadrivalent influenza vaccine in adults 18–60years of age in the Republic of Korea. Human Vaccines & Immunotherapeutics. 2018;14(3):587–92. doi: 10.1080/21645515.2017.1381808. PMID: WOS:000428053800022. Duplicate [PMC free article: PMC5861787] [PubMed: 28933625] [CrossRef]

Choi WS, Noh JY, Song JY, et al. Immunogenicity and safety of a cell culture-derived inactivated quadrivalent influenza vaccine (NBP607-QIV): A randomized, double-blind, multi-center, phase III clinical trial in adults and elderly subjects. Human vaccines & immunotherapeutics. 2017;13(7):1653–60. doi: 10.1080/21645515.2017.1297351. Intervention [PMC free article: PMC5512784] [PubMed: 28406746] [CrossRef]

Choi WS, Noh JY, Song JY, et al. Immunogenicity and safety of a cell culture-derived inactivated quadrivalent influenza vaccine (NBP607-QIV): A randomized, double-blind, multi-center, phase III clinical trial in adults and elderly subjects. Human Vaccines and Immunotherapeutics. 2017;13(7):1653–60. doi: 10.1080/21645515.2017.1297351. Duplicate [PMC free article: PMC5512784] [PubMed: 28406746] [CrossRef]

Choi YJ, Hur SY, Kim TJ, et al. A Phase II, Prospective, Randomized, Multicenter, Open-Label Study of GX-188E, an HPV DNA Vaccine, in Patients with Cervical Intraepithelial Neoplasia 3. Clinical Cancer Research. 2020 Apr;26(7):1616–23. doi: 10.1158/1078-0432.Ccr-19-1513. PMID: WOS:000522837300010. Intervention [PubMed: 31727676] [CrossRef]

Chong CR, Park VJ, Cohen B, et al. Safety of Inactivated Influenza Vaccine in Cancer Patients Receiving Immune Checkpoint Inhibitors. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2020;70(2):193–9. doi: 10.1093/cid/ciz202. Comparator [PMC free article: PMC6938975] [PubMed: 30874791] [CrossRef]

Choo S, Seymour L, Morris R, et al. Immunogenicity and reactogenicity of a pneumococcal conjugate vaccine administered combined with a haemophilus influenzae type B conjugate vaccine in United Kingdom infants. Pediatric Infectious Disease Journal. 2000 Sep;19(9):854–62. PMID: 11001109. Intervention [PubMed: 11001109]

Choo S, Zhang QB, Seymour L, et al. Primary and booster salivary antibody responses to a 7-valent pneumococcal conjugate vaccine in infants. Journal of Infectious Diseases. 2000 Oct;182(4):1260–3. PMID: WOS:000089712100037. Outcome [PubMed: 10979930]

Choo S, Zuckerman J, Goilav C, et al. Immunogenicity and reactogenicity of a group C meningococcal conjugate vaccine compared with a group A+C meningococcal polysaccharide vaccine in adolescents in a randomised observer-blind controlled trial. Vaccine. 2000 Jun 1;18(24):2686–92. PMID: 10781855. Study design [PubMed: 10781855]

Chotpitayasunondh T, Panpitpat C, Thisyakorn U, et al. Safety and immunogenicity of a Haemophilus influenzae type B polysaccharide-tetanus toxoid conjugate vaccine combined with diphtheria, tetanus and pertussis vaccines in Thai infants. Southeast Asian Journal of Tropical Medicine & Public Health. 1997 Mar;28(1):91–8. PMID: 9322290. Study design [PubMed: 9322290]

Chou JF, Kernan NA, Prockop S, et al. Safety and immunogenicity of the live attenuated varicella vaccine following T replete or T cell-depleted related and unrelated allogeneic hematopoietic cell transplantation (alloHCT). Biology of Blood & Marrow Transplantation. 2011 Nov;17(11):1708–13. PMID: 21664979. Study design [PMC free article: PMC3660138] [PubMed: 21664979]

Chouraqui JP, Van Egroo LD, Fichot MC. Acidified milk formula supplemented with bifidobacterium lactis: Impact on infant diarrhea in residential care settings. Journal of Pediatric Gastroenterology and Nutrition. 2004 Mar;38(3):288–92. PMID: WOS:000220589600010. Study design [PubMed: 15076628]

Chowdhury PR, Meier C, Laraway H, et al. Immunogenicity of yellow fever vaccine coadministered with MenAfriVac in healthy infants in Ghana and Mali. Clinical Infectious Diseases. 2015;61:S586–S93. doi: 10.1093/cid/civ603. Intervention [PMC free article: PMC4639505] [PubMed: 26553692] [CrossRef]

Christenson B, Hedlund J, Lundbergh P, et al. Additive preventive effect of influenza and pneumococcal vaccines in elderly persons. European Respiratory Journal. 2004 Mar;23(3):363–8. PMID: 15065822. Outcome [PubMed: 15065822]

Christenson B, Lundbergh P, Hedlund J, et al. Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older: a prospective study. Lancet. 2001 Mar 31;357(9261):1008–11. PMID: 11293594. Study design [PubMed: 11293594]

Christenson B, Pauksen K, Sylvan SPE. Effect of influenza and pneumococcal vaccines in elderly persons in years of low influenza activity. Virology Journal. 2008;5:52. PMID: 18442371. Outcome [PMC free article: PMC2390520] [PubMed: 18442371]

Christiansen CF, Thomsen RW, Schmidt M, et al. Influenza vaccination and 1-year risk of myocardial infarction, stroke, heart failure, pneumonia, and mortality among intensive care unit survivors aged 65 years or older: a nationwide population-based cohort study. Intensive care medicine. 2019;45(7):957–67. doi: 10.1007/s00134-019-05648-4. Intervention [PubMed: 31187170] [CrossRef]

Christie CD, Duncan ND. Rotavirus vaccine trial in Jamaica. West Indian Medical Journal. 2012 Jul;61(4):405–7. PMID: 23240476. Duplicate [PubMed: 23240476]

Christie CDC, Duncan ND. Rotavirus vaccine trial in Jamaica. West Indian Medical Journal. 2012;61(4). PMID: 2012529420. Study design

Christou EM, Wargon O. Stevens-Johnson syndrome after varicella vaccination. Medical Journal of Australia. 2012 5;196(4):240–1. PMID: 2012132562 MEDLINE PMID 22409681 (http://www​.ncbi.nlm.nih​.gov/pubmed/22409681). Study design [PubMed: 22409681]

Christy C, Madore HP, Treanor JJ. Safety and immunogenicity of live attenuated rhesus monkey rotavirus vaccine. Journal of Infectious Diseases. 1986 1986;154(6):1045–7. PMID: 1987030898 MEDLINE PMID 3023497 (http://www​.ncbi.nlm.nih​.gov/pubmed/3023497). Study design [PubMed: 3023497]

Chu DWS, Kwong ASK, Tsui WWS, et al. Cross-clade immunogenicity and safety of an AS03A-adjuvanted prepandemic H5N1 influenza vaccine in Hong Kong. Hong Kong Medical Journal. 2011 Feb;17(1):39–46. PMID: 21282825. Study design [PubMed: 21282825]

Chu K, Hu J, Meng F, et al. Immunogenicity and safety of subunit plague vaccine: a randomized phase 2a clinical trial. Human vaccines & immunotherapeutics. 2016;12(9):2334–40. doi: 10.1080/21645515.2016.1175261. PMID: CN-01208872. Intervention [PMC free article: PMC5027722] [PubMed: 27159397] [CrossRef]

Chu K, Xu K, Tang R, et al. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine: A randomized, double-blind, controlled phase III study in healthy population aged ≥3 years. Vaccine. 2020;38(37):5940–6. doi: 10.1016/j.vaccine.2020.06.071. Intervention [PubMed: 32732142] [CrossRef]

Chu K, Ying Z, Wang L, et al. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: A phase II, randomized, dose-finding trial. Vaccine. 2018;36(45):6782–9. doi: 10.1016/j.vaccine.2018.09.023. Intervention [PubMed: 30249424] [CrossRef]

Chu K, Ying ZF, Wang L, et al. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: A phase II, randomized, dose-finding trial. Vaccine. 2018 Oct;36(45):6782–9. doi: 10.1016/j.vaccine.2018.09.023. PMID: WOS:000449444100027. Duplicate [PubMed: 30249424] [CrossRef]

Chu TGT, Cachola D. Pneumococcal conjugate vaccine (non-typeable Haemophilus influenzae (NTHi) Protein D, diphtheria or tetanus toxoid conjugates) in prevention of acute otitis media in children: A cohort study. International Journal of Infectious Diseases. 2014 Apr;21:429-. doi: 10.1016/j.ijid.2014.03.1306. PMID: WOS:000209704000887. Study design [CrossRef]

Chuaychoo B, Kositanont U, Niyomthong P, et al. Comparison of immunogenicity between intradermal and intramuscular injections of repeated annual identical influenza virus strains post-pandemic (2011–2012) in COPD patients. Human Vaccines and Immunotherapeutics. 2019. doi: 10.1080/21645515.2019.1692559. Intervention [PMC free article: PMC7482887] [PubMed: 31770051] [CrossRef]

Chuaychoo B, Kositanont U, Rittayamai N, et al. The immunogenicity of the intradermal injection of seasonal trivalent influenza vaccine containing influenza A(H1N1)pdm09 in COPD patients soon after a pandemic. Human vaccines & immunotherapeutics. 2016;12(7):1728–37. doi: 10.1080/21645515.2016.1149276. Intervention [PMC free article: PMC4964808] [PubMed: 27153158] [CrossRef]

Chuaychoo B, Wongsurakiat P, Nana A, et al. The immunogenicity of intradermal influenza vaccination in COPD patients. Vaccine. 2010 28;28(24):4045–51. PMID: 2010290747 MEDLINE PMID 20412877 (http://www​.ncbi.nlm.nih​.gov/pubmed/20412877). Publication year [PubMed: 20412877]

Chung JR, Flannery B, Thompson MG, et al. Seasonal Effectiveness of Live Attenuated and Inactivated Influenza Vaccine. Pediatrics. 2016;137(2):e20153279. doi: 10.1542/peds.2015-3279. Intervention [PMC free article: PMC4732363] [PubMed: 26738884] [CrossRef]

Church JA, Parker EPK, Kosek MN, et al. Exploring the relationship between environmental enteric dysfunction and oral vaccine responses. Future Microbiology. 2018 Jul;13(9):1055–70. doi: 10.2217/fmb-2018-0016. PMID: WOS:000444865600010. Intervention [PMC free article: PMC6136084] [PubMed: 29926747] [CrossRef]

Church JA, Rukobo S, Govha M, et al. The impact of improved water, sanitation and hygiene on oral rotavirus vaccine immunogenicity in Zimbabwean infants: sub-study of a cluster-randomized trial. Clinical infectious diseases. 2019. doi: 10.1093/cid/ciz140. PMID: CN-01958714. Intervention [PMC free article: PMC6880336] [PubMed: 30770931] [CrossRef]

Ciarlet M, He S, Lai S, et al. Concomitant use of the 3-dose oral pentavalent rotavirus vaccine with a 3-dose primary vaccination course of a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine: immunogenicity and reactogenicity. Pediatric Infectious Disease Journal. 2009 Mar;28(3):177–81. PMID: 19209092. Study design [PubMed: 19209092]

Ciarlet M, Sani-Grosso R, Yuan G, et al. Concomitant use of the oral pentavalent human-bovine reassortant rotavirus vaccine and oral poliovirus vaccine. Pediatric Infectious Disease Journal. 2008 Oct;27(10):874–80. PMID: 18756184. Study design [PubMed: 18756184]

Ciarlet M, Schodel F. Development of a rotavirus vaccine: clinical safety, immunogenicity, and efficacy of the pentavalent rotavirus vaccine, RotaTeq. Vaccine. 2009 Dec 30;27 Suppl 6:G72–81. PMID: 20006144. Study design [PubMed: 20006144]

Cibula D, Mallmann P, Knapp P, et al. Dendritic cell vaccine (DCVAC) with chemotherapy (ct) in patients (pts) with recurrent epithelial ovarian carcinoma (EOC) after complete response (CR) to 1st-line platinum (Pt)-based ct: primary analysis of a phase 2, open-label, randomized, multicenter trial. Journal of clinical oncology. 2018;36(15). doi: 10.1200/JCO.2018.36.15_suppl.e17515. PMID: CN-01790708. Intervention [CrossRef]

Cimen P, Unlu M, Kirakli C, et al. Should patients with COPD be vaccinated? Respiratory Care. 2015;60(2):239–43. doi: 10.4187/respcare.03350. Intervention [PubMed: 25316894] [CrossRef]

Ciprero K, Zykov KA, Briko NI, et al. Safety and immunogenicity of a single dose 23-valent pneumococcal polysaccharide vaccine in Russian subjects. Human vaccines & immunotherapeutics. 2016;12(8):2142–7. Comparator [PMC free article: PMC4994758] [PubMed: 27149114]

Ciszewski A, Bilinska ZT, Brydak LB, et al. Influenza vaccination in secondary prevention from coronary ischaemic events in coronary artery disease: FLUCAD study. Eur Heart J. 2008 Jun;29(11):1350–8. doi: 10.1093/eurheartj/ehm581. PMID: 18187561. Publication year [PubMed: 18187561] [CrossRef]

Citron ML, Moss BM. Pneumococcal-vaccine-induced thrombocytopenia. JAMA. 1982 Sep 10;248(10):1178. PMID: 7109129. Study design [PubMed: 7109129]

Claesson BA, Trollfors B, Lagergard T, et al. Clinical and immunologic responses to the capsular polysaccharide of Haemophilus influenzae type b alone or conjugated to tetanus toxoid in 18- to 23-month-old children. Journal of Pediatrics. 1988 May;112(5):695–702. PMID: 3361379. Study design [PubMed: 3361379]

Claesson MH. Immunological Links to Nonspecific Effects of DTwP and BCG Vaccines on Infant Mortality. Journal of Tropical Medicine. 2011;2011:706304. PMID: 21760811. Intervention [PMC free article: PMC3134263] [PubMed: 21760811]

Claeys C, Chandrasekaran V, Garcia-Sicilia J, et al. Anamnestic Immune Response and Safety of an Inactivated Quadrivalent Influenza Vaccine in Primed Versus Vaccine-Naive Children. The Pediatric infectious disease journal. 2019;38(2):203–10. doi: 10.1097/INF.0000000000002217. Comparator [PMC free article: PMC6344072] [PubMed: 30325891] [CrossRef]

Claeys C, Drame M, Garcia-Sicilia J, et al. Assessment of an optimized manufacturing process for inactivated quadrivalent influenza vaccine: a phase III, randomized, double-blind, safety and immunogenicity study in children and adults. BMC infectious diseases. 2018;18(1):186. doi: 10.1186/s12879-018-3079-8. Intervention [PMC free article: PMC5907359] [PubMed: 29669531] [CrossRef]

Claeys C, Zaman K, Dbaibo G, et al. Prevention of vaccine-matched and mismatched influenza in children aged 6–35 months: a multinational randomised trial across five influenza seasons. The Lancet. Child & adolescent health. 2018;2(5):338–49. doi: 10.1016/S2352-4642(18)30062-2. Comparator [PubMed: 30169267] [CrossRef]

Clancy RL, Dunkley ML, Sockler J, et al. Multi-site placebo-controlled randomised clinical trial to assess protection following oral immunisation with inactivated non-typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Internal medicine journal. 2016;46(6):684–93. doi: 10.1111/imj.13072. Intervention [PubMed: 27009822] [CrossRef]

Clar C, Oseni Z, Flowers N, et al. Influenza vaccines for preventing cardiovascular disease. Cochrane Database Syst Rev. 2015 May 5(5):CD005050. doi: 10.1002/14651858.CD005050.pub3. PMID: 25940444. Intervention [PMC free article: PMC8511741] [PubMed: 25940444] [CrossRef]

Clark. Erratum: Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants (Journal of Pediatrics (February 2004) 144 (184–190)). Journal of Pediatrics. 2004 Apr;144(4):558. PMID: 2004161706. Outcome [PubMed: 14760258]

Clark A, Jit M, Andrews N, et al. Evaluating the potential risks and benefits of infant rotavirus vaccination in England. Vaccine. 2014;32(29):3604–10. doi: 10.1016/j.vaccine.2014.04.082. Study design [PubMed: 24814524] [CrossRef]

Clark DR, Omer SB, Tapia MD, et al. Influenza or Meningococcal Immunization during Pregnancy and Mortality in Women and Infants: A Pooled Analysis of Randomized Controlled Trials. Pediatric Infectious Disease Journal. 2020:641–4. doi: 10.1097/INF.0000000000002629. Intervention [PMC free article: PMC7279057] [PubMed: 32379201] [CrossRef]

Clark HF. Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants (vol 144, pg 184, 2004). Journal of Pediatrics. 2004 Apr;144(4):558-. PMID: WOS:000220760600058. Study design [PubMed: 14760258]

Clark HF, Bernstein DI, Dennehy PH, et al. Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants.[Erratum appears in J Pediatr. 2004 Apr;144(4):558]. Journal of Pediatrics. 2004 Feb;144(2):184–90. PMID: 14760258. Intervention [PubMed: 14760258]

Clark HF, Borian FE, Plotkin SA. Immune protection of infants against rotavirus gastroenteritis by a serotype 1 reassortant of bovine rotavirus WC3. Journal of Infectious Diseases. 1990 Jun;161(6):1099–104. PMID: 2161038. Intervention [PubMed: 2161038]

Clark HF, Burke CJ, Volkin DB, et al. Safety, immunogenicity and efficacy in healthy infants of G1 and G2 human reassortant rotavirus vaccine in a new stabilizer/buffer liquid formulation. Pediatric Infectious Disease Journal. 2003 Oct;22(10):914–20. PMID: 14551493. Intervention [PubMed: 14551493]

Clark HF, Lawley D, Mallette LA, et al. Decline in Cases of Rotavirus Gastroenteritis Presenting to The Children’s Hospital of Philadelphia after Introduction of a Pentavalent Rotavirus Vaccine. Clinical and Vaccine Immunology. 2009 Mar;16(3):382–6. PMID: WOS:000263854200014. Outcome [PMC free article: PMC2650872] [PubMed: 19158283]

Clark HF, Lawley D, Shrager D, et al. Infant immune response to human rotavirus serotype G1 vaccine candidate reassortant WI79-9: Different dose response patterns to virus surface proteins VP7 and VP4. Pediatric Infectious Disease Journal. 2004 March;23(3):206–11. PMID: 2004121117 MEDLINE PMID 15014293 (http://www​.ncbi.nlm.nih​.gov/pubmed/15014293). Outcome [PubMed: 15014293]

Clark LR, Luxembourg AT. CLINICAL TRIAL EXPERIENCE WITH THE 9-VALENT HPV VACCINE BY RACE/ETHNICITY: A COMBINED ANALYSIS FROM SEVEN PHASE III CLINICAL STUDIES. Journal of Adolescent Health. 2016 Feb;58(2):S118–S. doi: 10.1016/j.jadohealth.2015.10.246. PMID: WOS:000373428800226. Study design [CrossRef]

Clarke E, Bashorun AO, Okoye M, et al. Safety and immunogenicity of a novel 10-valent pneumococcal conjugate vaccine candidate in adults, toddlers, and infants in The Gambia-Results of a phase 1/2 randomized, double-blinded, controlled trial. Vaccine. 2020;38(2):399–410. doi: 10.1016/j.vaccine.2019.08.072. Intervention [PubMed: 31843266] [CrossRef]

Clarke E, Bashorun AO, Okoye M, et al. Safety and immunogenicity of a novel 10-valent pneumococcal conjugate vaccine candidate in adults, toddlers, and infants in The Gambia-Results of a phase 1/2 randomized, double-blinded, controlled trial. Vaccine. 2020 Jan;38(2):399–410. doi: 10.1016/j.vaccine.2019.08.072. PMID: WOS:000509612700039. Duplicate [PubMed: 31843266] [CrossRef]

Clarke E, Saidu Y, Adetifa JU, et al. Safety and immunogenicity of inactivated poliovirus vaccine when given with measles-rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non-inferiority trial in The Gambia. The Lancet. Global health. 2016;4(8):e534–47. doi: 10.1016/S2214-109X(16)30075-4. Intervention [PubMed: 27364568] [CrossRef]

Clarke M, Marshall H. Rotavirus vaccination for prevention of serious acute gastroenteritis and the importance of postlicensure safety monitoring. Journal of Infectious Diseases. 2012 1;206(1):3–5. PMID: 2012308449 MEDLINE PMID 22539816 (http://www​.ncbi.nlm.nih​.gov/pubmed/22539816). Study design [PubMed: 22539816]

Clarke SC. Control of pneumococcal disease in the United Kingdom - The start of a new era. Journal of Medical Microbiology. 2006 August;55(8):975–80. PMID: 2006387505 MEDLINE PMID 16849715 (http://www​.ncbi.nlm.nih​.gov/pubmed/16849715). Study design [PubMed: 16849715]

Clarkson A, Conroy S, Burroughs K, et al. Surveillance for adverse drug reactions in children: A paediatric regional monitoring centre. Paediatric and Perinatal Drug Therapy. 2004 2004;6(1):20–3. PMID: 2004358628. Study design

Classen JB, Classen DC. Association between type 1 diabetes and hib vaccine. Causal relation is likely. BMJ. 1999 Oct 23;319(7217):1133. PMID: 10531116. Study design [PMC free article: PMC1116914] [PubMed: 10531116]

Classen JB, Classen DC. Clustering of cases of insulin dependent diabetes (IDDM) occurring three years after hemophilus influenza B (HiB) immunization support causal relationship between immunization and IDDM. Autoimmunity. 2002 Jul;35(4):247–53. PMID: 12482192. Intervention [PubMed: 12482192]

Cleary BJ, Rice U, Eogan M, et al. 2009 A/H1N1 influenza vaccination in pregnancy: uptake and pregnancy outcomes - a historical cohort study. European journal of obstetrics, gynecology, and reproductive biology. 2014;178:163–8. doi: 10.1016/j.ejogrb.2014.04.015. Intervention [PubMed: 24793932] [CrossRef]

Cleary V, Wynne-Evans E, Freed J, et al. Ebola 2014: Setting up a port health sreening programme at an international train station. Journal of Business Continuity & Emergency Planning. 2016;10(2):177–87. Intervention [PubMed: 28376997]

Clements KM, Chancellor J, Nichol K, et al. Cost-effectiveness of a recommendation of universal mass vaccination for seasonal influenza in the United States. Value in Health. 2011 September-October;14(6):800–11. PMID: 2011512561 MEDLINE PMID 21914499 (http://www​.ncbi.nlm.nih​.gov/pubmed/21914499). Study design [PubMed: 21914499]

Clements-Mann ML, Dudas R, Hoshino Y, et al. Safety and immunogenicity of live attenuated quadrivalent human-bovine (UK) reassortant rotavirus vaccine administered with childhood vaccines to infants. Vaccine. 2001 Sep 14;19(32):4676–84. PMID: 11535316. Publication year [PubMed: 11535316]

Clements-Mann ML, Wright PF, Hoshino Y, et al. Safety and immunogenicity of live attenuated human-bovine (UK) reassortant rotavirus vaccines with VP7-specificity for serotypes 1, 2, 3 or 4 in adults, children and infants. Vaccine. 1999 4;17(20 21):2715–25. PMID: 1999235613 MEDLINE PMID 10418923 (http://www​.ncbi.nlm.nih​.gov/pubmed/10418923). Study design [PubMed: 10418923]

Clerici M, Rizzardini G, Cossu MV, et al. Probiotic strains BB-12(registered trademark) and L. casei 431(registered trademark) increase the immune response to an influenza vaccine: A randomized, double-blind, placebo-controlled study. European Journal of Pharmacology. 2011 September;668 SUPPL. 1:e3–e4. Study design

Clifford V, Crawford NW, Royle J, et al. Recurrent apnoea post immunisation: Informing re-immunisation policy. Vaccine. 2011 05;29(34):5681–7. PMID: 2011399970 MEDLINE PMID 21693156 (http://www​.ncbi.nlm.nih​.gov/pubmed/21693156). Study design [PubMed: 21693156]

Clothier HJ, Hosking L, Crawford NW, et al. Bacillus Calmette-Guerin (BCG) vaccine adverse events in Victoria, Australia: analysis of reports to an enhanced passive surveillance system. Drug safety. 2015;38(1):79–86. doi: 10.1007/s40264-014-0248-6. Intervention [PubMed: 25475539] [CrossRef]

Clothier HJ, Lawrie J, Lewis G, et al. SAEFVIC: Surveillance of adverse events following immunisation (AEFI) in Victoria, Australia, 2018. Communicable diseases intelligence (2018). 2020;44. doi: 10.33321/cdi.2020.44.46. Study design [PubMed: 32536336] [CrossRef]

Clothier HJ, Lee KJ, Sundararajan V, et al. Human papillomavirus vaccine in boys: background rates of potential adverse events. Medical Journal of Australia. 2013;198(10):554–8. PMID: 23725271. Study design [PubMed: 23725271]

Cocchio S, Zanoni G, Opri R, et al. A postmarket safety comparison of 2 vaccination strategies for measles, mumps, rubella and varicella in Italy. Human Vaccines and Immunotherapeutics. 2016;12(3):651–4. doi: 10.1080/21645515.2015.1101198. Duplicate [PMC free article: PMC4964739] [PubMed: 26528829] [CrossRef]

Cocchio S, Zanoni G, Opri R, et al. A postmarket safety comparison of 2 vaccination strategies for measles, mumps, rubella and varicella in Italy. Human vaccines & immunotherapeutics. 2016;12(3):651–4. doi: 10.1080/21645515.2015.1101198. Intervention [PMC free article: PMC4964739] [PubMed: 26528829] [CrossRef]

Coenders A, Koopmans NK, Broekhuijsen K, et al. Adjuvanted vaccines in pregnancy: no evidence for effect of the adjuvanted H1N1/09 vaccination on occurrence of preeclampsia or intra-uterine growth restriction. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2015 Apr;187:14–9. doi: 10.1016/j.ejogrb.2015.01.011. PMID: WOS:000353091800003. Intervention [PubMed: 25681994] [CrossRef]

Cohen C, Sullivan SG. Live attenuated influenza vaccines for African children. Lancet Respiratory Medicine. 2019 Aug;7(8):641–3. doi: 10.1016/s2213-2600(19)30145-6. PMID: WOS:000476735800006. Study design [PubMed: 31235406] [CrossRef]

Cohen J. Medicine. Rethinking a vaccine’s risk.[Erratum appears in Science 2001 Sep 14;293(5537):1997]. Science. 2001 Aug 31;293(5535):1576–7. PMID: 11533457. Study design [PubMed: 11533457]

Cohen PR. Injection Site Lichenoid Dermatitis Following Pneumococcal Vaccination: Report and Review of Cutaneous Conditions Occurring at Vaccination Sites. Dermatology and Therapy. 2016;6(2):287–98. doi: 10.1007/s13555-016-0105-x. Comparator [PMC free article: PMC4906099] [PubMed: 26988991] [CrossRef]

Cohet C, Haguinet F, Dos Santos G, et al. Effect of the adjuvanted (AS03) A/H1N1 2009 pandemic influenza vaccine on the risk of rejection in solid organ transplant recipients in England: a self-controlled case series. BMJ open. 2016;6(1):e009264. doi: 10.1136/bmjopen-2015-009264. Intervention [PMC free article: PMC4735133] [PubMed: 26823177] [CrossRef]

Colafrancesco S, Perricone C, Tomljenovic L, et al. Human papilloma virus vaccine and primary ovarian failure: another facet of the autoimmune/inflammatory syndrome induced by adjuvants. Am J Reprod Immunol. 2013 Oct;70(4):309–16. doi: 10.1111/aji.12151. PMID: 23902317. Comparator [PubMed: 23902317] [CrossRef]

Colburn A, Wright S, Lopez V, et al. Aerobic exercise and environmental heat stress as adjuvants to seasonal influenza vaccine. FASEB journal. 2018;32(1). PMID: CN-01613668. Participants

Coldiron ME, Guindo O, Makarimi R, et al. Safety of a heat-stable rotavirus vaccine among children in Niger: Data from a phase 3, randomized, double-blind, placebo-controlled trial. Vaccine. 2018;36(25):3674–80. doi: 10.1016/j.vaccine.2018.05.023. Intervention [PubMed: 29752026] [CrossRef]

Coldiron ME, Guindo O, Makarimi R, et al. Safety of a heat-stable rotavirus vaccine among children in Niger: Data from a phase 3, randomized, double-blind, placebo-controlled trial. Vaccine. 2018 Jun;36(25):3674–80. doi: 10.1016/j.vaccine.2018.05.023. PMID: WOS:000436202800018. Duplicate [PubMed: 29752026] [CrossRef]

Coleman BL, McGeer AJ, Halperin SA, et al. A randomized control trial comparing immunogenicity, safety, and preference for self- versus nurse-administered intradermal influenza vaccine. Vaccine. 2012 Sep 28;30(44):6287–93. doi: 10.1016/j.vaccine.2012.08.006. PMID: 22902784. Study design [PubMed: 22902784] [CrossRef]

Coleman BL, McNeil SA, Langley JM, et al. Differences in efficiency, satisfaction and adverse events between self-administered intradermal and nurse-administered intramuscular influenza vaccines in hospital workers. Vaccine. 2015;33(48):6635–40. doi: 10.1016/j.vaccine.2015.10.095. Intervention [PubMed: 26529074] [CrossRef]

Coleman HN, Greenfield WW, Stratton SL, et al. Human papillomavirus type 16 viral load is decreased following a therapeutic vaccination. Cancer immunology, immunotherapy. 2016;65(5):563–73. doi: 10.1007/s00262-016-1821-x. PMID: CN-01153200. Comparator [PMC free article: PMC4841729] [PubMed: 26980480] [CrossRef]

Colgate ER, Haque R, Dickson DM, et al. Delayed Dosing of Oral Rotavirus Vaccine Demonstrates Decreased Risk of Rotavirus Gastroenteritis Associated With Serum Zinc: a Randomized Controlled Trial. Clinical infectious diseases. 2016;63(5):634–41. doi: 10.1093/cid/ciw346. PMID: CN-01444818. Intervention [PubMed: 27217217] [CrossRef]

Colindres R, Wascotte V, Brecx A, et al. Post hoc analysis of reactogenicity trends between dose 1 and dose 2 of the adjuvanted recombinant zoster vaccine in two parallel randomized trials. Human Vaccines & Immunotherapeutics.6. doi: 10.1080/21645515.2020.1741312. PMID: WOS:000532057200001. Comparator [PMC free article: PMC7733973] [PubMed: 32347767] [CrossRef]

Colindres R, Wascotte V, Brecx A, et al. Reactogenicity profile of adjuvanted recombinant zoster vaccine after dose 2 according to the intensity of the same event experienced after dose 1. Open forum infectious diseases. 2019;6:S981–S2. doi: 10.1093/ofid/ofz360.2457. PMID: CN-02075022. Intervention [CrossRef]

Collignon P, Doshi P, Jefferson T. Ramifications of adverse events in children in Australia. BMJ. 2010;(2010) 340(7759):1262. PMID: 2010343617. Study design [PubMed: 20534663]

Collins AM, Wright AD, Mitsi E, et al. First human challenge testing of a pneumococcal vaccine. Double-blind randomized controlled trial. American journal of respiratory and critical care medicine. 2015;192(7):853–8. doi: 10.1164/rccm.201503-0542OC. Comparator [PubMed: 26114410] [CrossRef]

Collins CL, Salt P, McCarthy N, et al. Immunogenicity and safety of a low-dose diphtheria, tetanus and acellular pertussis combination vaccine with either inactivated or oral polio vaccine as a pre-school booster in UK children. Vaccine. 2004 Oct 22;22(31–32):4262–9. PMID: 15474717. Study design [PubMed: 15474717]

Colmegna I, Useche M, Rodriguez K, et al. Efficacy of high-dose versus standard-dose influenza vaccine in seropositive rheumatoid arthritis patients. Arthritis and rheumatology. 2018;70:927–8. doi: 10.1002/art.40700. PMID: CN-01791608. Participants [CrossRef]

Colmegna I, Useche M, Rodriguez K, et al. High Dose Influenza Vaccine in Seropositive Rheumatoid Arthritis Patients: Results of a Randomized Control Trial. Journal of Rheumatology. 2019 Jul;46(7):765-. PMID: WOS:000475840400025. Study design

Colmegna I, Useche ML, Rodriguez K, et al. Immunogenicity and safety of high-dose versus standard-dose inactivated influenza vaccine in rheumatoid arthritis patients: a randomised, double-blind, active-comparator trial. The lancet rheumatology. 2020;2(1):e14–e23. doi: 10.1016/S2665-9913(19)30094-3. PMID: CN-02085737. Duplicate [CrossRef]

Colmegna I, Useche ML, Rodriguez K, et al. Immunogenicity and safety of high-dose versus standard-dose inactivated influenza vaccine in rheumatoid arthritis patients: a randomised, double-blind, active-comparator trial. The Lancet Rheumatology. 2020;2(1):e14–e23. doi: 10.1016/S2665-9913(19)30094-3. Intervention [CrossRef]

Colombatto P, Brunetto MR, Maina AM, et al. HCV E1E2-MF59 vaccine in chronic hepatitis C patients treated with PEG-IFNα2a and Ribavirin: A randomized controlled trial. Journal of Viral Hepatitis. 2014;21(7):458–65. doi: 10.1111/jvh.12163. Intervention [PMC free article: PMC4166695] [PubMed: 24750327] [CrossRef]

Comeaux C, Bastian AR, De Paepe E, et al. Safety and immunogenicity of a seasonal influenza vaccine and AD26.RSV.pref vaccine with and without co-administration: a randomized, double-blind, placebo-controlled phase 2A study in adults aged ≥ 60 years. Open forum infectious diseases. 2019;6:S979. doi: 10.1093/ofid/ofz360.2452. PMID: CN-02074112. Intervention [CrossRef]

Committee on Obstetric P. ACOG Committee Opinion No. 521: Update on immunization and pregnancy: tetanus, diphtheria, and pertussis vaccination. Obstetrics & Gynecology. 2012 Mar;119(3):690–1. PMID: 22353979. Study design [PubMed: 22353979]

Compston DA, Vakarelis BN, Paul E, et al. Viral infection in patients with multiple sclerosis and HLA-DR matched controls. Brain. 1986 Apr;109 ( Pt 2):325–44. doi: 10.1093/brain/109.2.325. PMID: 3456817. Publication year [PMC free article: PMC7109889] [PubMed: 3456817] [CrossRef]

Confavreux C, Suissa S, Saddier P, et al. Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group. N Engl J Med. 2001 Feb 1;344(5):319–26. doi: 10.1056/NEJM200102013440501. PMID: 11172162. Publication year [PubMed: 11172162] [CrossRef]

Conlin AM, Bukowinski AT, Sevick CJ, et al. Safety of the pandemic H1N1 influenza vaccine among pregnant U.S. military women and their newborns. Obstetrics & Gynecology. 2013 Mar;121(3):511–8. doi: 10.1097/AOG.0b013e318280d64e. PMID: 23635612. Study design [PubMed: 23635612] [CrossRef]

Conlin AMS, Bukowinski AT, Levine JA, et al. A follow-up comparative safety analysis of pandemic H1N1 vaccination during pregnancy and risk of infant birth defects among U.S. military mothers. Vaccine. 2018;36(20):2855–60. doi: 10.1016/j.vaccine.2018.03.061. Intervention [PubMed: 29625766] [CrossRef]

Conlin AMS, Bukowinski AT, Sevick CJ, et al. Safety of the pandemic H1N1 influenza vaccine among pregnant U.S. military women and their newborns. Obstetrics and gynecology. 2013;121(3):511–8. doi: 10.1097/AOG.0b013e318280d64e. Duplicate [PubMed: 23635612] [CrossRef]

Conrad A, Perry M, Langlois ME, et al. Efficacy and Safety of Revaccination against Tetanus, Diphtheria, Haemophilus influenzae Type b and Hepatitis B Virus in a Prospective Cohort of Adult Recipients of Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation. 2020;26(9):1729–37. doi: 10.1016/j.bbmt.2020.05.006. Comparator [PubMed: 32428736] [CrossRef]

Conterno LO, da Silva Filho CR, Ruggeberg JU, et al. WITHDRAWN: Conjugate vaccines for preventing meningococcal C meningitis and septicaemia. Cochrane Database of Systematic Reviews. 2011(7):CD001834. PMID: 21735387. Outcome [PubMed: 21735387]

Conway JH, Davis JP, Eickhoff JC, et al. Brand-specific rates of pertussis disease among Wisconsin children given 1–4 doses of pertussis Vaccine, 2010–2014. Vaccine. 2020 Oct;38(45):7063–9. doi: 10.1016/j.vaccine.2020.09.016. PMID: WOS:000579804000016. Outcome [PubMed: 32921507] [CrossRef]